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SOME CLINICAL AND LABORATORY STUDIES OF LARGE PITUITARY TUMOURS
TREATED WITH DOPAMINE AGONISTS
41 075No. of words in the main text of Diesis ! ...
The patient with a large pituitary tumour presents a number of
management problems and conventional treatment with surgery and
radiotherapy is unsatisfactory. Reports between 1978 and 1982 showed
that some tumours regress during dopamine agonist (DA) therapy, though
thiB does not produce a permanent cure (Chapter 1). The aim of the
present work was to clarify the effect of DA therapy on different types
of large pituitary tumour and to characterise cells from both responsive
and unresponsive tumours.
Three conclusions resulted from the clinical studies (Chapter 2):
(1) Most macroprolactinomas shrink during DA therapy but the shrinkage
is often asymmetrical and results in fibrosis during long-term therapy,
both of which hamper subsequent surgery. (2) Disconnection hyper-
prolactinaemia may be considerable and lead to inappropriate DA therapy
for non-adenomatous lesions. (3) Non-functioning tumours do not regress
during DA therapy.
Tumour cells were characterised by tumour cell perifusion (methods
described in Chapters 3 and 4), dopamine receptor measurement using
[ H]spiperone as radioligand (methods described in Chapter 5) and
immunocytochemistry. Prolactin secretion rates from bromocriptine-
treated macroprolactinomas were greatly reduced compared with untreated
tumours. Most prolactinomas showed dose-related inhibition of prolactin
secretion by dopamine and bromocriptine but one tumour was partially
bromocriptine resistant in-vivo and in-vitro (Chapter 6). Fifty percent
of the non-functioning tumours did not contain, secrete or immunostain
for any known anterior pituitary peptide. The remainder secreted small
amounts of gonadotrophins or alpha subunit, but the secretion was not
inhibited by dopamine, immunostaining was confined to <102! of cells and
tumour contents were low (Chapter 7).
Despite their failure to regress during bromocriptine treatment, non¬
functioning tumours were shown to possess similar dopamine receptors to
prolactinomas and normal anterior pituitary (Chapter 8). Using a novel
immunoassay, bromocriptine was shown to be bound to non-functioning
tumour dopamine receptors in-vivo. In contrast, two TSH-secreting
adenomas were also unresponsive to dopaminergic manipulation but lacked
membrane-bound dopamine receptors (Chapter 9).
From these results, future clinical practice demands greater care in
selecting patients for dopamine agonist or surgical treatments. The
finding of dopamine receptors in non-functioning tumours suggests future
research on these enigmatic tumours aimed at defining the cell type
represented and post-dopamine receptor mechanisms (Chapter 10).
PGS/ABST/83 Use this side only
CHAPTER 1. INTRODUCTION
A. HISTORICAL ASPECTS OF PROLACTIN AND BROMOCRIPTINE
1. Prolactin: identification and measurement
"A galactorrhoeic non-pregnant woman is expected to have amenorrhoea"
[Hippocrates (460-375 BC) Aphorisms, V39]
The frequent association of galactorrhoea with amenorrhoea has been
rediscovered since Hippocrates. In the mid-nineteenth century Chiari
described the post-partum amenorrhoea-galactorrhoea syndrome and one
hundred years later Argonz and del Castillo (1953) reported "a syndrome
characterised by oestrogen deficiency, galactorrhoea, amenorrhoea and
decreased urinary gonadotrophins". Forbes et al (1954) later attributed
the condition to a pituitary adenoma but the full characterisation of
prolactin, the anterior pituitary hormone responsible for the above
syndromes, has only been possible over the past fifteen years.
During the 1950s and 60s a variety of bioassay studies demonstrated the
importance of the central nervous system in the control of the
"mammotroph hormone" and its central role in lactation was established;
Meites et al (1963) showed that prolactin secretion increased when the
pituitary gland was removed from intimate contact with the hypothalamus.
The existence of prolactin as a human pituitary hormone distinct from
growth hormone (which is also lactogenic) was surmised from histological
(Herbert and Hayashida, 1970), biochemical (Lewis et al, 1971) and
Forsyth et al., 1971
biological (Frantz and Kleinberg, 1970) evidence. Final confirmation
awaited its isolation and purification from human pituitary glands
(Hwang et al., 1972). The development of sensitive radioimmunoassays for
prolactin (Hwang et al., 1971; McNeilly, 1973) promoted extensive
investigation of prolactin secretion in normal and pathological states.
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In 1977 human prolactin was fully sequenced and shown to be a single
chain polypeptide of 198 amino acid residues, molecular weight 22554
daltons (Shome and Parlow, 1977). Despite its bioassay similarities to
growth hormone, the two hormones exhibit only 16% amino acid sequence
homology.
Fractionation of immunoreactive prolactin has revealed heterogeneity
both in pituitary extracts (Sinha and Gilligan, 1981; Meuris et al.,
1983) and in some peripheral blood samples (Farkouh et al., 1979). "Big"
prolactin is probably a dimer and "big-big" prolactin possibly an
aggregated form. However there is still controversy regarding the
analytical and biological significance of these different forms (Franks,
1983). Most of the prolactin bioactivity in serum samples from
prolactinoma patients appears to be due to monomeric prolactin (Rennie
et al., 1 985).
The human decidua also synthesises and secretes prolactin, apparently
identical to the pituitary hormone, and the large amounts in amniotic
fluid are derived from this source (reviewed by Franks, 1983). The mRNA
coding for human prolactin has been recently identified in this tissue
(Taii et al., 1984). The advent of human prolactin cDNA probes, first
produced from RNA extracted from prolactin-secreting adenomas (Cooke et
al., 1981), heralds a new era of investigation into prolactin gene
regulation. The human prolactin gene is about 10 kilobases in length,
contains 4 introns and is located on chromosome 6 as a single copy per
haploid genome (Martial et al., 1984).
2. Prolactin: secretory mechanisms in the lactotroph
The morphology of the normal lactotroph and the intracellular processing
and transport of secretory products have been recently reviewed by
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Pelletier et al (1984). The normal human lactotroph contains abundant
endoplasmic reticulum, a prominent Golgi apparatus and membrane-bound
secretory granules of a diameter ranging between 150-250 nm. Pulse chase
experiments and high resolution autoradiography using tritiated amino
acids have shown that prolactin is rapidly synthesised (within 30
minutes) by ribosomes attached to the outer surface of the endoplasmic
reticulum. Soon after synthesis commences (within 10 minutes) the
radiolabelled prolactin is transported to the Golgi apparatus, by a
transport mechanism that remains unclear. In the Golgi small immature
granules are formed which then mature into the final secretory granules.
Pelletier and Labrie (1982) found that 30 minutes after the beginning of
incorporation of radiolabelled leucine into rat lactotrophs, about 25%
of the radioactivity was associated with mature secretory granules.
The mature secretory granules must migrate to the plasma membrane for
prolactin secretion to occur and little is known of the factors that
influence this granule movement. A microtubule system seems to be
involved since inhibitors such as colchicine decrease secretion of
prolactin from rat lactotrophs (Antakly et al., 1979). Final prolactin
release occurs when the granule membrane fuses with plasma membrane and
hormone is extruded into the perivascular space by exocytosis. Increased
exocytosis can be observed at the electron microscopic level when
lactotrophs in-vitro are exposed to secretagogues such as cAMP
(Pelletier et al., 1972). Horseradish peroxidase membrane-labelling
experiments suggest that granule membranes are recycled from the plasma
membrane back to the Golgi apparatus where they are reused in the
formation of new granules (Pelletier et al., 1984).
3. Prolactin: neuroendocrine control of secretion
It has been known for some years that prolactin secretion is under tonic
3
inhibitory control from the hypothalamus. The major body of evidence
which suggests that most of this inhibition is exerted by release of
hypothalamic dopamine has been extensively reviewed (Macleod, 1970,1976; Ben-
Jonathan, 1980; Leong et al., 1983; de Greef and van der Schoot, 1985).
In brief, spontaneous prolactin secretion is inhibited by dopamine (Ben-
Jonathan, 1980) acting in small amounts (Foord et al., 1983); dopamine
receptors are found on pituitary membranes (Cronin and Weiner, 1979), in
particular membranes of lactotrophs (Goldsmith et al., 1979); and
dopamine is found in hypophysial stalk plasma in amounts sufficient to
inhibit prolactin release (Neill et al., 1981; Bethea, 1985). There is
some evidence that dopamine is not the only prolactin inhibiting factor
mediating tonic hypothalamic inhibition (de Greef and van der Schoot,
1985). GABA (gamma-amino-butyric acid) can also inhibit prolactin
release but controversy remains as to whether this is a physiological or
Franks, 1983
a pharmacological effect (Mulchahey and Neill, 1982). Overall, there
would seem little doubt that dopamine dominates physiological prolactin
inhibitory activity.
Some purified hypothalamic extracts contain prolactin releasing activity
and a wide variety of substances have been proposed as hypothalamic
prolactin releasing hormones (Leong et al., 1983). Of these TRH and
vasoactive intestinal peptide (VIP) have been the most studied and both
are present in stalk plasma in concentrations sufficient to provoke
prolactin secretion in-vitro. The involvement of TRH in the prolactin
responses to suckling will be mentioned again in Chapter 6. VIP-uptake
in the pituitary appears exclusively localised to the lactotrophs (Morel
et al., 1982) but its role in the physiological regulation of prolactin
secretion remains unclear. In-vitro, VIP stimulates prolactin secretion
from normal and tumourous lactotrophs (Spada et al., 1983) and the
potential use of membrane-bound VIP receptors as a marker of lactotroph-
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like cells will be returned to in Chapter 10.
An important aspect in the control of prolactin secretion is the "short-
loop" feedback whereby prolactin (which is not dependent on feedback
from a target endocrine organ) is able to regulate its own secretion.
The work which led to the description of this phenomenon has been
reviewed by Peters et al (1982) and suggests that prolactin release by
the pituitary is limited by a direct action of prolactin on hypothalamic
dopamine turnover, thereby increasing dopamine delivery to the pituitary
(Perkins et al., 1979; Foreman and Porter, 1981). This topic is further
discussed in Chapter 6.
4. Prolactin-secreting tumours
Following the development of prolactin radioimmunoassays in the early
1970s it became apparent that as many as 70% of pituitary tumours
previously considered to be functionless were associated with elevated
serum prolactin concentrations (Frantz et al., 1972; Franks et al,
1977). It is probable that a proportion of patients described in these
studies had non-functioning tumours causing disconnection
hyperprolactinaemia (Nabarro, 1982). Nevertheless human tumours
containing prolactin were identified in early immunocytochemical studies
(Kovacs et al., 1 976).
Prolactinomas in women are not uncommon, but most are less than 10 mm in
diameter and referred to as microprolactinomas. Although these patients
frequently have normal plain skull radiographs, high resolution
computerised tomography reveals small tumours in the majority (Jung et
al., 1982). Apparent abnormalities within the pituitary on computerised
tomography are not necessarily pathological however, and may represent
small cysts, areas of necrosis or artefacts (Chambers et al., 1982). On
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the other hand small clinically silent adenomas are a frequent finding
at necropsy; Burrow et al (1981) found an overall incidence of 27%,
though most were less than 2 mm in diameter, and 41% of the tumours
immunostained for prolactin.
The clinical manifestations of hyperprolactinaemia have been extensively
reviewed (Franks and Jacobs, 1983; Grossman and Besser, 1985).
Hyperprolactinaemia produces hypogonadism in both sexes, though
clinically evident prolactinomas are much less common in men, who
characteristically present late with larger tumours causing pressure
symptoms (Nabarro, 1982).
5. Bromocriptine: development and early clinical studies
In 1967, 2-bromo-alpha-ergocryptine mesylate (bromocriptine), a
semisynthetic ergot alkaloid, was specifically developed as an inhibitor
of prolactin secretion (Fluckiger and Wagner, 1968). Although introduced
into clinical research in 1971, bromocriptine was only later shown to
directly stimulate dopamine receptors and to compete with the specific
O
binding of [ H]dopamine to bovine anterior pituitary membranes (Calabro
and MacLeod, 1978). Early clinical studies showed the high efficacy of
this agent in the treatment of the galactorrhoea/amenorrhoea syndromes
with suppression of serum prolactin concentrations resulting in greatly
reduced galactorrhoea and reversal of hypogonadism (Besser et al., 1972;
Del Pozo et al., 1974; Thorner et al., 1974). The dopaminergic agonist
actions of the drug also proved useful in the suppression of puerperal
lactation (Rolland and Schellekens, 1973), and as an adjunct to other
treatments for acromegaly (Liuzzi et al., 1974; Wass et al., 1977;
Martyn and Bevan, 1980) and Parkinson's disease (Calne et al., 1974). In
women with microprolactinomas bromocriptine restored ovulatory cycles in
80-90% (Thorner and Besser, 1978), many of whom rapidly achieved
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pregnancy (Thorner et al., 1979). The effects of bromocriptine on
pituitary macroadenomas will be discussed in the next section.
The pharmacology of bromocriptine has been extensively reviewed (Mehta
and Tolis, 1979; Schran et al., 1980; Maurer et al., 1983) and various
aspects will be further discussed in the section on bromocriptine
measurement (Chapter 3.D). Bromocriptine is rapidly absorbed following
oral administration and peak plasma levels are achieved after 2-3 hours.
It has a prolonged duration of action on the pituitary and serum
prolactin concentrations remain suppressed up to 14 hours after a single
dose (Schran et al., 1980; see also Chapter 3.D). The drug is usually
administered twice or three times daily to achieve steady-state plasma
concentrations in the low nanomolar range (Thorner et al., 1980).
Following the development of bromocriptine as the prototype drug, other
ergot alkaloids with dopaminergic agonist activity have been introduced
for clinical use. These compounds can be divided into two broad
categories, the ergopeptines and the ergolines, both of which contain
the tetracyclic ergoline nucleus which confers the biological activity.
The ergopeptines, of which bromocriptine is an example, consist of d-
lysergic acid linked by an amide bridge to a cyclic tripeptide which is
extensively metabolised in-vivo (Rosenthaler et al., 1983). Ergolines
are derivatives of the tetracyclic skeleton of lysergic acid. Not
surprisingly these compounds have differing pharmacokinetic properties;
lisuride is shorter acting than bromocriptine (Chiodini et al., 1981),
while pergolide can be administered once daily (Franks et al., 1983).
Occasionally a patient intolerant or resistant to one drug may be better
suited by another compound (Grossman et al., 1985a; Ahmed and Shalet,
1986). However, bromocriptine remains the most widely prescribed and
best characterised dopamine agonist in clinical use.
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B. THE PROBLEM OF THE LARGE PITUITARY TUMOUR
The management of the patient with a large pituitary tumour presents a
variety of problems. The most frequent complication is upward extension
with compression of the visual pathways producing, classically, a
bitemporal field loss, though visual loss may he markedly asymmetrical
in up to one third of patients (Fahlbusch et al., 1981), and there is
frequently a delay of many months before the diagnosis is made. The
patient may present with a variety of other tumour mass effects; an
extreme suprasellar extension may block the foramen of Munro and result
in hydrocephalus, lateral extension into the temporal lobe may cause
fits and anterior extension into the frontal lobes may produce
personality change. Local invasion or compression of cavernous sinuses
may lead to cranial nerve palsies, particularly of the third and sixth
nerves, although this occurs mainly in the context of pituitary apoplexy
(Wakai et al., 1981). Rarely, macroadenomas metastasize within the
central nervous system (Martin et al., 1981; Gasser et al., 1985).
Two tumour types most commonly produce these clinical syndromes; non¬
functioning tumours in both sexes, and macroprolactinomas particularly
in men (Carter et al., 1 97 8; Teasdale, 1 983; Esiri et al., 1983). ACTH
and growth hormone secreting tumours less often grow to this size and
are not considered further in this thesis. Women with prolactinomas tend
to present earlier with symptoms of menstrual disturbance or
galactorrhoea, and usually have smaller tumours.
Large pituitary tumours may compromise anterior pituitary function
either by direct compression of pituitary tissue or by interference with
hypothalamic control mechanisms. This is particularly common with the
non-functioning tumours, probably reflecting the fact that, as a group,
they comprise the largest pituitary tumours (Bevan et al., 1987b). The
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hypogonadism frequently present has a number of interrelated components.
Firstly there may be direct interference with gonadotrophin release due
to pressure effects on hypothalamus or pituitary (Ambrosi et al., 1985).
Secondly, hyperprolactinaemia, whether from hypothalamo-pituitary
disconnection or tumour secretion, inhibits gonadotrophin pulsatility
probably by an action on the hypothalamic GnRH pulse generator (Moult et
al., 1982; Ambrosi et al., 1985). Thirdly, prolactin excess may inhibit
ovarian (but probably not testicular) steroidogenesis though this
remains controversial (McNeilly et al., 1983).
Tumour decompression is the most urgent need when a patient presents
with a large pituitary tumour, particularly if vision is impaired. Until
recently this was usually achieved by transcranial surgery which
frequently produced a good visual result (Elkington and McKissock, 1967;
Symon and Jakubowski, 1979). However the operation carries a significant
morbidity and, particularly in earlier series, an appreciable mortality
(10% overall in the series of Elkington and McKissock, 1967).
Furthermore, large tumours are virtually never cured by transcranial
surgery alone (Nabarro, 1982) making external radiotherapy essential
with the possible long-term prospect of hypopituitarism. Even with
this combination therapy the tumour recurrence rate was as high as 8%
(Elkington and McKissock, 1967).
Over the past two decades it has become apparent that tumours with large
suprasellar extensions can be satisfactorily decompressed via the
transsphenoidal route (reviewed by Teasdale, 1983), although in fact
this was well recognised by Harvey Cushing in the 1920s (Cushing, 1921).
The historical background of the transition from transcranial to
transsphenoidal surgery has been reviewed by Rosegay (1981).
Transsphenoidal surgery alone, although less traumatic for the patient,
seldom cures the large pituitary tumour (Nabarro, 1982; Randall et al.,
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1983; Bevan et al., 1987b) and radiotherapy is frequently applied for
long-term tumour control.
Most would regard radiotherapy to be unsuitable as sole therapy for the
large pituitary tumour. Although tumour mass is reduced in the long-term
(Johnston et al., 1986) the effect is too slow for the patient
presenting with visual failure. With prolactinomas serum prolactin
concentrations take many years to fall and rarely reach normal (Gomez et
al., 1977; Kelly et al., 1978; Sheline, 1981; Grossman et al., 1984).
Furthermore, radiation-induced hypothalamic damage may lead to increased
prolactin secretion from the normal pituitary and make the serum
prolactin a poor marker of residual tumour volume (Shalet, 1981;
Johnston et al., 1986). Radiotherapy undoubtedly reduces the recurrence
rate after surgery (Sheline, 1981) but the possibility of eventual
hypopituitarism necessitates repeated endocrine evaluation (Shalet,
1981).
Conventional therapies have therefore a number of major disadvantages.
The first suggestion that bromocriptine might cause tumour regression of
prolactinomas as well as suppressing prolactin secretion came from a
number of case reports in the late 1970s (Corenblum et al., 1975;
Nillius et al., 1978, Landolt et al., 1 979, McGregor et al., 1979a).
These were followed by early prospective studies on larger groups of
patients (McGregor et al., 1979b; Wass et al., 1979, 1982; Chiodini et
al., 1981; Sobrinho et al., 1981; Prescott et al., 1982; Nissim et al.,
1982; Spark et al., 1982) which showed clear radiological evidence of
tumour shrinkage in over one half of macroprolactinoma patients treated
with dopamine agonists, usually bromocriptine. In a proportion of these
medically treated patients it was unclear whether hyperprolactinaemia
was due to tumour secretion or to hypothalamo-pituitary disconnection
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and a number of non-functioning tumours were probably misclassified as
"bromocriptine-resistant prolactinomas".
In tumours that were clearly prolactin-secreting bromocriptine-induced
tumour shrinkage frequently produced improvement in visual failure
(Chiodini et al., 1981). In contrast to the deleterious effects of
transcranial surgery and radiotherapy on anterior pituitary function,
dopamine agonist therapy occasionally produced improvement in pituitary
function (Prescott et al., 1982; Wass et al., 1982), probably due to
relief of pressure on the normal pituitary and to restoration of
hypothalamic control. In addition to bromocriptine a number of other
dopamine agonist drugs were shown to have a similar effect on
macroprolactinomas including lisuride (Chiodini et al., 1981), pergolide
(Kendall-Taylor et al., 1982) and, more recently, mesulergine (Grossman
et al., 1985a).
The effect of dopamine agonist therapy on the size of pituitary tumours
other than prolactinomas was unclear from these early studies. Some
reports suggested that a proportion of non-functioning tumours would
shrink during such therapy (Johnston et al., 1981; Spark et al., 1982;
Wolleson et al., 1982) whereas other workers described probable non¬
functioning tumours that had not regressed (McGregor et al., 1979b; Wass
et al., 1982). Similar uncertainty existed regarding growth hormone-
secreting tumours (Wass et al., 1982 and Spark et al., 1982 versus
McGregor et al., 1 97 9b).
In the early 1980s some authors were enthusiastically advocating
dopamine agonist therapy as the primary management of most patients with
large pituitary tumours (Spark et al., 1982; Lancet Editorial, 1982).
However uncertainties remained. The most important was whether dopamine
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agonist therapy alone provided a permanent cure or whether therapy, such
as surgery or radiotherapy, was required for long-term tumour control. A
related question was whether significant bromocriptine "resistance"
could emerge during long-term medical therapy. Furthermore it was
unclear whether tumour size reduction occurred in adenomas that were not
prolactin-secreting.
Eversmann et al (1979) demonstrated persistent lowering of prolactin
levels in some macroprolactinoma patients after withdrawal of long-term
bromocriptine. However serum prolactin concentrations rose in each case,
though not to pre-treatment levels, and the mean withdrawal period was
only 3 months. Several authors demonstrated prolactinoma re-expansion
after withdrawal of bromocriptine, in some cases given for as long as
one year (Thorner et al 1981; Nissim et al., 1982). More recent evidence
concerning the long-term efficacy of bromocriptine is discussed in
Chapters 6 and 10 and suggests that tumourous lactotrophs remain even
after seven years of bromocriptine treatment (Johnston et al., 1984).
Up to 30% of macroprolactinomas failed to shrink during dopamine agonist
therapy (Chiodini et al., 1981; Franks and Jacobs, 1983). The mechanism
of the failure was unclear since serum prolactin concentrations were
frequently reduced during therapy and the resistance extended to more
than one dopamine agonist (Chiodini et al., 1981). The occurrence of
"tumour escape" after initial tumour shrinkage with a dopamine agonist
drug appeared to be relatively unusual (Breidahl et al., 1983).
The balance of evidence suggested that additional therapy was required
for long-term control of large pituitary tumours after initial dopamine
agonist treatment. At the start of my work, there was little guidance on
the best type and timing of subsequent treatment. Some suggested that
radiotherapy was appropriate to avoid expensive and probably indefinite
1 2
treatment with bromocriptine (Edwards and Feek, 1981). However if
bromocriptine produced compact tumour shrinkage then it seemed possible
that the poor results of transsphenoidal surgery for larger tumours
might be improved by dopamine agonist pre-treatment. However
asymmetrical tumour shrinkage in some cases (Prescott et al., 1982)
raised the possibility that dopamine agonist therapy might produce a
more difficult surgical "target", though the literature provided no
information on the expected frequency of such shrinkage. There were also
few data on the time course of bromocriptine shrinkage; several reports
suggested rapid initial tumour regression (Thorner et al., 1981;
Chiodini et al., 1981; Nissim et al., 1982) but none described whether
this was a continuous process or whether maximum tumour shrinkage
occurred after a certain duration of dopamine agonist therapy. A
preliminary report suggested that previous bromocriptine therapy might
adversely influence surgery for prolactinomas (Landolt et al., 1982),
though the tumours described had not been specifically pre-treated in an
attempt to improve the surgical results.
The doses of bromocriptine in the early studies were highly variable and
ranged from 7.5 mg (Thorner et al., 1981) to 20 mg per day (Prescott et
al., 1982), and some workers used doses as high as 60 mg (Wolleson et
al., 1982; Wass et al., 1982). These very high doses frequently produce
if not taken during food,
side-effectsAwhich may have affected patient compliance.
The mechanism whereby bromocriptine produces pituitary tumour shrinkage
was unknown at the outset of these studies. The anti-mitotic action of
the drug had been known for some time (Lloyd et al, 1975), but in slow
growing human pituitary tumours it seemed an unlikely explanation for
the rapid tumour regression. Bromocriptine-induced tumour infarction was
another early explanation but patients treated with bromocriptine showed
improvement without clinical evidence of pituitary apoplexy, and this
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theory has not received support from subsequent histological studies
(Barrow et al., 1984; Esiri et al., 1986). A number of reports in 1982
suggested that tumour regression might be due to lactotroph cell size
reduction (Rengachary et al., 1982, Nissim et al., 1982, Tindall et al.,
1982). A remarkable feature was the apparent reversibility of this cell
shrinkage (Landolt et al., 1983) but the precise intracellular
mechanisms remained unclear and these will be further discussed at
various stages in the thesis.
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C. THE ENIGMA OF THE NON-FUNCTIONING TUMOUR
Approximately 25% of surgically removed pituitary adenomas are
unassociated with clinical or biochemical evidence of increased hormone
production (Asa and Kovacs, 1983) and this figure rises to around 70%
for large tumours causing visual failure (Teasdale, 1983). Some are
"clinically silent" adenomas in which immunocytochemistry shows positive
staining for one or more anterior pituitary hormones (Asa and Kovacs,
1983). A further group of tumours show significant oncocytic
transformation with most cells containing large numbers of abnormal
mitochondria (Roy, 1978). The significance of this phenomenon and the
functional capacity of the mitochondria is unknown. Kovacs et al (1980)
proposed the term null cell adenoma for tumours lacking immunostaining
for specific pituitary peptides or hormones; fifty-six tumours were so
classified out of a surgical series of 343 adenomas. Of these, 46 showed
completely negative immunostaining for anterior pituitary hormones and
their subunits. The remaining 10 showed scattered cells with positive
immunostaining for the glycoprotein hormones, alpha subunit or
prolactin.
Many null cell tumours may actually be poorly secreting rather than
completely non-secreting. Electron microscopic examination demonstrates
secretory granules in the majority, though these are rather smaller than
those present in the classical functioning adenomas (Kovacs et al.,
1980; Esiri et al., 1983). Furthermore, a secretory granule-specific
protein, chromogranin, is frequently identified in non-functioning
pituitary tumours (DeStephano et al., 1984). In cell culture, some
secrete pituitary hormones, most commonly gonadotrophins. However the
rate of secretion is low (Mashiter et al., 1981; Surmont et al., 1983)
and 25-50% do not secrete any known anterior pituitary hormone (Adams
and Mashiter, 1985).
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However it is far from proven that all of these tumours are derived from
gonadotroph cells. Firstly the gonadotrophin immunostaining, if present,
is invariably confined to scattered or small groups of cells, leaving
the identity of most of the cells unknown (Mashiter et al., 1981; Esiri
et al., 1983). Secondly the gonadotrophin contents are much lower than
those present in normal pituitary (De Marco et al., 1984b, Chapter 7 in
this thesis). Furthermore serum gonadotrophin concentrations are usually
within the normal range, although the differentiation of normal from
abnormal secretion may be difficult in a post-menopausal woman (Surmont
et al., 1983). Adenomas that are definitely gonadotrophin-secreting may
be distinguished from null cell adenomas by the presence of elevated
serum hormone concentrations and positive immunostaining in the majority
of tumour cells (Whitaker et al., 1985), ideally supported by in-vitro
secretion studies (Snyder et al., 1985).
The cell of origin of the non-functioning tumour remains an enigma.
Ultrastructurally identical cells have been identified in both non-
tumourous adenohypophysis and some functioning adenomas (Kovacs et al.,
1980). Whether they represent undifferentiated stem cells is unknown.
The presence of such cells in the normal human pituitary has yet to be
proved but animal experiments seem to support their existence. For
example, Shiino et al (1977) showed that Rathke pouches isolated from
rat foetuses and maintained in tissue culture or grafted into the
hypophysiotrophic area of the hypothalamus or under the kidney capsule
were capable of cytodifferentiation and pituitary hormone secretion.
Alternatively, null cells may be dedifferentiated mature cells in which
hormone synthesis is halted and some specific cell markers lost. There
is some experimental evidence which supports this phenomenon. Corenblum
et al (1977) showed that growth hormone cells undergo dedifferentiation
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in rats made hypothyroid with propylthiouracil. The GH cells lost their
granules and become unrecognisable morphologically, an effect which was
completely reversible when the antithyroid drug was withdrawn.
During pregnancy the percentage of lactotrophs in the anterior pituitary
increases from around 20% to approximately 50% (Asa and Kovacs, 1982).
It is unknown whether this occurs by lactotroph hyperplasia or by
differentiation of pluripotent stem cells, possibly the null cells.
In summary, the non-functioning tumour is interesting because its
tantalising resemblances to some normal anterior pituitary cells are
combined with apparent secretory inertia or silence. The responses of
cells from these tumours to hypothalamic releasing factors, dopamine and
bromocriptine are described in subsequent chapters.
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D. OBJECTIVES OF THE PRESENT STUDIES
1. Clinical objectives
The main clinical objectives were to investigate whether pre-operative
dopamine agonist therapy could improve the surgical outcome for patients
with large prolactin-secreting and non-functioning pituitary tumours and
to improve the diagnostic distinction between the two. I intended to
conduct a clinical trial of pre-operative bromocriptine in such
patients, with detailed clinical, biochemical and radiological
monitoring, in order to find the optimal dose and duration of therapy
prior to surgical intervention. As reviewed above, the response of non¬
functioning tumours to bromocriptine was unclear at the outset of these
studies so the usefulness of bromocriptine in patients with these
tumours was an important objective. Furthermore, the literature
suggested that perhaps 30% of prolactin-secreting macroadenomas exhibit
some degree of bromocriptine "resistance" in terms of tumour shrinkage
or prolactin suppression. I intended to examine the clinical
characteristics of such patients, and to correlate pre-operative
radiology and prolactin suppressibility with in-vitro tumour
characteristics, as detailed below, in an attempt to define the
mechanism of the "resistance". Eventual surgical treatment would ensure
that each tumour was accurately classified and possible disconnection
hyperprolactinaemia identified.
2. Laboratory objectives
The laboratory studies were linked with the clinical trial so that the
in-vitro characteristics of bromocriptine-responsive and non-responsive
tumours could be compared. A simple hypothesis to be tested was that
deficient or defective membrane-bound dopamine receptors might account
for the failure of some tumours to respond to dopamine agonist drugs. An
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important tool was therefore the validation of a radioreceptor binding
assay of sufficient sensitivity to measure dopamine receptors in the
relatively small amounts of tumour tissue obtained at surgery.
Parallel hormone secretion studies on the same tumours were to be
performed using a dynamic perifusion system. In the case of the non¬
functioning tumours the aim of such studies was to measure
gonadotrophins and alpha subunit as candidates for the secretory
product, if any, and to exclude prolactin secretion in patients with
pre-operative disconnection hyperprolactinaemia. For the prolactin-
secreting tumours, the objective was to compare dopamine and
bromocriptine dose responses for tumours responsive or non-responsive to
bromocriptine in-vivo. A comparison of in-vivo and in-vitro prolactin
responses to TRH in prolactinomas was also planned.
Since little was known of the mechanism of bromocriptine-induced
shrinkage, detailed immunocytochemical and electron microscopic studies
of the bromocriptine-treated tumours were to be performed, with
morphometric analysis of tumour cell size.
It was expected that the clinical studies would provide guidelines for
the use of dopamine agonist therapy in patients with pituitary
macroadenomas, and that recommendations could be made regarding the
nature and timing of subsequent therapy. I anticipated that the
laboratory studies would yield further insight into the cellular
mechanisms involved in tumour responses to bromocriptine and hoped to




CLINICAL STUDIES OF PROLACTINOMAS AND NON-FUNCTIONING TUMOURS
This chapter describes the clinical investigations and is in three
parts. The first is a comparison of serum prolactin concentration with
eventual histopathological diagnosis in patients referred as pituitary
adenomas, to find the diagnostic meaning of different prolactin levels.
The second examines the effectiveness of transsphenoidal surgery used as
primary treatment for patients with prolactinomas and non-functioning
tumours. The third describes the macroadenoma patients given pre¬
operative bromocriptine in a specific attempt to facilitate
transsphenoidal surgery.
The results of these studies have been recently published (Bevan et al.,
1987a, 1 987b).
A. SIGNIFICANCE OF THE SERUM PROLACTIN CONCENTRATION
1. Introduction
Any space occupying lesion in the pituitary region may disconnect
lactotroph cells in the anterior pituitary from hypothalamic inhibitory
control and lead to hyperprolactinaemia (Lundberg et al., 1981). Large
non-functioning tumours may masquerade as prolactinomas in this way
(Franks et al., 1977). Hence sellar enlargement associated with
hyperprolactinaemia is not always due to a prolactin-secreting pituitary
adenoma.
The distinction is of importance in view of the current widespread use
of dopamine agonists in the primary treatment of macroprolactinomas. If
the serum prolactin level is misinterpreted, inappropriate dopamine
agonist therapy may be given to patients with non-adenomatous pathology.
Furthermore, as will become apparent later in this thesis, dopamine
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agonist therapy may be given to patients with pituitary adenomas that do
not regress during such therapy.
This short section examines a series of 128 consecutive patients with a
definitive pathological diagnosis referred for treatment of a presumed
pituitary adenoma. It seeks to enable diagnostic interpretation of the
serum prolactin concentration in patients with fossa enlargement.
2. Patients
All patients referred to Oxford between 1979 and 1985 for treatment of
presumed pituitary tumour, without acromegaly or Cushing's syndrome,
were reviewed. Those with drug-related hyperprolactinaemia, primary
hypothyroidism or empty sellae diagnosed by computerised tomography were
excluded, as were patients with surgically proven microprolactinomas but
normal sellar radiology. This left 104 patients who had transsphenoidal
surgery and 25 who had transfrontal craniotomy, and in these a
definitive pathological diagnosis was made in all but one case. All had
enlargement of the pituitary fossa on plain radiographs and/or
extrasellar extension of the lesion.
3. Results
a. Non-adenomatous pathology
Fifteen of the 128 patients proved to have lesions other than pituitary
adenomas (Table 2-1). The commonest "pseudo-prolactinoma" was the
intrasellar craniopharyngioma. Serum prolactin concentration was raised
in 10 of the 13 patients in whom it was measured but in all except one
(of 5260) it was less than 2500 mU/L.
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Table 2-1: Noil adenomas




1 32 F Empty sella 210
2 9 F Dysgerminoma 340 diabetes insipidus
3 22 F Sterile abscess 550
4 67 M Adenocarcinoma
(unknown primary)
610
5 68 M Arachnoid cyst 6 90 CT diagnostic
6 36 F Empty sella 750 CT misleading
7 58 F Carcinoid 790 bronchial carcinoid ll
years previously.
8 61 F Lymphocyte
infiltrate




9 40 M Intrasellar
craniopharyngioma
1050 virtually normal foss,
size; anterior hypo¬
pituitarism.
10 59 F Aspergilloma 1200
11 50 M Meningioma 1500
12 24 F Intrasellar
craniopharyngioma
2250 diabetes insipidus
13 29 M II 5260
14 30 M If ND
15 36 M Chondrosarcoma ND calcification on xray






Plain fossa radiographs showed gross enlargement (>1500 mm ) in 12 of
the 15 patients but in cases 8 and 9 the combination of minimal fossa
enlargement and severe anterior pituitary failure made it likely that
the referral diagnosis of adenoma was incorrect. The dense calcification
in case 15 and the radiological appearances in case 5 also made a
diagnosis of pituitary adenoma unlikely. In the other 11 cases the plain
radiographs and computerised tomography were consistent with pituitary
adenoma, but in cases 2, 8 and 12 the presence of diabetes insipidus
suggested hypothalamic dysfunction rather than adenoma.
Four patients had received ineffective dopamine agonist therapy
elsewhere before referral in an attempt to shrink the presumed adenoma.
Visual failure had worsened in the patient with the meningioma during 4
months of pre-operative bromocriptine (Case 11). Since the above series
was reviewed a patient with a pilocytic astrocytoma has been operated
for deteriorating vision during inappropriate bromocriptine therapy
given elsewhere.
b. Pituitary adenomas
One hundred and thirteen patients had histologically proven pituitary
adenomas. Eighty-nine had preoperative serum prolactin concentrations
measured and these are shown in Figure 2-1. The tumours were subdivided
into four groups on the basis of immunocytochemistry as defined in the
legend to Figure 2-1.
All the prolactinomas had prolactin levels above 3200 mU/L. Macro-
prolactinomas (Group 3 as defined in section B.2) were associated with
prolactin levels between 3280 and 394000 mU/L. Mesoadenomas (Group 2)
produced prolactin levels between 3200 and 12180 mU/L.
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Figure 2—1: Pretreatment serum prolactin concentrations in
89 pituitary adenomas
Serum prolactin concentrations are plotted on a logarithmic scale.
Broken lines indicate upper limits of the normal laboratory range for
women (600 mU/L) and men (450 mU/L).
Open circles indicate minimum prolactin levels in samples not fully
diluted.
Immunostaining:
PRL = prolactin (positive in >90% cells)
NEG = immunostaining entirely negative
GT = gonadotrophin (positive for LH or FSH or both, but never in
>10% cells)
TSH = thyrotrophin (positive for TSH in 40% cells)
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In contrast, most tumours other than prolactinomas were associated with
prolactin levels below 3000 mU/L. However three patients with these
tumours had prolactin levels between 3000 and 8000 mU/L.
The magnitude of the prolactin responses to TRH did not distinguish
tumourous and non-tumourous hyperprolactinaemia (Figure 2-2). Both
groups of patients had grossly subnormal responses compared with normal
subjects who achieve peak prolactin concentrations of 6-7 times the
basal value following TRH (Cowden et al., 1979, Johnston et al., 1985).
Only one patient represented in Figure 2-2 achieved a peak prolactin
level of greater than 200% of the basal concentration. Furthermore, the
pattern of the TSH response to TRH did not define the patients with
disconnection hyperprolactinaemia, as recently suggested by Scanlon et
al (1986) - data not shown.
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Serum prolactin responses to 200 pg intravenous TRH in 38 patients with
large pituitary tumours. Values shown are mean +_ SEM.
A Non-functioning tumours with basal prolactin levels <600 mU/L
(343 +_ 35, mean +_ SEM, n=16)
B Non-functioning tumours with basal prolactin levels >600 mU/L
(1152 +_ 327, mean ± SEM, n=ll)
C Macroprolactinomas with basal prolactin levels in the range
3280-247000 mU/L (n=ll)
The results were analysed using the Mann-Whitney U test (statistical
significance was taken as P <0.05).
There was no difference between A and B at 20 or 60 minutes. Neither A
nor B was significantly different from C at 20 minutes, but each was
significantly higher than C at 60 minutes.
26
4. Conclusions
These patients clearly illustrate how difficult it is to fully interpret
a series of patients with sellar enlargement that have been medically
treated, in the absence of definitive pathology. For instance, 6 of the 7
bromocriptine-resistant prolactinomas described by Wass et al (1982)
may have been non-functioning tumours judging by the modest pre-treatment
prolactin levels.
The results suggest that a serum prolactin concentration greater than
8000 mU/L is always due to a prolactinoma. Twenty-seven of the adenomas
that did not immunostain for prolactin had elevated serum prolactin
concentrations, although these were generally below 3000 mU/L. An
adenoma of sufficient size to cause significant sellar enlargement
(>1500 mm ) but associated with a serum prolactin concentration of less
than 3000 mU/L is therefore most unlikely to be prolactin-secreting.
A "grey area" of overlap exists with prolactin levels between 3000 and
8000; the pituitary lesion may or may not be an adenoma and may or may
not be prolactin-secreting. Although modest fossa enlargement with a
prolactin level in this range is most likely to be due to a
mesoprolactinoma three patients with adenomas that did not immunostain
for prolactin had prolactin levels in the same range.
The prolactin response to TRH was unhelpful diagnostically. This is
consistent with the short loop positive feedback hypothesis whereby
increased circulating prolactin concentrations, of whatever cause, are
thought to increase hypothalamic dopamine release which, in turn, would
reduce TRH-induced prolactin release (Rodriguez-Arnao et al., 1983). As
will be seen in Chapter 6 most prolactinomas release prolactin in
response to TRH in-vitro but this can invariably be blocked by dopamine.
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The problem of the non-adenomatous lesion expanding the pituitary fossa
and causing disconnection hyperprolactinaemia is a potentially serious
one. These lesions are diverse as shown by Table 2-1 and primary
surgical biopsy is obviously desirable. The serum prolactin
concentration is usually less than 3000 mU/L though the occasional value
may fall into the above "grey area". Additional factors are often
important in the prediction of a non-adenomatous lesion. Computerised
tomography may give important clues with dense calcification and marked
cystic change being relative pointers to non adenomas. The presence of
diabetes insipidus strongly suggests hypothalamic and not primary
pituitary disease. Finally minor fossa enlargement associated with major
hypopituitarism is an unusual combination for a pituitary adenoma.
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B. RESULTS OF TRANSSPHENOIDAL SURGERY
1. Introduction
This section examines the Oxford experience in the use of
transsphenoidal surgery for the treatment of prolactinomas and non¬
functioning tumours. Factors affecting the surgical outcome in a large
series of 125 patients will be considered. Cure rates, relapses, effects
on anterior pituitary function and surgical complications for various
sub-groups of patients will be described and followed by a discussion of
the current indications for surgical treatment of these tumours.
2. Patients and methods
The series included 67 patients operated for prolactinoma and 58
patients operated for non-functioning tumour. Details of clinical
presentation are given below.
Pituitary fossa volumes were measured from plain skull radiographs by
the method of Lusted and Keats (1967), and supplemented by computerised
tomography (CT) and occasionally metrizamide cisternography. Invasion
was defined as radiological or surgical evidence of tumour in bone,
sphenoid sinus or cavernous sinus. When the surgical results were
analysed they were found to differ greatly in patients with surgical or
radiological evidence of invasion or if the fossa volume was greater
•j
than 1500 mm', and so three groups have been used.
Group 1 (normal plain radiographs, microadenomas) comprised tumours
•3
associated with fossa volumes of <900 mm , no evidence of invasion and a
suprasellar extension (SSE), if present, of less than 10 mm.
Group 2 (mesoadenomas) included tumours with fossa volumes between 900




Group 3 consisted of macroadenomas with fossa volumes >1500 mm and/or
evidence of invasion and/or >10 mm SSE.
All operations were performed by Mr CBT Adams (Radcliffe Infirmary,
Oxford) using a sublabial paraseptal approach. The visible amount of
normal pituitary remaining was carefully noted and biopsied if in doubt,
one of the objectives being to determine the functional validity of this
surgical assessment. If CSF was visible in the sella turcica or the
diaphragma sellae appeared incomplete the fossa and sphenoid sinus were
packed with fat and fascia taken from the thigh.
Tumour tissue was characterised by immunocytochemistry and electron
microscopy (Esiri et al., 1983) and this was supported by in-vitro
secretion studies on 30 tumours.
Pituitary function was assessed before and 3 to 7 weeks after surgery,
clinically and by the following tests: ACTH and GH function by peak
response to insulin hypoglycaemia (or glucagon if hypoglycaemia was
contraindicated), normal being Cortisol >550 nmol/L and GH >20 mU/L. TSH
function: normal serum total or free T4, irrespective of the TSH
response to TRH. Prolactin was considered normal if the mean of two
basal cannula samples was less than 700 mU/L in females (the highest
level at which menses and natural pregnancy occurred after operation,
and corresponding to the widened range of Davis et al., 1984), and 500
mU/L in males (the highest level shown by a patient with normal
testosterone and reproductive function after operation). Gonadotrophin
function in post-menopausal females was defined as normal if serum LH
was greater than 8 U/L irrespective of serum prolactin; in males it was
normal if plasma testosterone was normal (>14 nmol/L); and in
premenopausal females it was normal if there were regular menses or
pregnancy. Low testosterone in men, or amenorrhoea in women, associated
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with hyperprolactinaemia was recorded as unassessable gonadotrophin
function. The results of LHRH tests in all patients were not used as
evidence of gonadotrophin function.
3. Tumour presentation
The presenting features in the 125 patients are summarised in Table 2-2.
Group 1 and 2 prolactinoma patients were usually young women presenting
with menstrual disturbance associated with infertility. None of these
patients had significant impairment of anterior pituitary function at
presentation and there were only two men with small tumours.
However the largest prolactinomas occurred in men and frequently caused
visual failure. It was notable that even large prolactinomas were rarely
associated with significant impairment of ACTH or TSH function (7% of
Group 3 tumours).
Non-functioning tumours occurred in men and women with equal frequency
and patients were mostly in the sixth decade of life. Over 50% presented
with large tumours causing visual failure and one quarter were
associated with major pituitary hypofunction. In this older group of
patients infertility was seldom an issue though impotence in men was a
frequent clinical problem.
Nine patients with non-functioning tumours presented in more unusual
ways. Five presented with third or sixth nerve palsies and in four this
was caused by major tumour haemorrhage (Wakai et al., 1981). Two
patients with non-functioning tumours presented with pituitary abscesses
caused by bacteria presumed to have originated in air sinuses and upper
respiratory tract. Two women presented with galactorrhoea secondary to
disconnection hyperprolactinaemia.
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Table 2-2: Presenting symptoms in patients with prolactinomas
and non-functioning tumours
Number Mean Reproductive Symptoms of Pressure




Amen Gal Infert HA Visual
failur<
Women Group 1 24 31 85% 42% 83% 0 0 0
Group 2 13a 28 100% 38% 54% 0 0 0
Group 3 llb 29 91% 36% 18% 0 18% 9%
Men Group 1 0
Impot Gal Infert
Group 2 2 42 0 0 0




Women 26d 51 23% 15% 19% 65%





HA = major headache
a = 2 previous radiotherapy
b = 1 previous radiotherapy
c = 2 previous transfrontal surgery
d = 2 previous transfrontal surgery and radiotherapy
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4. Tumour cure rate
a. Cure of prolactinomas
Overall, serum PRL was reduced to normal ("biochemical cure") in 51% of
patients but this conceals large differences between subsets of
patients. Because there was strong correlation between fossa volume over
31500 mm , invasion and suprasellar extension over 10 mm Group 3 was
defined as possessing any of these features (including one tumour with
small sella volume and suprasellar extension of >10 mm), and in this
group the cure rate was 8 of 28 (29%). In patients with modest fossa
O
enlargement (900-1500 mm ) and no invasion (Group 2) the cure rate was
11 of 15 (73%) and in Group 1 (patients with fossa volumes less than 900
O
mm ) 16 of 24 (67%) were cured. Analysis of individual variables showed
the following. Twenty-seven of 40 patients (67%) with fossa volume less
3than 1500 mm were so cured, in contrast to 7 of 19 (37%) with larger
volumes without tumour invasion. Eight patients showed radiological or
surgical evidence of invasion and none was cured. These were all large
tumours, no evidence of invasion being found in the 40 tumours of fossa
O
volume below 1500 mm . Suprasellar extensions over 10 mm were present in
312 patients, 11 of them with fossa volumes over 1500 mm .
Surgical procedure: apparently complete but selective adenoma removal
leaving visible normal pituitary was possible in 22 patients with 16
O
(72%) being cured; and 20 of the 22 had fossa volumes below 1500 mm .
More radical surgery in 45 diffuse or invasive tumours of all sizes,
however, cured as many as 18 (40%).
Two patients showed later relapse. Of 11 Group 2 patients initially
cured and followed for 28.2 patient years (median 0.9, range 0.5-8.2)
one developed amenorrhoea and galactorrhoea at 3.1 years with a serum
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prolactin of 2400 mU/L. Of the 8 Group 3 patients initially cured and
followed for 6 patient years (median 1.1, range 0.3-2.6) one relapsed in
the third year (serum prolactin 1920 mU/L). Recurrent tumour was not
visible on CT scan in either of the two relapses. None of the 16 Group 1
patients initially cured has relapsed over 59.8 patient years of follow-
up (median 4.0, range 0.3-8.9).
The results for the three groups are shown in detail in Figure 2-3 and
summarised in Figure 2-4.
However biochemical cure of prolactin excess takes no account of
reproductive function. Of 19 men with prolactinomas only 1 was
biochemically cured and testosterone was subnormal post-operatively in
14. Of the 48 pre-menopausal women, two had been hysterectomised, 2 had
previous pituitary radiotherapy elsewhere, and one developed premature
menopause: in 6 others follow-up was incomplete. Twenty of the remaining
37 wished to become pregnant, and the results are shown in Figure 2-5.
Of the 17 not wishing pregnancy, 11 were cured of the
hyperprolactinaemia and 10 resumed normal menses.
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Figure 2-3: Serum prolactin concentrations before and after
surgery in 67 prolactinoma patients
Pre-operative and early post-operative serum prolactin concentrations
(logarithmic scale) in 67 patients operated for prolactinoma. Groups 1
defined in section B.2. Open circles indicate minimum prolactin levels
in samples not fully diluted. Broken line indicates 700 mU/L.
Figure 2-4: Reduction in serum prolactin concentrations
in the three prolactinoma groups
KEY
Normal >507° <507° reduction







~i 1 1 1 1
10 15 20 25 30
Number of patients




Figure 2-5: Pregnancies in women operated for prolactinoma
20desiring pregnancy
and followed > lyear
\i i r
Of the 20 women desiring pregnancy and followed for >1 year 14 were in
Group 1 , 4 in Group 2 and 2 in Group 3.
a Marked BC intolerance (2)
Unknown cause for infertility (1)
[Normal prolactin and menses during bromocriptine.
Normal LH responses to LHRH and clomiphene]
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b. Surgical results in non-functioning tumours
The lack of a chemical marker makes assessment of cure of non¬
functioning tumours a matter of recurrence rate on follow-up. Fifty-four
of the 58 were in Group 3; over half presented with visual failure and
severe headache was common (Table 2-2). Surgery improved visual failure
in 29 of the 33 who presented with it, to normal in 9. Headache was
relieved in all 10 patients in whom it was a major presenting symptom.
All 5 cranial nerve palsies resolved after tumour decompression.
Twenty-one patients were given radiotherapy to prevent recurrence,
especially if they were hypopituitary post-operatively. Thirty-two
patients, mostly with normal post-operative pituitary function, chose
biennial CT follow-up instead of radiotherapy, and 10 of these have been
followed in Oxford. Post-operatively all had sellae that were at least
30% empty on CT scan, and have been followed for 29.1 patient years
(median 2.1, range 1.0-6.4). The sellar contents have enlarged in two,
though remaining within the sella, and radiotherapy has been applied at
1.8 and 6.4 years respectively.
5. Effects of surgery on anterior pituitary function
a. Prolactinomas
ACTH, TSH and GH function before and after surgery for the three
prolactinoma groups is shown in Figure 2-6. Four patients required
corticosteroid replacement following surgery (one in Group 1, one in
Group 2 and two in Group 3) and two patients required thyroxine
replacement (one in Group 1 and one in Group 3). The reason for this was
obscure in the Group 1 and 2 patients since normal anterior pituitary
tissue was seen and preserved at the time of surgery in each case.
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Figure 2-6: Anterior pituitary function before and after surgery































For each hormone the left hand bar indicates the number of patients with
normal and impaired function preoperatively and the right hand bar the
corresponding number post-operatively. Only patients with pre- and post¬
operative data are included. Normal values are defined in section B.2.
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b. Non-functioning tumours
LH, GH, ACTH and TSH function before and after surgery is shown in
Figure 2-7. In contrast to the patients with prolactinomas no patient
operated for non-functioning tumour required corticosteroid or thyroxine
replacement as a consequence of the surgical intervention. However 25%
of patients with non-functioning tumours presented with ACTH or TSH
deficiency or both (Table 2-2). Several pre-operative hormone defects
were normalised by surgery; LH (4), GH (1), ACTH (5) and TSH (1).
Seventeen patients had elevated serum prolactin concentrations before
surgery presumably on a hypothalamo-pituitary disconnection basis
(Figure 2-7). Values up to 4350 mU/L were present in 14 of the 48
patients with non-functioning tumours and suprasellar extension over 10
mm, and was corrected by surgery in 10. Hyperprolactinaemia was present
in 3 of the 10 patients with suprasellar extension of less than 10 mm
and corrected by surgery in all. No patient acquired disconnection
hyperprolactinaemia as a result of surgery. The correction was not due
to complete restoration of normal control mechanisms since the post¬
operative prolactin response to TRH varied from absent to a 2.9 fold
increase.
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Figure 2-7: Anterior pituitary function before and after surgery
in patients operated for non-functioning tumour
Number of LH GH ACTH TSH PRL Number of
Same format as Figure 2-6
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6. Surgical complications
The surgical complications for both tumour groups are shown in Table 2-
3. The table includes the complications in bromocriptine-treated
macroprolactinomas and this will be referred to in section C.4.
Twelve of the 125 patients experienced transient diabetes insipidus;
this appeared rather commoner in the small tumours, and usually lasted
12-36 hours.
In two non-functioning tumour patients vision deteriorated after
surgery: one developed an intrasellar haematoma the day after surgery,
which was successfully evacuated transsphenoidally. In the second
patient, vision worsened 8 days post-operatively. There was no haematoma
and the (permanent) visual deterioration was presumed to be due to
vascular neural damage.
If the patients prospectively treated with bromocriptine and those with
temporary diabetes insipidus are excluded, 11 complications ensued in
108 patients of whom 71 had large tumours. The permanent sequelae of
surgery in non bromocriptine-treated patients comprised 3 cases of
permanent diabetes insipidus and the patient with visual loss described
above.
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Table 2-3: Surgical complications in patients operated for prolactinoma
and non-functioning tumour
Group 2 (15)
Diabetes insipidus CSF rhinorrhoea Miscellaneous
Trans Permanent Trans Operative
correction
PROLACTINOMAS


















(n=58) 21 1 Visual deter¬
ioration (2)c
a Transient diabetes insipidus requiring 1-3 pg DDAVP i.m.
b CSF rhinorrhoea requiring treatment with lumbar puncture-all resolved
within 6 days.
c Both cases described in text.





In common with other reports these data show that tumour size is a
predictor of surgical outcome for prolactinomas (Randall et al., 1983,
Fahlbusch et al., 1984, Scanlon et al., 1985 , Thomson et al., 1985). The
tumour groupings used in the above analysis, derived from fossa
measurements and computerised tomography, were useful in predicting the
likelihood of success from surgery alone. The early cure rate of 67% for
the Group 1 microprolactinomas was comparable to that reported in other
large transsphenoidal series (Fahlbusch et al., 1984, Thomson et al.,
1985). Group 3 were all macroadenomas of greater than 10 mm diameter and
surgery alone seldom resulted in normoprolactinaemia. The role of
surgery in the management of large prolactinomas will be considered in
greater detail in the next section.
An intermediate mesoadenoma grouping was useful (Group 2) because
although this group contained some tumours of greater than 10 mm
diameter it was associated with a 73% surgical cure rate. These results
confirm the findings of Scanlon et al (1985) who, although using a
different microsurgical approach, reported a high cure rate for similar
tumours between 10 and 19 mm in diameter.
What is the the current role of surgery for smaller prolactinomas ?
Management policies for patients with microprolactinomas have changed as
the benign natural history of this condition has become apparent. Long-
term follow-up indicates that presumed microprolactinomas seldom enlarge
and that serum prolactin concentrations remain constant over several
years or even decline (March et al., 1981; Rjosk et al., 1982; Martin et
al., 1985). Prolactin levels may remain suppressed for up to 5 years
after treatment of presumed microprolactinomas with bromocriptine,
particularly if pregnancy results (Hancock et al., 1985; Moriondo et
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al., 1985).
Figure 2-8 shows similar prolactin data obtained from 18 women with
presumed microprolactinomas followed in Oxford for longer than two years
(median 4.3 years, range 2.4-8.1 years). Thirteen women received interim
treatment with bromocriptine to restore reproductive function and
achieve pregnancy. No patient received bromocriptine for longer than 6
months and all but one patient, who had marked bromocriptine
intolerance, achieved pregnancy. During bromocriptine-induced
pregnancies serum prolactin concentrations rose no higher than 10,000
mU/L, though a similar prolactin increase during pregnancy may occur in
normal women (Woodhouse et al., 1985). On long-term follow-up serial
prolactin levels remained constant in 12 women and fell significantly in
6. Two women developed normoprolactinaemia following bromocriptine-
induced pregnancies.
The use of surgery for microprolactinomas has therefore declined.
However there are still patients with bromocriptine resistance or
intolerance who have a good chance of cure by selective adenomectomy.
The above results show that there is a small risk of endocrine
substitution therapy being required after such surgery, but no cured
patient has relapsed to date, the longest patient follow-up being 9.8
years.
The mesoadenoma is a more contentious issue. Presumably these are
tumours which, if left, would enlarge and develop into macroadenomas
(von Werder et al., 1983). The surgical results demonstrate that they
can be successfully treated by surgery, with little endocrine loss, and
a relapse rate similar to that found by Serri et al (1983) of up to 80%
at 5 years has not occurred (so far) in the Oxford series. Some would
advocate that women with tumours in this category should receive surgery
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Figure 2-8: Serum prolactin concentrations in 18 women
with presumed microprolactinomas
Serum prolactin concentrations at diagnosis and at latest follow-
up in 18 women with presumed microprolactinomas. No sample was
taken within 2 months of bromocriptine therapy.
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or radiotherapy prior to pregnancy, although the risk of tumour
expansion is low (Nillius and Bergh, 1984).
The results demonstrate that the management of non-functioning
tumours by transsphenoidal surgery was, in many ways, extremely
satisfactory. Tumour pressure effects were substantially improved
without significant endocrine penalty or peri-operative morbidity. This,
together with the frequent improvement in impaired anterior pituitary
function, enabled several patients to be followed without immediate
post-operative radiotherapy. Subsequent CT scans suggest the majority
may eventually need radiotherapy but its postponement in younger
patients with fertility needs has been advantageous. Other workers have
reported a similar improvement in impaired anterior pituitary function
after surgical decompression of non-functioning tumours (Arafah, 1986).
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C. MICROADENOMAS GIVEN PRE-OPERATIVE BROMOCRIPTINE
1. Introduction
It has been shown in the preceding section that transsphenoidal surgery
alone seldom cures large prolactinomas. The tumour-shrinking properties
of bromocriptine and other dopamine agonists have been reviewed in
Chapter 1. This section describes 15 patients with macroadenomas who
were given pre-operative bromocriptine in an attempt to facilitate
transsphenoidal surgery. In addition the study was designed to examine
the time course of tumour shrinkage and to provide guidelines on the
dose and duration of bromocriptine required. At the outset of this work
it was unclear whether non-functioning tumours regressed during dopamine
agonist therapy and although the management of non-functioning tumours
by primary transsphenoidal surgery was, in some respects, satisfactory
(section B) the effect of bromocriptine treatment on subsequent surgery
was investigated.
2. Patients and clinical methods
Fifteen patients with large pituitary tumours (7 prolactinomas and 8
non-functioning tumours) were studied. Anterior pituitary function
testing was performed as described in section B. Visual assessment
included Goldmann perimetry and was performed by an independent
optician. Neuroradiology involved 4th generation computerised tomography
with intravenous contrast.
Patients were randomised to either 10 or 20 mg bromocriptine daily and
commenced treatment with 2.5 mg daily, increasing the dose in 2.5 mg
increments every 2 days until the final dose was achieved. Goldmann
perimetry and computerised tomography were performed at intervals during
treatment and tumour volumes were calculated by planimetry (Breiman et
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al., 1982). Serial prolactin concentrations were measured during
treatment and pituitary function testing was repeated on at least one
occasion. Surgery was performed at various times during bromocriptine
therapy and the drug was continued to within 4 days of surgery in all
cases. Each patient gave informed consent to the bromoctiptine treatment
and the study was approved by the Central Oxford Research Ethics
Committee.
Table 2-4 gives the clinical, biochemical, radiological and
bromocriptine treatment details for each patient.
3. Clinical, biochemical and anatomical responses to bromocriptine
Serum prolactin concentrations and visual changes during bromocriptine
treatment in 5 patients with prolactinomas and 5 patients with non¬
functioning tumours presenting with visual failure are shown in Figure
2-9. Impaired vision in all 5 patients with prolactinomas started to
improve within one week of commencing bromocriptine and became
clinically normal within one month of treatment in 4 patients. Visual
improvement was associated with marked suppression of the greatly
elevated prolactin concentrations; four of the 5 patients attained
levels of less than 1000 mU/L. In one patient (P6 in Table 2-4) the
prolactin level remained above 10,000 mU/L throughout 20 weeks of
treatment. None of the 5 patients with non-functioning tumours showed
improvement in visual field loss during bromocriptine treatment. Serum
prolactin suppression in these patients presumably represented
inhibition of prolactin secretion from normal pituitary.
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Table 2-4: Details of macroadeiiomas given pre-operative bromocriptine
Sex/ BC-daily dose Pretreatment Height Visual status
Age and duration serum PRL + hormone of SSE and duration
(mU/L) deficiency (mm) (weeks)
PROLACTINOMAS
PI M 54 lOmg (3 weeks) 9100 GH 10 N
P2 M 27 lOmg (3 weeks) 394000 GH,TSH
ACTH
26 CS (6)
P3 M 31 lOmg (12 weeks) 300000 GH 28 HH (16)
P4 M 25 lOmg (12 weeks) 101000 GH 22 BH (4)




182000 Nil 0 N
P6 M 45 lOmg (20 weeks) 247000 GH 20 BH (4)
P7 M 45 20mg (36 weeks) 8880 GH 20 BH (12)
NON--FUNCTIONING TUMOURS
N1 F 43 lOmg (3 weeks) 2 820 GH, ACTH 15 BH (10)
N2 F 81 7 .5mg; (4 weeks)^ 770 GH 10 BH (6)
N3 F 54 lOmg (6 weeks) 1030 GH,TSH 10 BH (12)
N4 F 37 lOmg (12 weeks) 6 80 Nil 5-10 TH (32)
N5 F 39 20mg (24 weeks) 160 GH,TSH 16 BH (16)
N6 M 63 20mg (28 weeks) 400 GH, ACTH 5-10 N
N7 M 55 20mg (48 weeks) 260 GH 15 N







BC = bromocriptine, PRL = prolactin, SSE = suprasellar extension.
a Dose doubled since headache was not abolished on 10 mg daily,
b Failed to reach 10 mg because of bromocriptine intolerance,
c Dose doubled because there was no tumour regression on lower dose.
Anterior pituitary hormone deficiencies - see definitions and discussion
on p.30.
Visual status: N = normal, CS = central scotoma,
BH = bitemporal hemianopia, TH = temporal hemianopia,
HH = homonymous hemianopia
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Figure 2-9: Changes in serum prolactin and vision during bromocriptine





















Changes in serum prolactin concentration (logarithmic scale) and vision
during bromocriptine therapy in ten patients with large tumours causing
visual failure: 5 prolactinomas (left) and 5 non-functioning tumours
(right). Key to visual changes shown in figure. Normal vision indicates
normal Goldmann perimetry and visual acuities.
Only the prolactinomas shrank during bromocriptine therapy. Tumour
regression to approximately 50% of the original tumour volume occurred
in these tumours and maximum tumour shrinkage had taken place after 6
weeks of bromocriptine (Figure 2-10). In contrast none of the non¬
functioning tumours showed tumour regression. Three of the patients with
non-functioning tumours, but without visual failure, were treated with
20-40 mg bromocriptine daily for over 6 months without effect. In these
3 patients "therapeutic" steady-state plasma bromocriptine
concentrations of 2-5 nmol/L were demonstrated using the assay described
in Chapter 3.D.
Testosterone concentrations in two men with prolactinomas increased to
within the normal range but otherwise there was no improvement in
impaired anterior pituitary function in the 15 patients during
bromocriptine therapy.
The serum prolactin responses to 200 pg TRH or 2.5 mg bromocriptine
yielded no additional diagnostic information to the basal prolactin
concentration, and were unhelpful in predicting the likelihood of tumour
regression during bromocriptine treatment. The TRH responses for the 15
patients are included in Figure 2-2. In the prolactinoma patients serum
prolactin concentrations fell to between 14 and 44 % of the pre-
treatment values within 6 hours of the first 2.5 mg tablet of
bromocriptine (See Chapter 3.D). The serum prolactin concentrations in
the non-functioning tumour patients fell to less than 100 mU/L within 6-
12 hours of the same bromocriptine challenge.
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Figure 2-10: Changes in tumour volume during bromocriptine
Tumour volume changes during bromocriptine therapy in 15 patients with
large tumours: 7 prolactinomas (left) and 8 non-functioning tumours
(right).
53
4. Effects of bromocriptine on subsequent surgery
Bromocriptine therapy neither facilitated nor hindered surgery in non¬
functioning tumours. No alteration in tumour consistency was apparent at
operation and in 4 out of 5 patients visual failure was substantially
improved by surgery. There were no peri-operative complications in these
patient s.
In contrast, bromocriptine therapy of more than 10 weeks duration
severely hampered subsequent surgery of macroprolactinomas. There were
two main problems: asymmetrical tumour shrinkage and tumour fibrosis.
Asymmetrical shrinkage occurred in 4 of the 7 bromocriptine-treated
prolactinomas and in the most extreme case resulted in a virtually empty
sella, but with residual suprasellar tumour on one side which was
inaccessible via the transsphenoidal route. The irregular shrinkage of
these tumours therefore presented a much more difficult surgical
"target".
Bromocriptine-related fibrosis produced a tough tumour consistency which
made surgical removal extremely difficult. The degree of fibrosis and
the surgical difficulty increased with the duration of bromocriptine
treatment and was particularly severe in patients P3-P7 (see p.59).
Normoprolactinaemia was restored in only 1 prolactinoma patient (Pi) by
subsequent transsphenoidal surgery and this patient had received
bromocriptine for only 3 weeks (Figure 2-11). The prolactinoma fibrosis
was responsible for increased peri-operative morbidity in these
patients, 3 of the 7 suffering 5 major complications (Table 2-3). The
worst example was patient P7 who had received the highest bromocriptine
exposure pre-operatively (20 mg daily for 9 months). Despite
considerable tumour shrinkage there was still 15 mm suprasellar
extension and surgery was advised prior to radiotherapy. The fibrous















Serum prolactin concentrations in 7 patients with macroprolactinomas.
(1) At diagnosis and prior to bromocriptine, (2) Lowest value on
bromocriptine and prior to surgery, (3) Post-operation and off
bromocriptine, (4) Post-operation and during further bromocriptine
therapy (2.5-7.5 mg daily).
* = P7
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suprasellar extension could not be delivered into the fossa and the
patient developed fixed dilated pupils one hour later. Computerised
tomography showed diffuse tumour swelling and he underwent transfrontal
tumour removal. The tumour and surrounding brain were swollen and
removal of fibrous tumour was difficult. Following this the patient was
rendered panhypopituitary, developed a CSF leak requiring reoperation
and had severe permanent visual failure and dementia.
5. Pathology of bromocriptine-treated tumours
a. Introduction
At the outset of this work there were few reports of the pathological
changes in pituitary tumours exposed to bromocriptine (Rengachary et
al., 1982, Tindall et al., 1982). This sub-section describes the
immunocytochemical and electron microscopic appearances of the above
tumours. It also includes a quantitative study of the amount of fibrous
tissue present in bromocriptine-treated prolactinomas and non¬
functioning tumours. Two control groups of macroadenomas, matched for
tumour size, that had not been exposed to bromocriptine (8 prolactinomas
and 7 non-functioning tumours) were studied for comparison. A brief
discussion setting these findings in the context of the current
literature concludes this sub-section. The work has been recently
published (Esiri et al., 1986) and the pathology methods are included as
an Appendix.
b. Light microscopy and immunocytocheanistry
Prolactinomas that had not been exposed to bromocriptine all showed
uniform immunostaining for prolactin in greater than 90% of tumour
cells. By contrast prolactinomas from bromocriptine-treated patients
showed greatly reduced prolactin staining which was present in less than
20% of cells.
All non-functioning tumours were entirely negative for prolactin
immunostaining. Three of the non-functioning tumours from bromocriptine-
treated patients showed immuno staining for LH, FSH or both, though this
was confined to less than 10% of cells in each case. Gonadotrophin
staining was accompanied by immunostaining for alpha sub-unit in the
same cells. One tumour showed a small number of cells staining for alpha
sub-unit alone. Two of the control non-functioning tumours stained in
similar fashion for gonadotrophins. Bromocriptine treatment did not
appear to alter any of the light microscopic features in non-functioning
tumours.
c. Electron microscopy
Prolactinomas from bromocriptine-treated patients showed clear evidence
of cell size reduction at the electron microscopic level compared with
control tumours. There was a 54% reduction in total cell area after
bromocriptine, with decreases in both cytoplasmic and nuclear
components, particularly the former (Table 2-5). The cytoplasmic
shrinkage was mostly due to marked involution of the rough endoplasmic
reticulum and Golgi apparatus.
Bromocriptine produced no changes in non-functioning tumour cell
morphology at the ultrastructural level although this was not formally
quantified. Four control and five bromocriptine-treated non-functioning
tumours had significant oncocytic change (>10% tumour cells containing
an abundance of mitochondria).
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Table 2-5: Cell morphometry of macroprolactinomas from
bromocriptine-treated and untreated patients
Total cell Nucleus Cytoplasmic
area area area
BC-treated 0.1558+0.0106 0.0674+0.0051 0.0884+0.0072
(n=5)
Untreated 0.3355+0.0423 0.1182+0.0131 0.2173+0.0307
(n=4)
P value for 0.008 0.008 0.008
difference
2
Values are mean +_ SEM. Cell areas are given in mm
Statistical analysis was with the Mann-Whitney U test.
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d. Tumour fibrous tissue content
In view of the tough fibrous consistency of bromocriptine-treated
macroprolactinomas at operation the effect of bromocriptine exposure on
fibrous tissue content of prolactinomas and non-functioning tumours was
studied. Fibrous tissue content was measured using a point-counting
technique on tumour sections stained for reticulin (see Appendix). The
results are shown in Figure 2-12. Most untreated prolactinomas contained
very little fibrous tissue and the tumour area occupied by fibrous
tissue varied from 4-19%. Prolactinomas exposed to bromocriptine
contained a clear excess of fibrous tissue and after 12 weeks of
bromocriptine therapy all values for the proportion of tumour area
occupied by fibrous tissue lay above the range for untreated patients.
Furthermore there was a significant tendency for tumour fibrous tissue
content to increase with the duration of bromocriptine therapy (r =
0.82, P <0.005, Figure 2-12 [left]).
Non-functioning tumours from untreated patients contained similar
amounts of fibrous tissue to the control prolactinomas and the tumour
area occupied by fibrous tissue varied from 1-19%. In contrast to the
prolactinomas however there was no increase in fibrous tissue following
bromocriptine (Figure 2-12 [right]).
e. Discussion
The finding of markedly reduced prolactin immunostaining in cells from
bromocriptine-treated macroprolactinomas was in agreement with other
reports (Rengachary et al., 1 982 , Barrow et al., 1984, Gen et al.,
1984). However Bassetti et al (1984) found that prolactin immunostaining
was increased in some treated prolactinomas and speculated that in these
tumours bromocriptine was exerting a different net effect on prolactin
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The relationship of fibrous tissue to duration of pre-operative
bromocriptine treatment in patients with prolactinomas and non¬
functioning tumours.
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release and synthesis. These observations are of some relevance to the
mechanism of action of bromocriptine on the tumourous lactotroph and
will be discussed in more detail in Chapter 10.
The lactotroph cell size reduction described above confirms the findings
of other workers (Barrow et al., 1984, Bassetti et al., 1984). It seems
likely that this explains the striking shrinkage of macroprolactinomas
during bromocriptine therapy. It was intriguing that the size reduction
of individual lactotrophs of approximately 50% was similar to the
average percentage reduction in overall tumour volume (Figure 2-10).
There was certainly no gross cell necrosis in the bromocriptine-treated
tumours and this has also been the experience of most others (Tindall et
al., 1 982 , Barrow et al., 1 984, Bassetti et al., 1984), although Gen et
al (1984) described some cell necrosis in macroprolactinomas treated
with bromocriptine for 14-36 weeks.
Macroprolactinomas treated with bromocriptine for more than 3 months and
to within 4 days of surgery contained a clear excess of fibrous tissue.
These light microscopic findings complement the observations of Landolt
and Osterwalder (1984) who carried out a quantitative electron
microscopic study and found a significant increase in perivascular
fibrous tissue in 21 prolactinomas treated with bromocriptine for more
than 3 months. The tumours they studied were considerably smaller than
those described above, and bromocriptine was withdrawn for a
considerable time before surgery (several weeks to 5 years), which may
explain why they were unable to relate severity of fibrosis to duration
of treatment. In contrast, there was a strong correlation between
fibrosis and treatment duration in the macroprolactinomas presented
here. The findings of Landolt and Osterwalder (1984) suggest that there
is increased deposition of connective tissue, not simply collapse of the
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connective tissue stroma already present, to explain the increased
proportion of tumour occupied by connective tissue. This, they suggest,
is secondary to bromocriptine-induced cell size reduction. Certainly the
increase in fibrous tissue after bromocriptine treatment occurred only
in the macroprolactinomas and not in the non-functioning tumours, none
of which shrank during treatment.
6. Pre-operative bromocriptine: general conclusions
There have been few reports of specific bromocriptine pre-treatment of
macroprolactinomas in an attempt to facilitate subsequent surgery. Weiss
et al (1984) claimed that prior bromocriptine treatment of
macroprolactinomas improved the surgical results. However a proportion
of their 19 tumours given bromocriptine for 8-14 weeks probably fell
into my mesoadenoma grouping; only 3 of the 9 cured tumours had initial
serum prolactin levels greater than 10,000 mU/L although all had some
degree of extrasellar extension. There was no mention of adverse tumour
consistency in prolactinomas treated with bromocriptine for up to 14
weeks. Barrow et al (1984) reported that macroprolactinomas pre-treated
with bromocriptine for 6 weeks had a softer and more fluid tumour
consistency which facilitated removal by suction. In contrast, Fahlbusch
et al (1984) found that pre-operative bromocriptine for 2-3 weeks did
not improve the cure rate for macroprolactinomas and felt that even this
short treatment period led to a firm tumour consistency which increased
the surgical difficulty.
There is also controversy regarding the time course of prolactinoma
shrinkage during bromocriptine therapy. Weiss et al (1983) and Barrow et
al (1984) found that most tumour shrinkage had occurred after 6 weeks of
treatment. Others have demonstrated further tumour regression over
longer periods of time (Gen et al., 1984; Clayton et al., 1985; Molitch
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et al., 1985).
The above results provide clarification of these two issues. It is quite
clear that bromocriptine treatment of macroprolactinomas for longer than
10 weeks severely hampers subsequent surgery due to tumour fibrosis
producing a tough tumour consistency. The degree of fibrosis and
surgical difficulty were directly proportional to the duration of
therapy. In fact the bromocriptine trial in its original form was
discontinued after relatively few patients because it became rapidly
clear that prolonged bromocriptine treatment was so hampering to later
surgery as to be unethical. Furthermore sequential computerised
tomography showed that most tumour regression had occurred after 6-8
weeks of bromocriptine and little further anatomical gain accrued during
treatment for up to 32 weeks.
These results are important for the management of patients with
macroprolactinomas. At present there is still no convincing evidence
that bromocriptine therapy alone is curative. The infrequent occurrence
of major tumour re-expansion after short-term withdrawal of long-term
bromocriptine therapy (Johnston et al., 1984) is presumably due to
bromocriptine-related tumour fibrosis. The frequent reappearance of
significant hyperprolactinaemia under these circumstances suggests the
continuing presence of functioning tumourous lactotrophs and one would
expect tumour enlargement in the long-term. Most centres would therefore
advise additional therapy to bromocriptine in the form of radiotherapy,
surgery or both. The results presented in this chapter would suggest
that if surgery is to be performed on a bromocriptine-treated
macroprolactinoma then it is prudent to limit the duration of pre¬
operative bromocriptine therapy to 2-4 weeks; most anatomical advantage
has been gained and, even after this short period of treatment, early
tumour fibrosis may be present. If surgery is not wished, or if the
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tumour is clearly invasive, bromocriptine provides excellent
decompression of most macroprolactinomas as a prelude to definitive
radiotherapy.
The adverse effect of bromocriptine on surgery for prolactinoma appears
to be confined to the large tumours. Ten Group 1 and six Group 2
prolactinomas described in section B had been previously exposed to
bromocriptine, although this had been generally stopped more than 3
months prior to surgery. The surgical cure rates in these two sub-groups
of patients were 60% and 67% respectively, not significantly different
from the overall results for Groups 1 and 2.
Early reports suggested that a proportion of non-functioning tumours
would regress during long-term bromocriptine therapy (Johnston et al.,
1981, Wolleson et al., 1982). The above results, and those of others
(Verde et al., 1985; Zarate et al., 1985; Grossman et al., 1 985b; Pullan
et al., 1985), have shown that the major shrinkage commonly encountered
with prolactinomas is unlikely to occur with non-functioning tumours
even during prolonged therapy. Bromocriptine had no clinical or
pathological effects on these tumours and, at present, surgery remains
the treatment of choice.
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D. GENERAL CONCLUSIONS FROM THE CLINICAL STUDIES
The implications of these results for patient management are discussed
fully in the final chapter. This section presents the conclusions in
summary form before the thesis moves on to the laboratory studies.
1. Macroprolactinomas
A large pituitary lesion associated with a serum prolactin concentration
of greater than 5000 mU/L is likely to be a macroprolactinoma and
transsphenoidal surgery, although it relieves pressure effects, seldom
results in cure. Bromocriptine causes tumour regression of most
macroprolactinomas by reducing lactotroph cell size. Such shrinkage does
not however improve the poor surgical results because the regression is
frequently asymmetrical and prolonged treatment (>10 weeks) causes
tumour fibrosis, both of which make surgery more difficult. Maximum
shrinkage occurs after about six weeks of treatment. In most patients,
tumour decompression with bromocriptine is best followed by
radiotherapy. If surgery is required the duration of pre-operative
bromocriptine should probably be limited to one month.
2. Disconnection hyperprolactinaemia
A large variety of lesions in the pituitary region may disconnect the
anterior pituitary from hypothalamic inhibition and result in
hyperprolactinaemia, though the serum prolactin concentration is usually
less than 3000 mU/L. However four patients described above had higher
levels than this (maximum 8000 mU/L). Large pituitary lesions associated
with prolactin levels of less than 5000 mU/L are unlikely to be
prolactinomas and require surgery for diagnosis and decompression. The
prolactin responses to TRH do not differentiate between tumourous and
non-tumourous hyperprolactinaemia. Other features, such as diabetes
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insipidus, may point to a diagnosis other than pituitary adenoma.
3. Non-functioning tumours
Large non-functioning tumours may be associated with disconnection
hyperprolactinaemia up to 3000 mU/L (and exceptionally as high as 8000
mU/L). These tumours do not regress during dopamine agonist therapy,
even when high doses are used for several months. Bromocriptine does not
cause fibrosis of such tumours and neither hampers nor facilitates
surgery. The treatment of choice is transsphenoidal surgery which
relieves pressure effects, with little peri-operative morbidity, and
often produces some improvement in impaired anterior pituitary function.
Radiotherapy is indicated as an adjunct to surgery in most cases
although this may be delayed in selected patients who retain normal
pituitary function.
The studies raised a number of fundamental questions. Why do
prolactinomas and non-functioning tumours respond differently to
dopamine agonist therapy ? What is the mechanism of cell size reduction
in bromocriptine-treated macroprolactinomas ? What pituitary cell-type
is represented in the non-functioning tumour ? These and other questions
will be addressed in the following chapters which deal with laboratory
studies of bromocriptine-treated and untreated prolactinomas and non¬
functioning tumours.
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CHAPTER 3. LABORATORY METHODS I: IMMUNOASSAYS
This chapter describes the validation of the immunoassays. Firstly, the
prolactin radioimmunoassay is considered in some detail because of its
central importance to both the clinical studies in Chapter 2 and the
perifusion studies in Chapters 6 and 7. This is followed by a short
section summarising the methods for measuring growth hormone, TSH, FSH
and LH. Alpha subunit radioimmunoassay is then described in greater
detail to highlight some of the special problems of this assay. Lastly
125there is a section on the development of a novel I-based
radioimmunoassay for bromocriptine.
A. RADIOIMMUNOASSAY OF HUMAN PROLACTIN
1. Introduction
The relatively recent characterisation of this hormone and its
measurement by radioimmunoassay have been reviewed in Chapter 1. Monomer
prolactin is a single polypeptide of 198 amino acid residues and is
relatively easily radioiodinated. The radioimmunoassay described below
features a particularly robust separation step involving a solid phase
second antibody.
2. Materials
1. Buffer: Stock phosphate buffer (0.5 M) contained 57.4 g anhydrous
disodium hydrogen orthophosphate and 13.07 g anhydrous potassium
dihydrogen orthophosphate dissolved in 1 litre of deionised water.
Working buffer comprised 100 mL stock buffer, 5 g bovine serum albumin
(Fraction V, Sigma) and 1 g sodium azide made up to 1 litre with
deionised water (pH 7.4).
2. Standards: Human prolactin standard prepared from amniotic fluid and
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calibrated against IRP 75/504 was obtained from the Chelsea Hospital for
Women (London). The addition of 500 pL working buffer to each ampoule
produced a standard of 5600 mU/L. For the routine assay this was
serially diluted to give standards over the range 90 to 5600 mU/L.
3. Controls: Lyophilised human control sera (Diagnostic Products
Corporation, Los Angeles) were used in all assays since there was no
protein matrix effect in the prolactin assay when serum volumes of 100-
200 pL were used.
4. Antisera: Rabbit anti-human prolactin antiserum (PRL-001, Steranti
Research, St Albans, vial designated 500 tubes) was reconstituted in 0.5
mL deionised water and stored at -20°C. This was further diluted 1:60
with working buffer to produce a working antiserum dilution of
1:450,000. This solution was stable for at least 4 weeks at 4°C. Donkey
anti-rabbit antiserum coupled to cellulose beads (Sac-Cel, Wellcome
Diagnostics, Dartford) was used to separate antibody-bound label.
3. Prolactin iodination
A glass column (1.0 cm i.d.) was packed to a height of 14 cm with
Sephadex G-150 Superfine (Pharmacia, Sweden) and equilibrated with 0.05
M phosphate buffer (pH 7.4). The column was pre-run with 2.0 mL 10%
bovine serum albumin in 0.05 M phosphate buffer.
A 1 mg/mL solution of Iodo-Gen (Pierce and Warriner (UK) Ltd., Chester)
in dichloromethane was diluted 1:25 in dichloromethane. A 30 pL volume
was pipetted into a small glass vial and the solvent evaporated under a
stream of nitrogen. To the reaction vessel were added 10 pL 0.5 M
1 2S
phosphate buffer, 10 pL Na I (lmCi, Amersham International, Amersham,
Bucks) and 5 pg human prolactin (National Hormone and Pituitary Program,
Maryland, USA). The contents were mixed by gentle swirling and the
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reaction allowed to proceed at room temperature for 10 minutes, when 200
pL of 0.05 M phosphate buffer were added.
The total contents of the vial were then transferred to the Sephadex G-
150 column and eluted with 0.05 M phosphate buffer. Fractions of eight
drops were collected into plastic tubes (LP4, Luckhams, Sussex)
containing 100 pL 2% bovine serum albumin in 0.05 M phosphate buffer
containing a trace of thiomersal (BDH, Poole). The radioactivity in a 10
pL aliquot of each 500 pL fraction was counted. A typical elution
profile is shown in Figure 3-1 a. Fractions around peak B were pooled and
stored in aliquots at -20°C. For use in the assay radiolabel was diluted
in working buffer to produce about 200,000 cpm/mL (20,000 cpm per assay
tube). This dilute radiolabel was stable for at least 2 weeks at 4°C.
Each batch of prolactin radiolabel could be used for up to 3 months
during which time binding ([Bo~NSB]/T) fell from 50% to around 20%. A
typical repurification profile is shown in Figure 3—lb; binding using
peak b radiolabel was restored to around 50%. The shoulder (A) to peak B
following an iodination possibly represented prolactin aggregates; this
radiolabel bound more avidly to the prolactin antiserum than peak B
radiolabel but was not easily displaceable by non-radioactive prolactin
standard. The proportion of prolactin radiolabel in high molecular
weight form increased during storage.
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4. Assay procedure
Volumes of standards, controls and samples (100 pL) were pipetted, in
duplicate, into small plastic tubes (LP3, Luckhams). This was followed
by 100 pL radiolabel (20,000 cpm) and 100 pL of antiserum. Tubes were
vortex-mixed and incubated overnight at room temperature. The following
morning anti-rabbit Sac-Cel (100 pL) was added to each tube except those
for total counts and tubes were vortex-mixed and incubated at room
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Figure 3-1: Iodination of prolactin and repurification of radiolabel
Sephadex G-150 (Superfine) chromatography
Column: 14 x 1.0 cm. Eluting buffer: 0.05 M phosphate (pH 7.4)
(a) A typical elution profile following prolactin iodination.
Percent binding: A (prolactin aggregate ?) 73%, B (prolactin
monomer) 45%, C (free iodide) 0%.
(b) Repurification of prolactin radiolabel following storage at
-20°C for 13 weeks.
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temperature for 15 minutes. Finally 1.5 mL of 0.1% (v/v) Triton X-100
(BDH, Poole) in deionised water was added and the tubes centrifuged at
2000 g for 5 minutes. Supernatant fluid was aspirated and the Sac-Cel
pellet was counted for 1 minute on a multihead gamma counter
(Multigamma, LKB Ltd., Selsdon, Surrey). Percentage binding [100(B-
NSB)/(B0~NSB)] of standard samples was calculated and fitted to a spline
function; results of unknown samples were calculated automatically.
5. Assay validation
An antibody dilution curve of the anti-prolactin antiserum showed that a
final dilution of 1:1,350,000 gave 45% binding of tracer at zero dose
(Fig 3-2) and this dilution was used in all routine assays. Maximum
first antibody binding required overnight incubation at room temperature
(Fig 3-3a).
The volume of solid phase second antibody required to precipitate the
anti-prolactin antibody completely was investigated by the addition of
different volumes of undiluted Sac-Cel to zero dose and non-specific
binding tubes. Incubations were at room temperature, and overnight for
the first incubation between tracer and anti-prolactin antiserum and for
15 minutes with the Sac-Cel. For routine use a 100 pL volume of
undiluted Sac-Cel was used to precipitate the first antibody (Figure 3-
3b) .
The time required to attain equilibrium between anti-prolactin antiserum
and Sac-Cel (100 pL) at room temperature was about 5 minutes and 15
minutes was the time used in all assays (Figure 3-3c).
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Final antibody dilution ( K)
Solid circles indicate binding at zero dose and open circles the binding
in the presence of non-radiolabelled prolactin (16,000 mU/L). The final
antibody dilution was that present in a reaction volume of 300 pL.
72





















The effect of incubation time on binding of prolactin tracer to anti-
prolactin antiserum at zero dose (a); the effect of Sac-Cel volume on
zero dose binding (b); the effect of incubation time on second antibody
reaction at zero dose (c).
Non-specific binding was less than 2.5% for Sac-Cel volumes of lOOpL or
less.
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The standard curves were highly reproducible and between batch
coefficients of variation for serum controls were always less than 10%.
The within batch coefficient of variation was 3.8% at a prolactin
concentration of 500 mU/L. A set of consecutive assays performed over a
period of 8 weeks is represented in Figure 3-4.
The standard assay (section A.4) was satisfactory for measuring serum
prolactin concentrations and for most of the perifusion analyses.
However, as will be seen in Chapter 6, prolactinomas that had received
pre-operative bromocriptine secreted relatively little prolactin in-
vitro and a more sensitive assay was required. This was achieved by
increasing the sample volume and adding the radiolabelled prolactin
after an initial overnight incubation with first antibody alone. These
experiments are illustrated by Figure 3-5; a 200 pL sample volume
combined with a sequential incubation lowered the detection limit to 15
mU/L.
There was no protein matrix effect and serum samples or samples in
phosphate buffer or perifusion medium diluted parallel to the standard
curve. Crossreactivity studies were performed with other anterior
pituitary hormones and there was negligible antibody crossreactivity
(less than 5% displacement of prolactin tracer) with GH (200 mU/L,
acromegalic serum sample measured against the 4th UK working standard),
TSH (200 mU/L, MRC 68/38) and LH (50 IU/L, IRP 68/40).
Figure 3-4: Standard displacement curve for prolactin
loo n
O-1 , t 1
100 1000 10000
Prolacti n ( mll/L)
Eight consecutive prolactin assays performed with the same batch of
tracer over a period of 8 weeks. Binding of tracer ([B0~NSB]/T) was 48%
in the first assay and had fallen to 27% at 8 weeks. Values shown are
mean + SEM.
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Figure 3-5: Increasing the sensitivity of the prolactin assay
Prolactin (mU/L)
1.Sample volume: 100 pL
Incubation: Overnight anti-prolactin antiserum and tracer (•)
Overnight anti-prolactin antiserum alone followed
by a further 5 hours with tracer present (O)
2.Sample volume: 200 pL
Incubation: Overnight anti-prolactin antiserum and tracer (■)
Overnight anti-prolactin antiserum alone followed
by a further 5 hours with tracer present (□)
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6. Rapid prolactin assay
It will be obvious from Chapter 2 that the most crucial investigation in
determining the management of a patient with a large pituitary tumour is
the basal serum prolactin concentration. A simple assay was therefore
established to provide a rapid estimation of the serum prolactin level
in urgent patients with visual failure. The method was identical to that
described for the routine assay in section A.4 except that the
incubation was for 60 minutes at 37°C. Tubes were prepared in
singlicate; standards contained 0, 350, 700, 1400 and 2800 mU/L
prolactin and the unknown sample was assayed neat and at 1:10 and 1:100
dilutions. Tracer binding using label less than 6 weeks old averaged 21%
of total counts. Rapid prolactin reports were issued in the ranges shown
in Figure 3-6 which illustrates the excellent correlation with the
formal reports eventually provided by the routine immunoassay
laboratory. The rapid prolactin assay accurately predicted the 2
prolactinomas and prevented unnecessary bromocriptine therapy being
given to the remainder.
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< 350 350 700 700-1400 1400-2800 > 14000 > 70000
Rapid prolactin report (mU/L)
Comparison of rapid prolactin report with the actual prolactin value
eventually assigned to serum samples from 19 newly-presenting patients
with large pituitary tumours, 12 of whom had visual failure.
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B. RADIOIMMUNOASSAY OF OTHER ANTERIOR PITUITARY HORMONES
This section describes the materials and methods used for the
radioimmunoassay of growth hormone, TSH, FSH and LH in serum, perifusion
medium and tumour extracts. The methods have several similarities to the
prolactin assay and these common aspects will not be described in
detail.
Each assay used the working phosphate buffer described in the prolactin
method. None of the assays exhibited significant matrix effects except
that for growth hormone; the inclusion of 0.05% (v/v) Triton X-100 in
the buffer completely overcame this phenomenon. Each assay used a 100 pL
sample volume except for growth hormone where 50 pL was chosen.
Lyophilised human control sera (Diagnostic Products Corporation, Los
Angeles) were used in all assays. Each assay involved the addition of
100 pL diluted antiserum and 100 pL diluted radiolabel (20,000 cpm per
assay tube).
All the primary antisera had been raised in rabbits and the separation
step already described for the prolactin assay, employing solid phase
donkey anti-rabbit antiserum (Sac-Cel), was used in each method. All
between assay coefficients of variation were less than 10% and all
within assay coefficients of variation were less than 6%, at hormone
concentrations which produced approximately 50% displacement of tracer.
The following paragraphs give details of standard source, assay working
range, primary antiserum, radiolabel and incubation procedure for each
assay.
1. Growth hormone
1. Standard: 4th UK Working Standard (EQAS, Edinburgh)
2. Working range: 0.6-40 mU/L
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3. Primary antiserum: Rabbit anti-HGH (6B) was supplied by R.Bacon
(EQAS, Edinburgh). Final dilution 1:125,000.
1254. Radiolabel: I-HGH was produced in the laboratory using
identical methodology to that described for prolactin (section A.3).
Five pg of highly purified HGH (Boehringer Mannheim, Lewes) was the
iodination substrate.
5. Incubation: Overnight with primary antiserum followed by 3 hours with
label.
2. TSH
1. Standard: MRC 68/38 (NIBSC)
2. Working range: 1.6-100 mU/L
3. Primary antiserum: Rabbit anti-TSH (Lot No.1112) was obtained from
Radioimmunoassay Ltd (Cardiff). Final dilution 1:45,000.
1254. Radiolabel: I-TSH was produced in the laboratory using the
methodology of section A.3. Five pg of highly purified TSH (Flow
Laboratories Ltd, Rickmansworth) was the iodination substrate.
5. Incubation: Four hours with primary antiserum followed by overnight
incubation with label.
3. FSH
1. Standard: A lyophilised preparation of IRP 78/549 (40 mlU/vial)
was obtained from the Chelsea Hospital for Women (London)
2. Working range: 0.6-40 IU/L
. Primary antiserum: Rabbit anti-human FSH was obtained from Cambridge
Medical Diagnostics (CMD) Inc. (Mass, USA). Final dilution was
1:30,000.
1 9S
. Radiolabel: I-FSH was obtained from CMD.




1. Standard: A lyophilised preparation of IRP 68/40 (50 mlU/vial) was
obtained from the Chelsea Hospital for Women (London).
2. Working range: 1.6-50 IU/L
3. Primary antiserum: Rabbit anti-human LH was obtained from CMD.
Final dilution was 1:300,000.
4. Radiolabel: ^^I-LH was obtained from CMD.
5. Incubation: Overnight with primary antiserum followed by 6 hours with
label.
5. Crossreactivity studies
These studies were hampered by the relative impurity of some of the
international reference preparations of pituitary hormones, notably the
glycoprotein hormones TSH, FSH and, to a lesser extent, LH. IRP 78/549
(FSH) also contains LH, TSH and HGH, and MRC 6 8/3 8 (TSH) contains
significant amounts of FSH and LH. Patient samples containing
pathologically high levels of pituitary hormones were therefore used in
some experiments to determine crossreactivity.
Table 3-1 summarises the results of the crossreactivity studies.
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Table 3—1: Crossreactivity of pituitary hormone antisera
(A) Crossreactivities in the PRL, HGH, TSH and FSH assays
Hormone assay
PRL HGH TSH FSH
Test Hormone
PRLa (mU/L) - 50,000 100,000 50,000
HGHb (mU/L) 200 - 100 60
TSHC (mU/L) 200 600 - 25d
FSHe (ng/mL) ND ND 6.3 -
LHf (IU/L) 50 200 200 100
Alpha (ng/mL)
subunit®
ND ND 80 22
Table (A) shows the maximum hormone concentration producing negligible
crossreactivity (<5% displacement of tracer binding).








Table (B) shows the percentage crossreactivities calculated on a weight
basis.
KEY
a = Prolactinoma patient sample (186,000 mU/L against IRP 75/504)
b = Acromegalic patient sample (204 mU/L against 4th Working Std)
c = MRC 68/38
d = Sample from hypothyroid prepubertal boy (180 mU/L against MRC
6 8/3 8)
e = NIBSC research preparation of highly purified FSH (83/575)
f = IRP 6 8/40
g = NIADDK standard (National Hormone and Pituitary Program, USA)
ND = not done
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C. RADIOIMMUNOASSAY OF ALPHA SUBUNIT
1. Introduction
The glycoprotein hormones TSH, FSH, LH and chorionic gonadotrophin
comprise an alpha and beta subunit (Saxena and Rathnam., 1971). The beta
subunit is unique to each hormone and confers specificity of biological
action. In contrast, the alpha subunits of the four hormones are
virtually identical (Vaitukaitis et al., 1976). Alpha subunit consists
of 89 amino acid residues together with polysaccharide side-chains and
has an approximate molecular weight of 14700 daltons (Keutmann et al.,
1978)
Alpha subunit has been demonstrated in a number of different types of
pituitary adenoma. Those which secrete gonadotrophins usually secrete
alpha subunit in addition (Snyder et al., 1980) and some apparently
functionless pituitary adenomas produce alpha subunit alone (Ridgeway et
al., 1981). The presence of an increased serum alpha subunit/TSH molar
ratio in a patient with inappropriate secretion of TSH favours a
diagnosis of TSH-secreting pituitary tumour rather than thyrotroph
hyperplasia (Faglia, 1984). Beck-Peccoz et al (1986) showed that alpha
subunit was secreted by a sub-group of growth hormone-secreting
pituitary adenomas.
The following section describes the validation of a radioimmunoassay for
alpha subunit used for measurement in serum, perifusion medium and
tumour extracts.
2. Alpha subunit iodination
A glass column (1.0 cm i.d.) was packed to a height of 27 cm with
Sephadex G-100 Superfine (Pharmacia, Sweden) and equilibrated with 0.05
M phosphate buffer (pH 7.4). The column was pre-run with 2.0 mL 10%
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bovine serum albumin in 0.05 M phosphate buffer.
Twenty pL 0.5 M phosphate buffer and 2 pg (10 pL) FSH alpha subunit
(Batch 2, NIADDK, National Hormone and Pituitary Program, USA) were
IOC
dispensed into a small polythene vial and mixed. 10 pL of Na I (1 mCi,
Amersham International) was then added. The reaction was started with 10
pL of Chloramine T (2.0 mg/mL, Sigma) and allowed to proceed for 20 s at
room temperature. The iodination was terminated with a 100 pL volume of
sodium metabisulphite solution (1.0 mg/mL, BDH, Poole).
The total contents of the vial were then transferred to the Sephadex G-
100 column and eluted with 0.05 M phosphate buffer. Fractions of eight
drops were collected in plastic tubes containing 100 pL 2% bovine serum
albumin in 0.05 M phosphate buffer containing a trace of thiomersal. A
typical elution profile is shown in Figure 3-7. Peak c presumably
represented monomeric alpha subunit since this was the only peak which
showed radiolabel binding to the alpha subunit antiserum (Figure 3-7,
inset). Peaks a and b probably represented aggregates of alpha subunit
and peak d free iodide. Peak c radiolabel was stored in aliquots at
-20°C and could be used for up to 3 months. A gel filtration column of
at least 20 cm in length was required to reveal peak c containing the
125monomeric I-alpha subunit.
3. Assay validation
The antibody dilution curve of anti-alpha subunit antiserum showed that
a final dilution of 1:120,000 gave 55% binding of tracer at zero dose
(Figure 3-7) and final dilutions of 1:120,000-1:160,000 were used in all
assays. The separation step with solid phase second antibody was
identical to that described for the prolactin method. The buffer used
was the working phosphate buffer previously described supplemented with
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Figure 3-7: Iodination of alpha subunit and antibody dilution curves
Sephadex G-100 (Superfine) chromatography following alpha subunit
iodination. Column 27 x 1.0 cm. Eluting buffer: 0.05 M phosphate (pH
7.A)
Inset figure shows antibody dilution curves for the four iodination
peaks. 100 pL diluted rabbit anti-FSH alpha subunit (Batch 1, NIADDK)
was incubated overnight with 100 pL diluted radiolabel (20,000 cpm).
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0.05% (v/v) Triton X-100. The surfactant was necessary to overcome the
matrix effects observed when high alpha subunit concentrations in tissue
extracts were measured. This was probably due to alpha subunit
aggregation, a phenomenon possibly suggested by the gel filtration
profile following an iodination (Figure 3-7).
The effects of sample volume and incubation conditions on the standard
displacement curve were investigated and Figure 3-8 illustrates two sets
of conditions, one optimised for serum measurements and the other for
tissue extract measurements. Crossreactivity studies were performed with
other pituitary glycoprotein hormones and on a weight basis the
following crossreactivities were obtained; TSH (0.8%, MRC 68/38), FSH
(6.6%, NIBSC 83/575), and LH (10%, IRP 68/40). These values were similar
to those reported by other authors using alpha subunit assays based on
NIADDK materials (Ridgeway et al., 1981; Surmont et al., 1983).
86
















Alpha sub-unit ( ng/mL)
(•) Sample volume 100 pL.
Overnight incubation with primary antiserum and tracer.
Working range 0.6-40 ng/mL.
Suitable for tissue content measurement.
(O) Sample volume 200 pL.
Overnight incubation with primary antiserum alone followed
by a further 5 hours with tracer present.
Working range 0.2-10 ng/mL.
Suitable for serum measurement.
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4. Serum alpha subunit concentrations
Serum alpha subunit concentrations were measured in a group of euthyroid
control subjects and compared with those in postmenopausal women and
patients with primary hypothyroidism to establish normal and
pathological reference ranges. Several patients with non-functioning
pituitary tumours were also investigated. The results are shown in
Figure 3-9 and were in good agreement with previously published data
(Ridgeway et al., 1981, Faglia et al., 1984). The non-functioning
tumours from the two patients with serum levels above 6 ng/mL contained
a number of cells which immunostained for both alpha subunit and FSH.
Three non-functioning tumours in which a minority of cells immunostained
for alpha subunit alone were removed from patients with normal serum
alpha subunit levels. In these patients alpha subunit was not a reliable
tumour marker. Two patients with TSH-secreting macroadenomas had
elevated alpha subunit levels (4.5 and 10.4 ng/mL) as will be discussed
in Chapter 9.
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Confidence limits, where marked, indicate the 95% level.
Euthyroid controls (n=13) TSH <5 mU/L
(8 women, 5 men, age 38.1 ±5.4 years [Mean ± SEM])
Primary hypothyroidism (n=14) TSH >40 mU/L
(10 women, 4 men, age 69.9 ± 4.8 years [Mean ± SEM])
Open circles indicate 6 women who were, in addition, post¬
menopausal .
Post-menopausal euthyroid women (n=14) FSH >40 IU/L
(age 50.4 ±2.3 years [Mean ± SEM])
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D. RADIOIMMUNOASSAY OF BROMOCRIPTINE
1. Introduction
The opportunity to develop a radioimmunoassay for bromocriptine arose
125from my attempts to produce an I-labelled radioligand to improve the
sensitivity of the pituitary membrane dopamine receptor assay as will be
further discussed in Chapter 5. Some aspects of the chemistry of
bromocriptine and its relation to the compound's pharmacological
properties have been covered in Chapter 1. The structural formulae of
bromocriptine and two other dopamine agonists relevant to this section
are shown in Figure 3-10.
An assay capable of measuring therapeutic concentrations of
bromocriptine in plasma has to be exquisitely sensitive. Plasma
concentrations of bromocriptine are low due to the small therapeutic
dose required and the high hepatic extraction ratio and extensive
metabolism of the drug (Maurer et al., 1983). Early pharmacokinetic
studies on the drug were limited to sensitive but nonspecific methods
involving the administration of radiolabelled drug (Aellig et al.,
1977). The development of antibodies which recognized the intact, and
metabolically labile, tripeptide portion of the molecule led to the
development of specific radioimmunoassays for bromocriptine (Schran et
al., 1979, Rosenthaler et al., 1983). All radioimmunoassays described to
date have employed ergopeptines labelled with tritium and as a
consequence have lacked the convenience, precision and sensitivity of
12 5the method to be described which employs iodine.
125 •
This section describes the production of a I-labelled derivative of
dihydroergocriptine and its use in a rapid and sensitive
radioimmunoassay which employed a specific antiserum directed against
the tripeptide moiety of bromocriptine. The method was used to measure
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Figure 3-10: Structural formulae of bromocriptine, dihydroergocriptine
and pergolide
Ergopeptines ri r2 r3
Bromocriptine ch(ch3)2 ch2ch(ch3)2 Br
Dihydroergocriptine ch(ch3)2 ch2ch(ch3)2 h
Ergoline
Pergolide ch2sch3 ch2ch2ch3 h
Dihydroergocriptine and pergolide are reduced at the 9-10 double bond.
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plasma bromocriptine concentrations following the oral administration of
2.5 mg bromocriptine to patients with pituitary tumours. Chapter 8
describes the further use of this assay in the measurement of
bromocriptine in pituitary tumour extracts. The method has been recently
published (Bevan et al., 1986).
2. Materials
1.Buffer: Assay buffer comprised 13.23 g citric acid and 10.51 g
anhydrous disodium hydrogen orthophosphate per litre, pH 3.9, and
contained 0.1% (w/v) sodium azide as preservative.
2.Standards: 2-bromo-a-ergocriptine methane sulphonate (bromocriptine)
was a gift from Sandoz Ltd, Basle, Switzerland. Bromocriptine was
initially dissolved in acidified ethanol and subsequently diluted in
pooled normal plasma to produce a stock standard of 100 nmol/L which was
stored in aliquots at -20°C for up to 2 months. For each assay an
aliquot was diluted in plasma to provide standard solutions over the
range 0.08-5.0 nmol/L.
3.Controls: Controls were prepared in drug free plasma in the range 0.2-
2.5 nmol/L and stored at -20°C in aliquots of 0.25 mL.
4.Antisera: Sheep anti-bromocriptine antiserum was a gift from
Dr.J.Rosenthaler of Sandoz Ltd, Basle, Switzerland. The conjugation
schedule involved linking bromocriptine to bovine serum albumin via the
indole nitrogen at position 1 (Figure 3-10). Lyophilised antiserum was
reconstituted in assay buffer to give a stock dilution of 1:1,600 which
showed no loss of binding after at least 5 freeze-thaw cycles. Stock
antiserum was further diluted in assay buffer to give a working dilution
of 1:40,000 which was stable for at least 2 weeks at 4°C.
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Donkey anti-sheep/goat antiserum coupled to cellulose beads (Sac-Cel,
Wellcome Diagnostics, Dartford) was used to separate antibody-bound
label.
3. Iodination and radiolabel
Dihydro-a-ergocriptine methane sulphonate [DHE] (gift from Sandoz Ltd,
Basle, Switzerland) was used as the substrate for this reaction. Its
structure is identical to bromocriptine except for the presence of a
hydrogen atom in place of the bromine at position 2 in the ergoline
moiety, and reduction of the 9-10 double bond (Figure 3-10).
Deionised water (70 pL) and 5 pg DHE (10 pL of a 500 pg/mL solution in
ethanol/water [1:9 v/v]) were dispensed into a small polythene vial and
1 o c
mixed. 10 pL of Na I (1 mCi, Amersham International, Amersham, Bucks)
was then added. The reaction was started with 10 pL of Chloramine T (0.5
mg/mL) and allowed to proceed for 2 minutes at room temperature. The
iodination was terminated with a 50 pL volume of sodium metabisulphite
solution (0.5 mg/mL). Experiments to optimise the iodination procedure
125 •
showed that no further -t^Ji was incorporated by incubating with
Chloramine T for longer than 2 minutes. Various concentrations of
Chloramine T were investigated and 5 pg was found to be optimal for the
iodination of 5 pg DHE and thin layer chromatography showed that




In the early experiments I-radiolabelled dihydroergocriptine ( I-
DHE) was separated from free iodide using Bio-Gel P2 (200-400 mesh, Bio-
Rad Laboratories, Richmond, California) gel filtration. The eluting
buffer was 0.05 M phosphate buffer (pH 7.4) and the inclusion of 0.5%
(v/v) Triton X-100 was essential to prevent non-specific adsorption of
the ^"'i-DHE to the column. ^-'i-DHE was thus obtained for initial
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evaluation of a suitable bonded silica extraction column for the direct
and convenient separation of the iodination reaction products. These
1 2Sstudies will not be described in detail but in summary 90% of an I-
DHE load could be recovered from a phenyl-substituted silica Bond-Elut
cartridge (Analytichem International, California) using 2 mL ethanol.
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I-DHE bound strongly to a C-18 substituted Bond-Elut and equivalent
recovery into ethanol was only 39%.
The following procedure was used to separate the products of DHE
iodination. A phenyl-substituted Bond-Elut was primed with 2 mL methanol
followed by 4 mL deionised water. The contents of the iodination vial
were then transferred to the top of the cartridge, together with two
reaction vial washings with 0.5 mL deionised water. This volume of
approximately 1.2 mL was forced through the cartridge under positive
pressure (fraction 1). Four washes each of 1 mL of deionised water were
similarly passed through and collected as separate fractions. Finally
four washes of 1 mL ethanol were applied and collected as separate
fractions. Figure 3-lla shows the radioactivity recovered in each
fraction during the initial Bond-Elut extraction to remove unreacted
iodide. Iodine incorporation of 45% suggested a minimum specific
activity for the radiolabel of 250 Ci/mmol.
A 10 pL aliquot of each fraction was diluted into 1 mL of assay buffer
and the radioactivity counted. The first ethanol fraction (fraction 6)
was evaporated to dryness under a stream of nitrogen at a temperature of
60°C. The unreacted DHE and ^^I-DHE were then taken up into 100 pL of a
9:1 mixture of chloroform and methanol and transferred to a bonded
silica column (Sepralyte, 40 pm particle size, Analytichem) for
IOC
separation of the I-DHE. The column was 14 cm in length (bed volume
2.8 mL) and equilibrated with 9:1 chloroform/methanol. Fractions were
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Typical Bond-Elut (phenyl) separation of unreacted iodide
(aqueous) from ^^I-DHE (ethanol).
125Silica gel chromatogram: solid circles show I-DHE
elution profile following an iodination, open circles show
a separate experiment, under identical conditions, with
eluted cold DHE detected by UV spectroscopy.
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collected every 1.5 minutes (250 pL approximately) and the eluted
1 2S
radioactivity counted. Clear separation of DHE from the I-DHE using
silica column chromatography is shown in Figure 3-1 lb.
Peak fractions were pooled and dried down under a stream of nitrogen at
room temperature. The radiolabel was then taken up in 250 pL ethanol and
stored protected from light and under nitrogen, in a silanised glass
vial at -20°C. The complete iodination procedure took approximately one
hour.
For use in the radioimmunoassay radiolabel was diluted in assay buffer
to produce about 300,000 cpm/mL (30,000 cpm/assay tube). The diluted
radiolabel was placed in a silanised vial protected from light.
Thin layer radiochromatography of the radiolabel was performed on silica
gel plates (silica gel 60, Merck, Darmstadt) using two different solvent
systems: (a) chloroformrmethanol (9:1, v/v) (b) chloroform:ethanol:
glacial acetic acid (9:5:1, by volume). Marker spots of bromocriptine
and dihydroergocriptine were visualised using 4-
dimethylaminobenzaldehyde (HC1).
125
The I-DHE proved to be stable when stored as described above; no
breakdown could be demonstrated using thin layer radiochromatography
after 8 months storage at -20°C (Figure 3-12). In each solvent system it
travelled as a single peak of radioactivity, close to bromocriptine. In
chloroform/methanol (9:1) the ^^I-DHE peak had an Rf of 0.59, ahead of
DHE (Rf 0.48) and just behind bromocriptine (R^ 0.65). Radiolabel
performance in the radioimmunoassay was limited only by the half-life of
125 I and it could be used for at least 3 months without significant
deterioration in the radioimmunoassay.
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DHE BC Solvent front
Distance travel led (cm)
Thin layer radiochromatography of ^I-DHE (2 pL stock) stored for
1 day (a) and 8 months (b).
Solvent: Chloroform/methanol (9:1).
Run time: 45 minutes




In common with bromocriptine and dihydroergocriptine, the I-DHE
showed a marked tendency to adsorb onto glass and plastic surfaces.
Aqueous solutions could, however, be diluted without losses if silanised
glass was used. Furthermore there were no losses on dilution in glass
and plastic containers if plasma was present. Identical standard curves
were generated in plastic, glass or silanised glass tubes provided 100
uL of plasma per tube was present.
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A second potential problem was photosensitivity of the I-DHE; if
diluted radiolabel were exposed to light at room temperature its
antibody-binding ability declined at a rate of 1.8 % per hour.
Protection from light reduced this to 0.4 % per hour. In practice,
provided tracer solutions were made up fresh for each assay,
photosensitivity was not a problem.
4. Assay procedure
Volumes of standards, controls and samples (100 pL) were pipetted, in
duplicate, into small plastic tubes (LP3, Luckhams) followed by 100 pL
of antiserum (1:40,000 dilution). Tubes were vortex-mixed and incubated
at room temperature for 30 minutes. Then 100 pL of radiolabel was added
and the tubes were vortex-mixed and incubated at room temperature for a
further 30 minutes. Anti-sheep/goat Sac-Cel (lOOpL) was added to each
tube except those for total counts and tubes were mixed and incubated at
room temperature for 15 minutes. Finally 1.5 mL of 0.1% (v/v) Triton X-
100 in deionised water was added and the tubes centrifuged at 2000 g for
5 minutes. Supernatant fluid was aspirated and the Sac-Cel pellet was
counted for 1 minute on a multihead gamma counter. Percentage binding
[100(B-NSB)/(Bq-NSB)] of standard samples was calculated and fitted to a




An antibody dilution curve of the anti-bromocriptine antiserum showed
that a working dilution of 1:40,000 gave 50% binding of the radiolabel
at zero dose, in the presence of 100 pL of plasma. This was equivalent
to a final 1:120,000 dilution in the assay. First antibody equilibrium
was reached after 20-40 minutes incubation at room temperature (Figure
3-13a)
The volume of solid phase second antibody required to precipitate the
anti-bromocriptine antiserum completely was investigated by the addition
of different volumes of undiluted Sac-Cel to zero dose and non-specific
binding tubes, in the presence of 100 pL of plasma. Incubations were at
room temperature, and for 30 minutes for the first incubation between
radiolabel and anti-bromocriptine antiserum and for 15 minutes with the
Sac-Cel. For routine use a 100 pL volume of undiluted Sac-Cel was used
to precipitate the first antibody (Figure 3-13b). The time required to
attain equilibrium between anti-bromocriptine antiserum and Sac-Cel (100
pL) at room temperature was about 5 minutes (Figure 3-13c)
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The effect of incubation time on binding of I-DHE to bromocriptine
antiserum at zero dose (a); the effect of Sac-Cel volume on zero dose
binding (b); the effect of incubation time on second antibody reaction
at zero dose (c).
Non-specific binding was less than 4% for Sac-Cel volumes of 100 pL or
less.
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The working range of the assay was established by altering the sample
volume and 100 pL was chosen for routine use, giving 50% displacement at
approximately 1.0 nmol/L bromocriptine (Figure 3-14). The detection limit
with this sample volume was 0.05 nmol/L, the bromocriptine concentration
corresponding to 2.5 times the standard deviation of percent antibody-
binding in the zero standard. Recovery of bromocriptine added to plasma
ranged between 93 and 113% (104.9 +_ 2.4, mean +_ SEM, n=8).
When neutral buffers were used, direct addition of plasma resulted in
falsely elevated apparent bromocriptine concentrations, which did not
dilute parallel to the standard curve. This plasma effect was greatly
reduced by using acid buffer but standard curves in buffer and plasma
were still not identical. Attempts to remove this residual matrix effect
using low concentrations of surfactant (0.01% Triton X-100), methanol or
a variety of blocking agents, including the ergoline pergolide, were
unsuccessful and denatured the anti-bromocriptine antibody. For these
reasons standard curves were generated in normal pooled plasma. Inter-
patient variation in non-specific binding was small (range 4.5-6.0%)
relative to total binding, so it was unnecessary to use a patient's pre-
treatment plasma to construct the standard curve for that patient's
samples as has proved necessary in most of the tritium based assays
(Thorner et al., 1980).
The standard curves were highly reproducible and between batch
coefficients of variation for bromocriptine controls were less than 10%.
The within batch coefficient of variation was 3.4% at a bromocriptine
concentration of 1 nmol/L.
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Figure 3-14: Standard displacement curve for bromocriptine
0.01 "in" 1.0 10.0
B romoc ripti ne ( nmol ID
Sample volume: 100 pL
Eight consecutive bromocriptine assays performed with the same batch of
tracer over a period of 4 weeks. Binding of tracer was 55% in the first
assay and 44% in the final assay.
Values shown are mean + SEM.
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6. Crossreactivity
The specificity of the anti-bromocriptine antibody has been extensively
investigated by Sandoz Ltd and it is directed against the intact
tricyclic peptide moiety of the bromocriptine molecule (Rosenthaler et
al., 1983). In a limited number of experiments using the present assay
DHE produced a displacement curve identical to bromocriptine itself.
Pergolide (Lilly, Surrey), an ergoline of similar structure to the
lysergic acid moiety of bromocriptine but without the tricyclic peptide
(Figure 3-10) showed no crossreactivity at concentrations up to 10
pmol/L.
7. Measurement of bromocriptine in plasma
Twelve patients with large pituitary tumours were studied and
immunocytochemistry of the resected adenomas showed that 8 were
prolactin-secreting, 1 was thyrotrophin-secreting, and 3 were non¬
functioning. An indwelling intravenous cannula was inserted into a
forearm vein and, after basal samples were taken at 0900 hours, one 2.5
mg tablet of bromocriptine was administered with a light snack of 2
sandwiches and a glass of milk. Blood was collected for bromocriptine
and prolactin estimation at 0, 1, 2, 3, 6, 12 and 24 hours. Samples for
bromocriptine estimation were placed into lithium heparin tubes and the
plasma separated within 2 hours and stored at -20°C until analysis. This
acute bromocriptine suppression test was the prelude to a course of pre¬
operative bromocriptine therapy in 7 of the 12 patients.
Plasma bromocriptine concentrations in the 12 patients following 2.5 mg
orally are shown in Figure 3-15. The mean peak concentration was 0.51 _+
0.07 (SEM) nmol/L and mean time to peak concentration was 2.3 +_ 0.2
(SEM) hours.
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Figure 3-15: Plasma bromocriptine concentrations
Plasma bromocriptine concentrations in 12 patients with large pituitary
tumours given 2.5 mg bromocriptine orally.
Values shown are mean + SEM
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In prolactinoma patients serum prolactin concentrations fell
dramatically at, or just after, the time of the bromocriptine peak
(Figure 3-16). Lowest prolactin levels were obtained 6 hours after
bromocriptine was given. Prolactin levels rose towards pre-treatment
values again at 12 to 24 hours, when bromocriptine concentrations fell
below 0.15 nmol/L.
8. Discussion
The combination of iodine radiolabel and specific bromocriptine
antiserum produced a specific radioimmunoassay for measuring plasma
bromocriptine concentrations of greater simplicity, precision and
sensitivity than previous radioimmunoassays employing tritium.
Ergot peptide alkaloids are extensively metabolised in the liver with
hydroxylation at the 8'-position (Figure 3-10) forming the probable
first metabolic step (Rosenthaler et al., 1983). This is followed by
further hydroxylation at the 9'-position, eventually resulting in ring
opening at C-8' to produce a glutamic acid derivative of the molecule.
These metabolites of bromocriptine do not possess the biological actions
of the parent molecule as evidenced by the discrepancy between the
duration of action on prolactin secretion (usually complete in 12-14
hours after a small oral dose) and the long second-phase elimination
half-life found in radiolabelled drug disposition studies (up to 50
hours following a 1 mg dose, Aellig et al., 1977).
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Figure 3-16: Serum prolactin and plasma bromocriptine concentrations
following acute dosing
Serum prolactin and plasma bromocriptine concentrations in 8
prolactinoma patients given 2.5 mg bromocriptine orally
Pre-treatment basal prolactin levels varied between 2,240 and
196,000 mU/L.
Values shown are mean + SEM.
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It is important therefore to use an antiserum which recognizes the
intact tripeptide moiety in pharmacokinetic studies of bromocriptine.
This will be essential when examining plasma bromocriptine levels
following slow-release formulations that have been developed (Landolt et
al., 1984; Benker et al., 1 986; Grossman et al., 1986). The antiserum
used in this assay had been raised with these criteria in mind, the
conjugate being produced by linkage through the indole nitrogen at
position 1 in the ergoline moiety. The 8'-hydroxyl derivative of
bromocriptine showed 0.005% crossreactivity in a tritium based
bromocriptine radioimmunoassay using the same antiserum (Rosenthaler et
al., 1983). The plasma bromocriptine concentration profiles obtained in
this study after 2.5 mg bromocriptine orally are broadly similar to
those obtained by Thorner et al (1980) using a comparable protocol and a
tritium assay employing a similar tripeptide specific antiserum.
The product of DHE iodination was not identified but the binding results
would suggest that the iodine had been incorporated into the ergoline
portion of the molecule as predicted theoretically. An apparently
identical product was formed from DHE, as judged by thin layer
radiochromatography, using Iodo-Gen or N-bromosuccinimide iodination
125 • •
techniques. The stability of I-DHE on storage, its high specific
activity compared with most tritiated ergopeptines (Schran et al., 1979)
and the ease with which it could be made were all attractive features of
the new radiolabel.
Two sequential incubations, firstly with antiserum and secondly with
radiolabel, increased the sensitivity of this assay three-fold, compared
with the simultaneous addition of antiserum and radiolabel. The method
could be used to detect as little as 0.05 nmol/L of bromocriptine using
100 pL of plasma; this represents 5 fmol/assay tube. It could be
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sensitised further by the use of a 200 pL sample volume, if desired,
without increasing non-specific binding excessively. Using a tritiated
radiolabel a previous bromocriptine radioimmunoassay required a 500 pL
sample volume to achieve a detection limit of 0.23 nmol/L (Rosenthaler
et al., 1983).
The assay had additional advantages in terms of precision and
convenience. A typical tritium assay used to measure patient samples had
between and within assay coefficients of variation of 21 and 13%
respectively (Thorner et al., 1980). All variabilities in the present
assay were <10%. This was probably due mainly to the robust nature of
Sac-Cel second antibody separations compared to more temperamental
charcoal methods (Moore, 1985). Undoubtedly gamma counting, rather than
beta counting using liquid scintillation, would also have contributed to
the improved precision. The method had high throughput and the total
turnaround time for a batch containing 50 unknowns was approximately 2.5
hours.
The marked tendency of ergot peptide alkaloids to bind to glass/plastic
surfaces and plasma proteins was investigated with particular care. The
dilution of bromocriptine standards in plasma to avoid losses was found
to be of critical importance. The choice of acid buffer greatly reduced
tracer binding to plasma proteins. Antibody binding was thereby enhanced
and the inclusion of gelatin to protect the antibody at low pH was
unnecessary. The situation was analogous to the use of low pH buffer to
prevent the binding of Cortisol to transcortin (Rolleri et al., 1976)
but in this present assay, buffer and plasma standard curves did not
become superimposable. The use of the surfactant Triton X-100 overcame a
similar problem in the radioimmunoassay of buprenorphine (Hand et al.,
1986); for bromocriptine, however, concentrations of Triton X-100 as low
as 0.01% simply inhibited tracer binding to antibody. In view of its
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structural similarities to the ergoline moiety of bromocriptine the use
of pergolide (10 pmol/L) as a blocking agent was attempted but with no
success.
Finally standard curves were made in plasma. Tritium methods, although
frequently developed using a normal plasma pool to construct standard
curves (Schran et al., 1979), in practice, when used to measure patient
samples, have to use pre-treatment plasma from a patient to make a
standard curve for the measurement of that patient's samples (Thorner et
al., 1980). A major advantage of the new assay was that, provided plasma
samples had been stored frozen for less than 2 months, interpatient
variation in non-specific binding was so low relative to antibody-bound
counts that several patients' samples could be measured against the same
standard curve made in normal pooled plasma.
In trials of pituitary tumour shrinkage with bromocriptine it is
important to be able to demonstrate that a patient whose tumour has not
regressed is actually taking the drug, which in high doses not
infrequently produces side-effects. The three non-functioning tumours in
this study showed no tumour shrinkage after bromocriptine therapy (20-40
mg daily) despite plasma bromocriptine concentrations of 2 to 5 nmol/L
(See Chapter 2.C.3).
109
CHAPTER 4. LABORATORY METHODS II: TUMOUR CELL PERIFUSION
This chapter describes the validation of a tumour cell perifusion system
which was used to characterise hormone secretion by pituitary tumour
cells and to investigate the effects of a variety of physiological and
pharmacological agents on hormone release.
A. INTRODUCTION
1. Purpose of the perifusion studies
The initial purpose was to examine the secretory behaviour of pituitary
tumours specifically pre-treated with bromocriptine before surgery, and
to correlate the results with in-vivo bromocriptine responsiveness. It
was hoped to study any macroprolactinomas that had proved resistant to
bromocriptine in-vivo in terms of lack of tumour shrinkage, failure of
prolactin to suppress or both. The aim was to examine the dose
responsiveness of such tumours to dopamine and bromocriptine and compare
the results with tumours fully responsive to bromocriptine in-vivo and
also those not given pre-operative bromocriptine. As will be seen these
aims were only partly realised, largely because of the unexpected
deleterious effects of bromocriptine on subsequent surgery for
macroprolactinomas that have been described in Chapter 2. Furthermore
most of the prolactinomas studied were responsive to bromocriptine.
A second aim was to characterise secretory products, if any, from non¬
functioning tumours, particularly those that had been exposed to pre¬
operative bromocriptine. In tumours secreting gonadotrophins or their
sub-units the effects of dopamine, TRH and LHRH on secretion were to be
studied. An important aim was to exclude prolactin secretion by large
tumours associated with mild hyperprolactinaemia when the latter was
presumed to be on the basis of hypothalamo-pituitary disconnection.
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Since prolactinomas seldom respond to TRH in-vivo (Chapter 2.A.3) I
wished to examine the responsiveness of prolactinoma cells to TRH in-
vitro and to investigate whether dopamine could inhibit such a response.
If this were the case it would provide further evidence consistent with
the presence of increased hypothalamic dopaminergic tone in patients
with hyperprolactinaemia.
A critical factor in the choice of method for the secretion studies was
the relatively small amount of human tissue obtained at surgery,
particularly as I wished to conserve as much as possible for dopamine
receptor measurements on the same tumours.
2. Previous studies
Since the early 1970s there have been numerous reports concerning the
regulation of pituitary hormone secretion in animal pituitary tissues,
particularly from the rat, and, more recently, in human pituitary
tumours. A variety of techniques have been used including short-term
incubation of cells (Prysor-Jones et al., 1981), hemipituitaries (Shaar
and Clemens et al., 1974) or tissue fragments (Peillon et al., 1983),
long-term cell culture (Adams et al., 1979) and perifusion of cells
(Lowry et al., 1974) or tissue fragments (Lawton et al., 1981). Each
system has advantages and disadvantages as will be discussed.
Dispersed cell preparations require enzymatic treatment which may alter
the secretory responsiveness of the cells (MacLeod and Cronin, 1983) and
destroys the intercellular junctions between pituitary cells which are
probably of importance in the local paracrine control of secretion
(Denef, 1986). Cronin and Weiner (1979) showed that pronase treatment
reduced the dopaminergic binding of [ H]spiperone to bovine pituitary
membranes. Furthermore enzyme dispersal is relatively expensive in terms
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of the amount of pituitary tissue required to produce an adequate cell
yield.
During long-term cell culture hormone secretion frequently decreases and
cellular responsiveness to various stimuli may change with time.
Furthermore the duration of exposure to various stimuli is frequently
non-physiological or non-pharmacological (Surmont et al., 1983; Adams et
al., 1979).
With static incubation of cells, hemipituitaries or fragments secretory
products accumulate in the medium and may themselves have feedback
effects. Hemipituitaries particularly may suffer from poor diffusion of
substances into and out of cells which are not in direct contact with
the incubation medium and this may lead to cell necrosis as discussed by
Lowry et al., 1974. Continuous perifusion of pituitary cells suspended
on an inert matrix was first described by Lowry et al (1974) and
obviates a number of these problems. The use of small tissue fragments
in a similar system avoids the need for enzyme treatment and does not
result in internal cell necrosis (see below). Dieguez et al (1984)
described a method for culturing anterior pituitary cells within
artificial capillaries in a system which although technically
complicated exhibited the advantages of both cell culture and
perifusion.
Perifusion techniques have been criticised on a number of grounds.
Firstly, several investigators have not used control columns to exclude
the possibility of declining secretion rates due to poor cell viability.
This is particularly important when examining the inhibitory effects of
compounds such dopamine or bromocriptine (Yeo et al., 197 9; Delitala et
al., 1980). Secondly, tumour tissue obtained at surgery is occasionally
contaminated with normal anterior pituitary. None of the reports
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describing tumour perifusions mention this as a potential problem
(Lawton et al., 1981; Bression et al., 1 982; Chihara et al., 1984) or
describe any methods to identify normal pituitary on column. These two
factors have been assessed critically in the validation of the
perifusion system to be described.
Although some researchers have correlated in-vivo dynamic tests with in-
vitro secretory responses (Chihara et al., 1984) there have been no
reports, to the best of my knowledge, comparing dynamic tests and tumour
shrinkage of adenomas specifically pre-treated with dopamine agonists
with the in-vitro secretory characteristics of the tumour cells.
Furthermore although non-functioning tumours have been studied in cell
culture (Mashiter et al., 1981; Surmont et al., 1983) there have been no
reports of such tumours studied in a dynamic perifusion system. The
following studies also describe some unique experiments in which
pituitary tumour and normal anterior pituitary from the same patient




Fragments of pituitary adenoma were collected at the time of
transsphenoidal surgery and placed immediately into 10 mL of sterile
perifusion medium supplemented with 5 pM dopamine at room temperature.
The basic perifusion medium was Earle's balanced salt solution (EBS,
Gibco Ltd, Paisley) containing human albumin (0.2%, w/v, salt poor
fraction, Blood Products Laboratory, Elstree, Herts), penicillin (30
pg/mL, Glaxo Laboratories Ltd, Greenford) and streptomycin (50 pg/mL,
Evans Medical Ltd, Beaconsfield) and gassed with 95% oxygen and 5%
carbon dioxide. Solutions of dopamine hydrochloride were protected from
oxidation by the inclusion of ascorbic acid (100 mg/L) after Delitala
et al (1980).
a. Dispersed cells
Early experiments were performed on enzyme-dispersed tumour cells using
the general approach of Yeo et al., (1979). In brief, pituitary adenoma
tissue was cut into small fragments and placed in a Teflon dispersal
apparatus with 5 mL of EBS containing dopamine (5 pM) and trypsin (2.5
mg/mL, Worthington Bioc. Corp., New Jersey, USA). The medium was gassed
and maintained at 37°C. The stirring paddle was driven at 200 rpm and
four or five 15-minute harvests were pooled and spun at 800 rpm for 40
minutes. The cells were resuspended in 1.0 mL EBS, filtered through 100
micron gauze and counted using a haemocytometer. Pre-swollen Bio-Gel P2
was then added and the cell columns prepared as described below (1-3 x
10^ cells per column). The initial perifusate contained lima bean
trypsin inhibitor (1.0 mg/mL, Worthington).
Trypsin dispersal was abandoned for several reasons. Firstly,
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particularly from bromocriptine-treated macroprolactinomas, there was
sometimes less than 100 mg tissue available. This would have been
insufficient for enzyme dispersal but was sufficient for four fragment
columns. Secondly, tumours did not digest uniformly; some were resistant
to digestion, and this would certainly have been a problem with the
fibrosed prolactinomas, whereas others digested excessively with loss of
tumour tissue. Lastly, although >95% dispersed cells excluded trypan
blue in most cell preparations there were some tumours whose cells
exhibited blebs and other deformities when examined at the light
microscopic level and hormone release progressively declined throughout
the perifusion. Other workers have dispersed tumour cells using
mechanical means, for example, repeated trituration through a Pasteur
pipette (Peillon et al., 1983); in my experience this resulted in 40-50%
cells being unable to exclude trypan blue. There were other reasons why
tumour fragments were finally chosen and these will be described below.
b. Tumour fragments
Adenoma tissue was distributed to weighed 5 mL sterile plastic tubes
each containing 1.0 mL gassed EBS with dopamine (5 pM). The tubes were
reweighed and the tumour weights calculated. The tissue for each column
*5
was diced into small fragments (1 mm ) using a sterile scalpel and mixed
with 0.5 g pre-swollen Bio-Gel P2. Up to four tumour fragment columns
for each tumour were then prepared.
The following figures give an indication of the amount of tissue used
per column; untreated prolactinomas (32.9 _+ 3.0 mg, mean ± SEM, n=16),
bromocriptine-treated prolactinomas (35.5 _+ 5.4 mg, n=13), non¬
functioning tumours (110.3 +_ 5.6 mg, n=l 8) and periadenomatous pituitary
(13.2 +_ 5.9 mg, n=4)
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2. Perifusion apparatus
Cell columns were prepared by a modification of the methods of Lowry et
al (1974) and Yeo et al (1979). A cell column and the complete
perifusion system are shown in Figure 4-1.
The columns were constructed from disposable polystyrene 2 mL syringes
(Gillette UK Ltd, Isleworth, Middlesex). A 21 gauge disposable needle
was inserted through the septum of the plunger and broken off flush with
the surface. The surface of the plunger was covered with 20 micron nylon
gauze and the needle connected to a polythene exit line (0.5 mm i.d.).
Cells or tumour fragments were mixed with Bio-Gel P2 (200-400 mesh, Bio-
Rad Laboratories, Richmond, CA, USA) which had been swollen overnight in
sterile saline and equilibrated with perifusion medium on the day of the
experiment; each column contained 0.5 g gel. The tumour-gel mixture was
drawn into the perifusion chamber which was connected, nozzle uppermost,
to the perifusion apparatus. The cells and Bio-Gel were packed down
under the flow of perifusion medium. When this was complete the syringe
was disconnected and the plunger raised so that only 0.1 mL of liquid
remained between the top of the gel and the syringe nozzle. The syringe
was then reconnected and placed in a water bath at 37°C.
Using an eight-channel peristaltic pump up to four columns were perfused
with medium which was debubbled just before it reached each column The
flow rate through each column was 0.56 mL/min and 5 minute fractions
were collected. The deadspace of the system was approximately 2 mL, or
just less than one fraction. The cells or fragments were perifused with
medium which usually contained dopamine (5 pM) for 2 hours before each
experiment was started, to allow the cells to recover from the
preparation and to achieve a stable hormone baseline.
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Upper panel shows the perifusion system for one column. The pickup probe
could be moved to different test solutions each of which was gassed and
pre-warmed to 37°C. A and B denote two heating coils maintained at the
same temperature. The peristaltic pump was manufactured by Technicon
(Model AA1). Flow rate to the column was 0.56 mL/min and flow rate to
waste (debubbler) was 0.18 mL/min. A single fraction collector (Ultrorac
II, LKB, Sweden) was used to collect the eluate from all four columns.
Lower panel shows the detail of each cell column (described in the
text).
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3. Preparation of test solutions
This brief sub-section gives details of the test solutions used in the
perifusion studies. All solutions were made up fresh on the day of the
experiment. The Earle's balanced salt solution contained the following
ionic concentrations; Na+, 144 mmol/L; K+, 5.3 mmol/L; Ca++, 1.8 mmol/L;
Mg++, 0.81 mmol/L. The salts were supplemented with glucose (5.6 mmol/L)
and buffering was achieved using phosphate and bicarbonate systems.
Dopamine A stock solution (2.56 mmol/L) of dopamine hydrochloride
(Sigma) was prepared by dissolving 5.0 mg in 10 mL sterile saline (0.9%,
w/v, Ivex Pharmaceuticals Ltd, Larne, N.Ireland) which contained
ascorbic acid (100 mg/ L) and penicillin/streptomycin. Solutions in the
range 1-5000 nmol/L were then prepared by dilution in EBS which
contained ascorbic acid.(100 mg/L) in addition to the human albumin and
antibiotics previously described.
Bromocriptine Bromocriptine methane sulphonate was initially dissolved
in ethanol and then diluted in 5 mM tartaric acid to produce a stock
solution of 1.0 mmol/L. This was prepared in a silanised glass container
to prevent adsorptive losses. Stock bromocriptine was then serially
diluted in perifusion medium to produce test solutions covering the
range 0.01-10.0 nmol/L.
Thyrotrophin releasing hormone (TRH) TRH (Roche Products Ltd, Welwyn
Garden City) was dissolved directly in basic medium to give solutions of
1-100 ng/ml (2.76-276 nmol/L).
Gonadotrophin releasing hormone (LHRH) LHRH (Hoechst UK Ltd, Hounslow,
Middlesex) was dissolved directly in basic medium to give solutions of
1-100 ng/mL (0.85-84.6 nmol/L).
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4. Cell viability and identification
After initial equilibration of the tumour fragments the actual
perifusion experiment was rarely continued for longer than eight hours
during which time careful attention was paid to the oxygenation of the
perifusion medium and its maintenance at 37°C. It was important however
to make an assessment of cell viability at the start and finish of each
study.
One method which was examined to assess both the viability and the
identity of the perifused cells was the use of depolarising
concentrations of potassium (55 mM) at the end of each experiment. This
seems to be a non-specific secretagogue for all anterior pituitary cell
types (Eto et al., 1974) and acts by opening voltage-dependent calcium
channels leading to calcium influx (Tan et al., 1984). Viable cells with
maintained membrane potentials would be expected to show a marked
secretory response to depolarising concentrations of potassium in medium
containing physiological concentrations of calcium. This stimulus, given
for only five minutes, proved to be the most potent secretagogue in all
the studies reported in this thesis and indicated satisfactory cell
viability at the end of each experiment although, taken alone, this
evidence did not prove satisfactory viability of all the cells.
High K+ also proved to be a useful way of detecting anterior pituitary
contamination as shown in Figure 4-2. As expected from the hormone
contents of normal pituitary (McLean et al., 1981) the measurement of
growth hormone in the perifusate after high K+ was the most sensitive
and TSH the least sensitive indicator of anterior pituitary
contamination. All tumour perifusions described in this work, apart from
the two GH-secreting tumours, had virtually undetectable growth hormone
concentrations in the perifusate after cell depolarisation.
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Figure 4-2: Potassium depolarisation of normal & tumourous pituitary
cells
The release of PRL, HGH, LH, FSH and TSH from two different pituitary
adenomas and adjacent normal anterior pituitary tissues following
exposure to 55 mM R+ for 5 minutes (shaded area). Solid circles
represent tumour columns and open circles normal anterior pituitary
columns. Histology following the perifusions confirmed the purity of
tumour and normal anterior pituitary fragments from the different
columns.
(A) Prolactin-secreting adenoma (32.6 mg) and adjacent anterior
pituitary (30.6 mg). The adenoma immunostained for PRL alone.
(B) Growth hormone-secreting adenoma (23.7 mg) and adjacent anterior
pituitary (5.0 mg). The adenoma immunostained for HGH and, to a lesser
extent, PRL.
In both cases secretion of LH, FSH and TSH by adjacent normal anterior
pituitary is shown, but secretion of these by the tumour tissue is
completely absent.
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A further sign of cell viability was the constancy of hormone secretion
rates in control columns which were included in most perifusions (Figure
4-3). Preparation stability could also be demonstrated by applying the
same physiological stimulus at the start and finish of a perifusion, for
example the release of prolactinoma cells from dopamine inhibition, to
determine whether the response was similar at both times. The later
experiments illustrated in Figures 6-2 and 6-4 illustrate that tumour
fragments remained viable after at least 6 hours by this criterion.
A disadvantage of the dispersed cell column was that cells could not be
recovered at the end of an experiment for microscopic analysis. At the
end of each tumour fragment perifusion tissue from individual columns
was recovered into 10% neutral formalin for light microscopy if
required. On three occasions tissue was fixed in 2.5% glutaraldehyde and
examined ultrastructurally. No tumour showed evidence of cell disruption
or gross vacuolation following a six hour perifusion. Furthermore there
was no evidence of cell necrosis in the centre of the tumour fragments.
Several untreated prolactinomas were immunostained for prolactin
following a perifusion and all contained abundant immunoreactive
prolactin. Light microscopy was not performed in all cases but was
extremely useful in confirming the presence of suspected anterior
pituitary on a tumour column or determining the purity of an anterior
pituitary column.
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Figure 4-3: Control perifusion columns
Control columns for two different prolactin-secreting adenomas. DA = 5pM
dopamine. The solid vertical bar indicates the depolarising pulse of 55
mM K+.
Two different experimental protocols are shown:
In the upper panel tumour tissue (35.5 mg) was collected and
equilibrated in 5 pM dopamine. Removal of dopamine from the medium
resulted in a rebound increase in the prolactin secretion rate which
stabilised after 1 hour and remained constant for the rest of the
experiment.
In the lower panel tumour tissue (19.6 mg) was collected into medium
containing 5 pM dopamine but the latter was removed for the 2 hour
equilibration period (preceding time 0) and the prolactin secretion rate
remained constant throughout the perifusion.
1 22
C. ADVANTAGES OF TUMOUR FRAGMENT PERIFUSION
It has been shown that the use of tumour fragments in a perifusion
system had a number of advantages which will now be summarised in
conclusion to this section on perifusion methods.
Conservation of scarce human tissue.
The production of four perifusion columns from 100 mg prolactinoma
tissue permitted unused tissue to be stored for receptor studies. The
bromocriptine-treated macroprolactinomas could probably have not been
studied by cell dispersal.
Comparison of secretion rates between columns
The accurate weighing of fragments permitted the calculation of hormone
secretion rates which allowed comparisons between columns and between
experiments. There was generally excellent agreement between the
secretion rates for different fragment columns from the same tumour. The
hormone secretion rate for each fraction was calculated using the
following simple formula, which shows prolactin as an example:
PROLACTIN SECRETION RATE = PROLACTIN CONCENTRATION X 0.56
(pU/mg tissue/minute) (pU/mL eluate)
WEIGHT OF TISSUE ON COLUMN (mg)
(0.56 = column flow rate, mL/min)
Convenient, avoiding exposure to enzymes
Apart from the possible deleterious effects of enzyme exposure that have
been discussed, the avoidance of enzyme dispersal ensured a more
convenient and rapid method for establishing the cell columns. The cells
seemed to remain viable throughout the perifusion experiment. Some
authors using animal pituitary tissue have found responses of fragments
to secretory stimuli to be more sluggish than those of dispersed cells,
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presumably due to diffusion delays (MacLeod et al., 1983). This was not
a particular problem with these experiments on human tumours perhaps
because many were more friable than normal pituitary.
Recovery of fragments for microscopy
This, together with potassium depolarisation, was a major advantage for
the assessment of cell viability and identity following a perifusion
experiment.
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CHAPTER 5. LABORATORY METHODS III: DOPAMINE RECEPTOR ASSAY
A. INTRODUCTION
1. Purpose of the receptor studies
The role of dopamine as the main physiological inhibitor of prolactin
secretion by the anterior pituitary gland has been reviewed in Chapter
1. Many studies have shown that this inhibition is the result of a
direct effect of dopamine on anterior pituitary tissue (Shaar and
Clemens, 1974; Weiner and Ganong, 1978; Foord et al., 1983; Bethea,
1985). The first step in this process is thought to be the interaction
of dopamine with specific high affinity receptors in the plasma membrane
of the lactotroph. Using radioligand-binding techniques, dopamine
receptors have been measured directly in anterior pituitary membrane
preparations from several species, including man (see below). These
receptors fulfil the accepted criteria for receptor binding of
saturability, reversibility and specificity. Dopaminergic agonists, in
competing for dopamine receptors in particulate preparations of bovine
anterior pituitary glands, have a relative potency similar to that shown
by the same agents in inhibiting the secretion of prolactin by rat
anterior pituitary cells in monolayer culture (Caron et al., 1978). The
significance of dopamine receptors in the normal and abnormal pituitary
gland has been reviewed by Cronin and Evans (1983).
Using similar radioligand-binding techniques dopamine receptors have
been described in human pituitary adenomas, particularly prolactinomas
(Cronin et al., 1980a; Bression et al., 1980, 1982), although no
correlation has been made with in-vivo dopaminergic responsiveness.
Using intact prolactinoma cells in culture Bethea et al (1982)
demonstrated a strong correlation between dopaminergic receptor binding
and inhibition of prolactin secretion. At the start of my studies these
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were the only substantive publications concerning dopamine receptors and
human pituitary adenomas.
The ergot derivatives that had been shown to shrink pituitary adenomas
were all dopamine agonists and included bromocriptine (MacGregor et al.,
1979b; Prescott et al., 1982; Wass et al., 1982), lisuride (Chiodini et
al., 1981) and pergolide (Kendall-Taylor et al., 1982). It seemed likely
that the presence of dopamine receptors in the tumour membranes was
necessary for the tumour-shrinking action of these drugs. Conversely, I
hypothesised that the failure of some tumours to regress during dopamine
agonist therapy might be due to absent or malfunctioning membrane
dopamine receptors. Furthermore I wished to investigate whether there
was evidence of tumour dopamine receptor down-regulation during chronic
bromocriptine therapy.
The main aim of this work was to correlate dopamine receptor
measurements with the tumour shrinkage achieved during dopamine agonist
therapy in patients with pituitary macroadenomas. This work has been
recently published (Bevan and Burke, 1986) and is the only correlative
study of its type in the literature.
2. Previous studies of pituitary dopamine receptors
The first reports of dopamine receptors in membranes derived from rat,
sheep and cow anterior pituitaries appeared in the late 1970s (Brown et
al., 1 976; Caron et al., 1 97 8; Calabro and Macleod, 1 978; Cronin et al.,
1978; Cronin and Weiner, 1979; Stefanini et al., 1980). Enzyme marker
studies suggested that the majority of the binding sites were associated
with the plasma membrane fractions (Caron et al., 197 8) and subsequent
studies demonstrated their presence on intact cells (Bethea et al.,
1982; Foord et al., 1983). A variety of tritiated dopamine agonists and
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antagonists were used and the relative merits of each will be discussed
later. These early studies showed that individual dopamine agonists and
• • • ^
antagonists had equivalent potency in the displacement of [ H]ligand
binding to anterior pituitary dopamine receptors and the modulation of
prolactin secretion in-vitro, suggesting a close relationship between
the two events (reviewed by Cronin and Evans, 1983).
The receptor methodology developed using normal animal pituitary was
applied to the study of human tumours by Cronin et al (1980a) and
Bression et al (1980). Cronin et al (1980a), using the dopamine
antagonist [ H]spiperone, demonstrated dopaminergic binding sites in
five samples of pooled prolactinoma cell membranes. These receptors were
of similar affinity to those present in normal pituitaries removed from
patients with metastatic cancer but the number of binding sites was
greater in the tumour membranes. Bression et al (1980) used
O
[ H]domperidone to demonstrate dopamine receptors in membranes from 26
human prolactinomas. In competition experiments these were shown to have
the pharmacological characteristics of a dopaminergic binding site. In
contrast to the findings of Cronin et al (1980a) the number of binding
sites in prolactinoma membranes appeared to be similar to those in
membranes from normal anterior pituitaries obtained at necropsy.
Furthermore, [ H]domperidone defined two dopaminergic binding sites of
high and low affinity. Two non-functioning adenomas described in the
same paper showed no saturable binding at concentrations of up to 40
nmol/L [ H]domperidone.
A variety of rat lactotroph cell clones have been used as models of the
tumourous human lactotroph and have been investigated in an attempt to
define possible receptor or post-receptor defects. Early studies
emphasised the importance of membrane-bound dopamine receptors in the
mediation of the action of bromocriptine. For example, bromocriptine had
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no effect on the growth of the prolactin-secreting 235-1 clone in which
radioligand binding studies had revealed no dopaminergic binding sites
(Cronin et al., 1982). Similarly, dopamine did not reduce the secretion
from GHg cells, another prolactin-secreting clone without dopamine
receptors (Cronin et al., 1980b). In contrast, the clone 7315a was
refractory to dopamine despite the presence of apparently normal
dopamine receptors (Cronin et al., 1981). In a series of elegant
experiments Judd et al (1985) have recently deduced that the post-
dopamine receptor defect in this clone is related to the intracellular
mobilisation of calcium and the inhibitory action of dopamine was
restored in the presence of calcium ionophores.
3. Choice of radioligand
Firstly I shall consider the ideal properties of a radioligand for the
identification of dopamine receptors in pituitary tissues. This will
then be followed by a discussion of the properties of the various
radioligands that have been used in previous pituitary studies. The
O
reasons for my selection of [ H]spiperone for the tumour studies
will then be enumerated.
The ideal radioligand would have the following properties:
1. Ligand binding to the pituitary dopamine receptor would be of high
affinity.
2. The ligand would bind to dopaminergic receptors alone and not, for
example, to adrenergic receptors.
3. The ligand would exhibit a close correlation between dopamine
receptor binding and modulation of secretion or a linked
intracellular process such as adenylate cyclase activity.
4. Non-specific binding of the ligand would be low. (1) Lipid
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solubility would be low to prevent non-specific binding to membrane
components and the subsequent evaluation of specific binding over a
large "blank" value. (2) It would be advantageous if the ligand did
not bind non-specifically to inert materials such as glass or
plastic since this might result in losses of non-radioactive ligand
during the preparation of solutions which could not be corrected
for.
5. The specific activity of the radioligand would be as high as
possible to maximise the sensitivity of the assay.
6. The ligand would be chemically stable under incubation conditions
and not susceptible to oxidation or to metabolism by the
biological material being investigated.
7. The kinetics of ligand dissociation from the dopamine receptor would
be slow enough to permit the separation of bound and free
radioactivity.
No dopaminergic radioligand meets this specification and each of those
used in previous pituitary studies has some disadvantages.
Dopamine itself was used in some early studies (Calabro and Macleod,
O
1978; Cronin et al., 1978) but [ H]dopamine was unsatisfactory for
several reasons. It was an unstable compound and required the presence
of an anti-oxidant, usually ascorbate. Furthermore dopamine may be
metabolised by pituitary monoamine oxidase and an inhibitor of this
enzyme was routinely included in the assay buffer (Calabro and Macleod,
1978). The dissociation constant for dopamine (65 nM, rat and sheep
anterior pituitary) was an order of magnitude higher than that obtained
O
for [ H]dihydroergocriptine in the same tissues and specific binding was
only 30-35% (Cronin et al., 1978). Lastly, [^H]dopamine rapidly




The ergopeptine [ H]dihydroergocriptine, which is structurally very
similar to bromocriptine (see Figure 3-10), has been used by several
investigators to examine dopaminergic binding in normal anterior
pituitary (Caron et al., 1978; Cronin et al, 197 8; Sibley and Creese,
1983; Foord et al., 1983). There is an excellent correlation between
receptor binding and biological action (Caron et al., 1978). However the
specific binding of 50-60% at concentrations in bovine anterior
pituitary (Sibley and Creese, 1983) compared unfavourably to the values
of 75-90% obtained in bovine tissue by Cronin and Weiner (1979) using
O
[ H]spiperone. In an early paper Creese et al (1977) argued that only
O
half of the [ Hjdihydroergocriptine binding to anterior pituitary
homogenates was to dopamine receptors, with the remaining binding
accounted for by a-adrenergic interactions. This was not the experience
of Caron et al (1978) or Cronin et al (1978) who found little
radioligand displacement by noradrenaline or phentolamine. However a
recent report by Ramsdell et al (1985) has suggested that
3t H]dihydroergocriptine binds with equal potency to both dopaminergic
and a-adrenergic receptors in human prolactinoma membranes.
[ H]spiperone is a dopamine antagonist which binds with high affinity to
the pituitary dopamine receptor and values of between 0.2 and 0.85
have been obtained in normal animal anterior pituitaries (Creese et al.,
1977; Cronin and Weiner, 1979; Sibley et al., 1982). Spiperone is the
most potent drug known to antagonise the inhibition of prolactin release
by dopamine or dopaminergic agonists (Denef and Follebouckt, 1978). The
high specific binding of this ligand has been mentioned above and there
is plentiful evidence supporting a good correlation between receptor
binding and reversal of dopaminergic inhibition of prolactin secretion
(Denef and Follebouckt, 197 8; Cronin and Weiner, 1 97 9; Bethea et al.,
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1982). Sibley et al (1982) showed that bromocriptine caused 50%
3displacement of [ H]spiperone binding to bovine anterior pituitary
membranes at a concentration of around 6 nmol/L, a value similar to the
ICcjq values for bromocriptine inhibition of prolactin release from
normal lactotrophs (Caron et al., 1978; Delitala et al., 1980). There
has been some concern that spiperone also binds to serotonin receptors
(Baudry et al., 1979). However these receptors are not present in the
normal pituitary and high concentrations of serotonin failed to cause
O
significant displacement of [ H]spiperone from anterior pituitary
membranes (Cronin et al., 1979, Stefanini et al., 1980). Similar results
O
are described in Chapter 8 for [ H]spiperone binding to human pituitary
tumour membranes.
Many of the remarks about spiperone could also be made about the
dopamine antagonist domperidone which has been used to investigate
dopaminergic binding in the normal and abnormal pituitary (Bression et
al., 1980; Sibley and Creese, 1982; Foord et al., 1983). These studies
indicate satisfactory performance as a specific dopaminergic radioligand
though the compound is marginally less potent than spiperone and shows
slightly lower specific binding values (Sibley and Creese, 1982).
A general comment which applies to all of these tritiated radioligands
is that the specific activities are low and usually in the range 10-30
Ci/mmol. This is a particularly important factor in studies of human
tumours since the amount of available tissue is small and maximal assay
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sensitivity is desired. The possibility of using I-radiolabelled
dopaminergic ligands of much higher specific activity is discussed
below.
Secondly, many of the compounds exhibit non-specific adsorption to glass
and/or plastic; spiperone and dihydroergocriptine are two good examples.
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The special precautions required will be mentioned in section B.2.b.
O
[ H]spiperone was selected as the most suitable radioligand for the
tumour studies primarily because of its high affinity for the pituitary
dopamine receptor and its low non-specific binding to pituitary
membranes. There was sound evidence that the receptor defined by this
radioligand was relevant to the inhibition of prolactin secretion and to
the action of bromocriptine.
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B. DOPAMINE RECEPTOR METHOD
Since an individual pituitary adenoma usually yielded less than one gram
of tissue the dopamine receptor assay was established and validated
using membranes prepared from bovine anterior pituitary glands. The
final method derived from the techniques described by Cronin et al
(1979, 1980a) and Bression et al (1980).
1. Materials
a. Pituitary tissues
(i) Bovine anterior pituitary glands
Bovine pituitary glands were obtained from Friesian steers within 15
minutes of death at a local slaughterhouse (FMC, Thame, Oxon). The skull
was split and the complete pituitary was removed from above and placed
immediately into ice-cold membrane buffer (without ascorbate). The
tissue was transported to the laboratory within 30 minutes where each
anterior pituitary was bisected and dissected free from connective
tissue and neurointermediate lobe. The various pituitary components were
verified histologically. Each animal, on average, yielded 1.75 g of
anterior pituitary and batches of six pituitaries were routinely
collected. The tissue was processed to the end of the low-speed
centrifugation step described below and supernatant stored at -70°C
until further use.
(ii) Human anterior pituitary glands
Normal human pituitary glands were obtained at necropsies performed
within 48 hours of death on previously healthy males (aged 20-50 years)
who had died in road traffic accidents. Whole glands were stored at
-70°C until membrane preparation at which time posterior pituitary
tissue was separated and discarded.
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(iii) Pituitary adenomas
Pituitary adenoma tissue was obtained at the time of transsphenoidal
adenomectomy. Small tissue fragments were immediately fixed for light
and electron microscopy and the remainder was gently washed in Earle's
balanced salt solution at room temperature. Tissue for receptor studies
was weighed and stored at -70°C until membrane preparation.
b. Chemicals
O O
[ H]spiperone (benzene ring H, SA 24.5 Ci/mmol) and [ Hjdihydro-
O
ergocriptine (9,10- H, SA 26.7 Ci/mmol) were purchased from New England
Nuclear (Boston, USA). (+)Butaclamol was obtained from Research
Biochemicals (Wayland, USA), domperidone from Janssen (Wantage, Oxon)
and dopamine, pargyline, serotonin and adrenaline from Sigma. The
following compounds were gifts: non-radiolabelled spiperone (Janssen,
Wantage, Oxon), (-)butaclamol (Ayerst Laboratories, Rouses Point, NY)




Adenoma or normal tissue was diced using a scalpel to produce
approximately 3 mm cubes and then homogenised (10%, w/v) in ice-cold
0.33M sucrose buffer using a Teflon glass homogeniser. The buffer used
in these studies comprised 15 mM Tris, 120 mM NaCl, 5 mM KC1, 1 mM
MgClj, 2 mM CaCl2 and 0.1% (w/v) ascorbic acid (pH 7.4 at 20°C). The
homogeniser was motor driven at 400 rpm and the initial step was 10
strokes with a loose fitting pestle (0.24 mm clearance on the diameter).
This was particularly necessary for the initial processing of normal
anterior pituitary tissues since these were generally of firmer
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consistency than the adenomas. Homogenisation was completed with 20
strokes of a more tightly fitting pestle (0.1 mm clearance). An ice-
jacket was used throughout the homogenisation procedure. Dopaminergic
binding to bovine anterior pituitary membranes was similar whether 10 or
20 strokes were made with the tighter pestle. Homogenates of greater
than 10% (w/v) did not homogenise satisfactorily using the motor driven
apparatus. The use of sonication (Bression et al., 1980) for initial
tissue disruption was not investigated.
(ii) Centrifugation
The homogenate was centrifuged twice at 850g for 3 minutes at 4°C to
remove cell nuclei and debris (Beckman TJ6 refrigerated centrifuge).
The supernatant following the second spin was separated (Si) and
centrifuged at 100,000g for 60 minutes at 4°C (Beckman L8-70M
Ultracentrifuge) to produce the final membrane pellet (P2). The high¬
speed supernatant (S2) was stored in aliquots at -20°C for subsequent
hormone and, where appropriate, bromocriptine analyses. In early
experiments using bovine anterior pituitary, high-speed centrifugation
at 26,000g for one hour produced a membrane pellet containing marginally
less dopaminergic binding than that obtained following centrifugation at
100,000g (data not shown). The latter speed was therefore chosen for
routine use. Other investigators have used a wide range of
centrifugation forces ranging between 11,000 (Bression et al., 1980) and
145,000g (Cronin et al., 1980a), although most have used >30,000g.
(iii) Membrane pellet
The membrane pellet P2 from bovine anterior pituitary was bilayered with
a brown upper layer and grey-white lower layer. This was similar to the
findings of Caron et al (1978) who found that the brown layer contained
the plasma membranes and dopaminergic binding sites and that the white
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layer consisted of secretory granules. A similar pellet was obtained
from prolactin-secreting adenomas but non-functioning tumours produced a
more uniform pellet. Following high-speed centrifugation of several of
the non-functioning tumour homogenates a fat layer was observed floating
on the top of the supernatant. This was separated and discarded and it
was noted that these tumours usually showed large lipid inclusion bodies
on ultrastructural examination. Caron et al (1978) mechanically
separated the membrane and secretory granule layers in the high-speed
pellet from bovine anterior pituitaries. This would not have been
practical for the small pellets obtained from 300 mg or less of
pituitary adenoma so in all experiments the complete pellet was
resuspended in sucrose-free buffer. This was performed using a 1 mL
glass-glass minihomogeniser (10 strokes by hand) and the resulting
membrane suspension was that used in the binding assay.
(iv) Tissue storage
All tissues were stored at -70°C until final processing and radioligand
binding. Unprocessed bovine anterior pituitary showed no deterioration
in membrane specific binding after such storage for at least 4 months.
Similarly bovine Si and final membrane suspension were stable for at
least 2 months. This was in agreement with other workers (Cronin and
Weiner, 1979) and validated the use of frozen material for receptor
assay. However there was insufficient adenoma tissue to ascertain
whether the same receptor stabilities applied to the human tumours
during storage.
(v) Protein determination
Membrane protein was determined by the Coomassie Brilliant Blue dye-
binding assay (Bradford, 1976) using dye reagant obtained from Bio-Rad
Laboratories. The protein standard was bovine serum albumin (Bio-Rad)
and covered the range 0.15-1.21 mg/mL. The assay method will not be
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described in detail but the standard curve is shown in Figure 5-1. The
between assay coefficient of variation was 4.6% at 0.9 mg/mL (n=16). The
protein-dye complexes were stable for at least 60 minutes and optical
density measurements were routinely made after 20 minutes. In early
experiments membrane samples were incubated with 0.1% Triton X-100 for
15 minutes prior to protein determination to solubilise membrane
protein. However it was found that serial dilution of pituitary
membranes in 0.1% Triton X-100 produced a non-linear effect; the greater
the sample dilution the higher the apparent protein concentration. In
contrast, dilution of samples in membrane buffer alone was completely
linear. Since tumour membrane suspensions required variable dilution for
protein estimation the Triton X-100 solubilisation step was omitted.
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Figure 5-1: Standard curve for the protein assay
Standard curves from 16 consecutive protein assays. Values are mean +_
SEM.
100 pL of samples and standards were mixed with 5 mL diluted Coomassie
Blue dye reagant. After 20 minutes the optical densities were measured
using a Pye-Unicam SP8-150 spectrophotometer and polystyrene cuvettes.
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b. Radioligand binding
(i) Radioligand and early assay problems
The radioligand binding assay proved difficult to establish and a number
of pitfalls were encountered. The earliest experiments were performed
O
using T H]dihydroergocriptine as radioligand and specific binding to
bovine anterior pituitary membranes was low compared with previous
literature values (approximately 10% of the binding reported by Caron et
al., 1978). In retrospect, this was due to a combination of factors.
Ascorbic acid was routinely included in the assay buffer as an anti-
O
oxidant and without it specific binding of [ H]dihydroergocriptine was
reduced to virtually zero, which was in accord with the observations of
Leff et al (1981). However in early experiments the addition of ascorbic
acid to the 15 mM Tris buffer reduced its pH from 7.4 to 3.9 and several
assays were inadvertently carried out at acid pH. Cronin and Weiner
O
(1979) had demonstrated that specific binding of [ Hjspiperone was
O
abolished at pH 2.3. When [ H]dihydroergocriptine incubations were
performed at pH 7.4, and not pH 3.9, the specific binding increased but
still appeared low compared with literature values. This was found to be
largely due to the over-estimation of membrane protein concentrations
caused by Triton X-100 solubilisation as discussed above.
When these two factors were corrected, binding was similar to that
described by Caron et al (1978), but specific binding of
O
[ H]dihydroergocriptine to bovine membranes was only 30-65% of total
O
bound counts. [ H] spiperone was therefore finally chosen and specific
binding with this radioligand increased to 65-90% of membrane-bound
count s.
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The structure of spiperone is shown in Figure 5-2, together with
• . . ....
dopamine for comparison. Specific dopaminergic binding of [ Hjspiperone
was determined by displacement of bound radioligand using the potent
dopamine antagonist (+)butaclamol. The principle of the dopamine
receptor assay is illustrated by the experiment shown in Figure 5-3.
Other workers have used a lOOOx excess of non-radioactive ligand to
define specific binding (Bression et al., 1980) but this may define
binding to sites other than dopamine receptors. (+)Butaclamol was
dissolved in ethanol acidified with glacial acetic acid (2%, v/v) and
then diluted in membrane buffer. The acetic acid was necessary for the
complete dissolution of the (+)butaclamol but did not lower the pH of
the final incubate.
O
The specific binding of [ H]spiperone was directly proportional to the
amount of anterior pituitary membrane protein in the range 0.05-1.22 mg
protein per assay tube (Figure 5-4).
O O
[ H]spiperone (and [ H]dihydroergocriptine) showed non-specific
adsorption to glass and plastic. This was demonstrated by serial
dilution of radioligand using various combinations of glass and plastic
O
pipettes and containers. [ H]spiperone could be diluted in buffer
without losses if silanised glass containers and polythene pipette tips
were used (data not shown). Similar precautions were taken during the
preparation of solutions of non-radioactive spiperone and (+)butaclamol.
The radioligand binding assays were performed in silanised glass test-
tubes (75 x 12 mm) since the membrane-bound counts were significantly
lower when plastic tubes were used, presumably due to non-specific
adsorption. Glassware was silanised in the laboratory using
dimethyldichlorosilane solution (BDH Chemicals Ltd, Poole, Dorset)
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■^denotes the site of tritium incorporation in [^H]spiperone
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Bovine anterior pituitary membranes (0.61 mg protein per tube) were
incubated for 60 minutes at 30°C with [3H]spiperone in increasing
concentrations either alone (total dpm) or in the presence of 10 pM
(+)butaclamol (non-specific dpm). Specific dpm (or saturable binding)
refers to the difference between the two values. Abscissa: total
[H]spiperone concentration in the incubation (free + total bound). Each
point was determined in triplicate.
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Figure 5-4: [ H]spiperone binding and membrane protein concentration
AP membrane protein (pg/tube)
Effect of the amount of membrane protein on [ H]spiperone binding to
bovine anterior pituitary membranes.
O
Membranes were equilibrated with 5.1 nM [ H] spiperone for 60 minutes at
30°C. Each point was determined in duplicate and the individual results
are shown in the lower panel. Specific binding was defined using 10 pM
(+)butaclamol. NSB indicates the non-specific filter binding of 5.1 nM
[ H]spiperone.
The top panel shows the linear relationship between specific binding
(fmol spiperone) and membrane protein (pg/tube)
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Dihydroergocriptine was radio-iodinated in an attempt to produce a
radioligand of higher specific activity which might improve the
sensitivity of the tumour dopamine receptor assay. The iodination
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technique has been described in Chapter 3. Although I-
dihydroergocriptine bound to bovine membranes none of the radioactivity
was displaced by (+)butaclamol indicating that the binding was not to
dopamine receptors. In retrospect this was perhaps not surprising since
1 23
the subsequent immunoassay data suggested that the I had been
incorporated into the ergoline part of dihydroergocriptine which confers
dopaminergic agonist activity to the molecule. A recent report has
described the production of an radio-iodinated dopaminergic radioligand,
IOC
(N-(p-amino-m-[ I] iodophenylethyl) spiroperidol), with an estimated
SA of >2000 Ci/mmol (Amlaiky et al., 1984). This agent defined dopamine
receptors in bovine anterior pituitary and also offers considerable
promise as an affinity ligand for the purification and characterisation
of solubilised dopamine receptors from pituitary membranes.
O
(ii) Rate of [ H]spiperone binding
Specific binding to bovine anterior pituitary membranes occurred
rapidly, reaching equilibrium within 15 minutes of the start of
incubation at 30°C (Figure 5-5A). Binding was temperature-dependent and
took at least 30 minutes to reach equilibrium at 4°C (Figure 5-5A).
Binding at 37°C was complete within 5 minutes. Routine incubations were
for 60 minutes at 30°C. Analagous experiments were not performed with
tumour membranes because of the small amounts of tissue available but
the same kinetic parameters were assumed to apply.
144
o
Figure 5-5: Time and temperature dependence of [ H]spiperone binding
(A) Effect of time and temperature on the binding of 4.9 nM
[ H]spiperone to bovine anterior pituitary membranes (178 pg
protein/tube). •0=4°C, AA=30°C. Membranes were incubated with (open
symbols) and without (closed symbols) 10 pM (+)butaclamol.
(B) Rate of association and dissociation between 3.0 nM [ H]spiperone
and bovine anterior pituitary membranes (565 pg protein/tube). Duplicate
tubes were incubated at 30°C. The triangles indicate incubations with
(A) and without (A) 10 pM (+)butaclamol from the start of the
experiment.
Dissociation was examined by the addition of 10 pM (+)butaclamol (arrow)
after equilibrium between ligand and membranes had been attained (60
minutes). The [ H] spiperone remaining bound to the membranes was
measured by filtrations at various times following this addition and is
indicated by the solid circles.
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The dissociation for [ H]spiperone was determined by the addition of an
excess of (+)butaclamol (10 pM) to membranes at equilibrium (Figure
5-5B). Dissociation was virtually complete within one hour of
(+)butaclamol addition.
At the end of a routine incubation 3 mL membrane buffer was added to
each tube prior to vacuum filtration to facilitate transfer to the
filters. Despite this dilution, radioligand dissociation was
shown to be negligible for at least 5 minutes following this addition of
buffer.
(iii) Separation of bound and free radioligand
Membrane-bound radioligand was separated from free radioactivity by
filtration under vacuum through glass microfibre filters (Whatman GF/C,
Whatman Ltd, Maidstone, Kent).
Pre-soaked filter discs were mounted on the support screens of a 12-
channel sampling manifold (Model 1225-Millipore (UK) Ltd, London) and
the vacuum applied (20"Hg, Speedivac, Edwards High Vacuum, Crawley).
Prior to filtration 3 mL ice-cold membrane buffer was added to each
assay tube. Samples were then poured onto the filters and each filter
was washed with 3x10 mL ice-cold membrane buffer with the vacuum still
applied. Washing of each filter took less than 5 seconds. Filters were
then placed into plastic scintillation mini-vials (Griffiths and Nielsen
Plastics Ltd, Billingshurst, England) and dried at 60°C for one hour.
Figure 5-6 shows the effect of volume of wash buffer on filter bound
counts. Filter washing was necessary to remove free radioligand from the
filter and the 30 mL volume used in all assays provided a very adequate
wash. Non-specific binding of [ H]spiperone to the filters was directly
proportional to the total f H]spiperone concentration and constituted
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Figure 5-6: Effect of filter washing
Aliquots of bovine anterior pituitary membranes (80 pg protein/tube)
were equilibrated with 10.1 nM [ H]spiperone for 60 minutes at 30°C.
3 mL ice-cold membrane buffer was then added to each tube and the
contents applied to filters under vacuum. Various volumes of wash buffer
were used, as indicated in the diagram, and the bound radioactivity
counted. Determinations were made in triplicate; the circles indicate
the individual results.
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0.002% of total counts in the incubate. Estimations of non-specific
binding were not routinely included in each assay since this variable
applied equally to total and (+)butaclamol tubes and was cancelled in
the subtraction to derive specific binding.
(iv) Liquid scintillation counting
Membrane-bound tritium on the filters was measured by liquid
scintillation counting in Phase Combining System, a xylene/surfactant
scintillation cocktail (PCS, Amersham Corp, USA). Four mL PCS was added
to each minivial and allowed to equilibrate at room temperature for at
least 6 hours prior to counting, at which time the filters were
translucent. Each minivial was placed in a borosilicate glass vial
(Extra low background, Poulten, Selfe and Lee, UK) to act as a carrier.
Radioactivity was measured by a RackBeta scintillation counter (Model
1215-001, LKB Ltd, Selsden, Surrey) with a counting efficiency of 25-
40%. Quench correction was made using the sample channels ratio method
and the machine was standardised with a quench curve generated from a
O
series of acetone-quenched [ H]hexadecane standards (courtesy of Dr
G.E.Newman).
The presence of the glass filter did not cause quenching, neither was
its orientation critical. Provided the filters were dry and had been
equilibrated with scintillant for at least 6 hours, chemiluminescence
was generally less than 0.05%. Phase Combining System solubilised
approximately 90% of membrane-bound tritium following overnight
equilibration.
Two further scintillation cocktails were evaluated; Cocktail-T, a
toluene/Triton X-100 based mixture (BDH) and Ready-Solv CP, an
emulsifying cocktail for the elution of samples in filter counting
(Beckman). Compared with PCS, Ready Solv CP resulted in a much lower
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counting efficiency and Cocktail-T showed a lower capacity for aqueous
samples. All three cocktails eluted 90% of filter-bound radioactivity
and gave equivalent results after quench correction. PCS was chosen for
routine use.
(v) Data analysis
As already mentioned specific binding was estimated using (+)butaclamol
and was defined as the counts obtained with no competitor present minus
the counts in the presence of 10 pM (+)butaclamol. Data analysis was
performed using an iterative computer programme which produced best fit
Scatchard plots calculated by regression analysis (courtesy of Dr
D.R.Matthews). The programme estimated the minimal least squares
deviation by assuming a two component linear Scatchard plot (high and
low affinity) and subtracted the low affinity curve from the data
allowing an independent estimate of high affinity binding. It made no a-
priori assumptions about the intercept between the two regression lines.
(vi) Final assay procedure
The final assay procedure is summarised in Table 5-1. The reaction
volume of 400 pL was found to be optimal. All solutions were made up
fresh on the day of the experiment. [ H]spiperone solutions were made in
membrane buffer to produce final concentrations in the incubate of 0.07-
4.0 nM. Final spiperone concentrations of 4-54 nM were achieved by the
addition of non-radioactive spiperone. The latter was initially
dissolved in acidified ethanol, as for (+)butaclamol, and then diluted
in membrane buffer. Usual amounts of membrane protein were 200 pg (non¬
functioning tumours), 100 pg (normal anterior pituitary and TSH-
secreting adenomas) and 50-100 pg (prolactinomas) per assay tube. The
amount of membrane protein (mg) obtained per gram wet weight tissue was
similar for non-functioning tumours (17.7 +_ 1.0, mean _+ SEM, n=20) and
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prolactinomas (17.0 +. 1.9, mean + SEM, n=5). Normal pituitaries yielded
20.8 +_ 3.1 mg protein per gram tissue (mean +_ SEM, n=6). Aliquots of
bovine membrane suspension (stored at -70°C) were used as quality
controls in the tumour binding assays; these gave a between-assay
coefficient of variation of 12.2% (n=7) at a [H]spiperone concentration
of 4.5 nM.
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Table 5-1: Final assay procedure for tumour dopamine receptor analysis
ADDITION (in order) VOLUME OF ADDITION (pL/tube)
TOTAL BINDING (+)BUTACLAMOL NSBa TOTAL COUNTSb


















a Non-specific filter binding tubes were not routinely included.
O
b [ H]spiperone for total counts was dispensed directly into
scintillation vials.
Procedure:
1. The assay was performed in duplicate in silanised glass test-tubes
2. Membrane suspension was equilibrated at 30°C for 30 minutes prior to
assay. The assay was started by the addition of membrane suspension.
3. Tubes were vortex-mixed and incubated at 30°C for 60 minutes.
4. At the end of the incubation 3 mL ice-cold membrane buffer was added
to each tube, followed by rapid vacuum filtration.
5. Filters were dried at 60°C for 60 minutes.
6. 4 mL scintillation cocktail was added and membrane-bound tritium
measured by liquid scintillation counting; each sample was counted
for 20 minutes.
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CHAPTER 6. PERIFUSION RESULTS I: PROLACTINOMAS
The background to the perifusion studies and the method validation were
outlined in Chapter 4. This chapter describes the results of the
prolactinoma perifusion experiments and is in two main sections. The
first is concerned with dopaminergic control and the second with
TRH/dopamine interactions. The results are discussed, together with the
findings of other workers, at the end of each section.
A. DOPAMINERGIC CONTROL OF PROLACTIN SECRETION
1. Prolactin secretion rates
The prolactin secretion rates for bromocriptine-treated and untreated
macroprolactinomas are summarised in Figure 6-1. The last dose of
bromocriptine had been administered between 40 and 96 hours before
surgery to the four patients whose prolactinomas had shrunk during
bromocriptine; nevertheless each tumour showed persistent cell size
reduction on ultrastructural examination. However tumour regression and
fibrosis meant that little tissue was available for in-vitro study from
these patients.
During the initial perifusion period, when exposed to 5 pM dopamine, the
untreated prolactinomas had a significantly higher mean prolactin
secretion rate (19.3 pU/mg tumour/minute) than bromocriptine-treated
tumours (3.9 pU/mg/minute) (P = 0.005). However in the treated tumours,
the presence of excess fibrous tissue might have resulted in some
underestimation of lactotroph prolactin secretion since the secretion
rate was calculated using total tissue weight.
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TREATED (n ■ 7)
PROLACTINOMA
P 6
Prolactin secretion rates in three untreated prolactinomas (8 tumour
columns) and four bromocriptine-treated tumours (9 tumour columns).
Values shown are mean +_ SEM. DA = 5 pM dopamine and M = dopamine-free
medium. The secretion rate in DA was the mean of the first six fractions
of each perifusion and that in M was the mean of the last 6 fractions of
a one hour period of perifusion in dopamine-free medium following the
initial 30 minutes perifusion with 5 pM dopamine.
The three BC-treated tumours represented by the third and fourth bars
had received BC 10-20 mg daily for 3-36 weeks and BC was withdrawn 40,
72 and 96 hours before surgery.
Prolactinoma P6 received BC 10 mg daily for 20 weeks and BC was
withdrawn 96 hours prior to surgery.
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When dopamine was removed from the medium the mean prolactin secretion
rate from the untreated tumours rapidly increased to 6.7 times the basal
rate (129.7 pU/mg/minute). In contrast, three of the bromocriptine-
treated tumours showed no significant increase in the prolactin
secretion rate when dopamine was removed. In the fourth however there
was a significant increase under these conditions although not to the
level observed in untreated tumours. This patient (P6 in Table 2-4, page
50) had shown partial resistance to bromocriptine in-vivo since the
serum prolactin level had not fallen below 10,000 mU/L during chronic
bromocriptine therapy despite cell and overall tumour shrinkage.
2. Dopamine and bromocriptine dose responses
These studies examined the effects of various concentrations of dopamine
and bromocriptine on the prolactin secretion rates from bromocriptine-
treated and untreated prolactinomas. The basic experimental design is
illustrated by the individual perifusions shown in Figures 6-2 and 6-3.
Following perifusion in dopamine-free medium for 60-75 minutes tumour
fragments on separate columns were exposed to four different
concentrations of inhibitor, each for 60 minutes, followed by a further
60 minutes of medium alone. The perifusion was terminated by a
depolarising pulse of K+.
These perifusions contrast the rapid onset and offset of dopamine
inhibition of prolactin secretion with the more prolonged action of
bromocriptine. The lower prolactin secretion rate from bromocriptine-
treated tumours is clearly seen. The response to K+ at the end of each
experiment indicated satisfactory cell viability and excluded the
presence of contaminating anterior pituitary. The dopamine and
bromocriptine dose responses were reproducibly obtained in several
different tumours.
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Upper panel shows a macroprolactinoma (21 mg) not exposed to
bromocriptine in-vivo (pre-operative serum prolactin 80,400 mU/L). Note
the similar rebound increase in prolactin secretion rate following the
removal of 5 pM dopamine from the medium at both the beginning and end
of the perifusion.
Lower panel shows a macroprolactinoma (30.8 mg) from a patient given 10
mg BC daily for 3 weeks (last dose 40 hours prior to surgery). Note the
lower prolactin secretion rate and the less impressive increase in
secretion when dopamine was removed.
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Figure 6-3: Examples of prolactinoma perifusion: effect of bromocriptine
i 1 1 1 1 1 1 1 1
0 1 2 3 4 5 6 7 8
Time (hours)
0 12 3 4 5 6 7 8
Time (hoursl
Upper panel shows a macroprolactinoma (32.6 mg) not given bromocriptine
therapy immediately prior to surgery. In fact this patient had
previously shown some dopamine agonist resistance in-vivo but this was
not apparent in-vitro. Pre-treatment serum prolactin was 20,300 mU/L but
fell no lower than 3500 mU/L during therapy with bromocriptine (30 mg
daily) or pergolide (1000 pg daily) and amenorrhoea persisted; there was
little tumour shrinkage. No dopamine agonist was administered for six
months prior to surgery.
Lower panel shows the bromocriptine-treated macroprolactinoma (27.3 mg)
described in the lower panel of Figure 6-2.
Note the longer duration of action of bromocriptine compared with
dopamine (Figure 6-2) evidenced by persistent suppression of secretion
when the drug was withdrawn at the end of the experiment.
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The effects of dopamine on the prolactin secretion rates of seven
macroprolactinomas, four of which had regressed during pre-operative
bromocriptine therapy, are summarised in Figure 6-4. The untreated
prolactinomas showed a rapid increase in prolactin secretion when
dopamine was removed from the medium and all responded to dopamine with
a dose-dependent inhibition of prolactin release, including tumour "a"
which had shown partial bromocriptine resistance in-vivo (see legend to
Figure 6-3). In contrast, three of the four bromocriptine-treated
tumours appeared to have fully suppressed prolactin secretion rates,
even in the absence of dopamine, despite drug withdrawal for at least 40
hours prior to surgery. Dopamine dose responsiveness was therefore
impossible to evaluate in these tumours.
Overall, the 50 nM dose of dopamine reduced prolactin secretion rates by
approximately 50% in the prolactinomas studied.
The dose responses of eight macroprolactinomas to bromocriptine are
summarised in Figure 6-5 for comparison with the dopamine responses in
Figure 6-4. A clear dose-response over the concentration range 0.01 to
10 nmol/L, which includes the therapeutic range, was shown by the four
untreated tumours. In general, bromocriptine concentrations of 0.1-1.0
nmol/L, which are similar to the plasma concentrations measured in
Chapter 3.D, reduced prolactin secretion rates by at least 50%. Tumour
"a", which had shown in-vivo dopamine agonist resistance (Figure 6-3)
was fully responsive in-vitro to bromocriptine as well as dopamine.
The bromocriptine-treated tumours again showed virtually complete
suppression of basal prolactin secretion and in three cases a clear
dose-response relationship could not be seen.
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Effects of dopamine on prolactin secretion rates from bromocriptine
untreated (a-c, upper) and treated (e-h, lower) macroprolactinomas. In
each panel individual tumours are identified by the shading pattern.
Tumour "c" was equilibrated in dopamine-free medium hence there is no
bar for "c" under "dopamine".
The overall experimental design is illustrated by Figure 6-2. Values
shown in this figure are mean + SEM for the last six fractions of each
treatment period, except for K* which shows the secretion rate in the
fraction immediately following the high K+ depolarisation. SEM is not
shown if it was too small to be plotted.
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The format is the same as Figure 6-4 and the same seven tumours are
presented with the same code letter and shading. A further untreated
tumour was studied (d) which was equilibrated in dopamine-free medium.
Note that bromocriptine had a prolonged duration of action in all eight
patients but high K+ was able to overcome this inhibition.
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Bromocriptine showed a prolonged duration of action on the inhibition of
prolactin secretion which persisted when the drug was removed from the
perifusion medium. Depolarising concentrations of potassium were always
able to overcome this inhibition however.
3. Bromocriptine "resistance"
One bromocriptine-treated tumour (tumour "h" Figures 6-4 and 6-5, from
patient P6 in Table 2-4), which had shown partial bromocriptine
"resistance" in-vivo, showed in-vitro responses qualitatively similar to
untreated prolactinomas. The explanation for this was unclear.
Bromocriptine had been withdrawn for 96 hours prior to surgery so
perhaps its effect had started to reverse. However bromocriptine had
been given to this patient for 20 weeks and the biopsy specimen still
showed cell size reduction. There was no doubt that dopamine, and
bromocriptine, reduced prolactin secretion from this tumour in-vitro and
possibly a bromocriptine dose of greater than 10 mg daily would have
reduced the serum prolactin level to less than 10,000 mU/L. Only 90 mg
of tissue was obtained at surgery from this patient so dopamine receptor
studies could not be performed. However tumour fibrous tissue content
might have made the results difficult to interpret with confidence.
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4. Discussion
At the start of this work there was a vast literature on the control of
prolactin secretion in the rat but relatively few reports of in-vitro
secretion studies on human prolactinomas. Some authors reported
significant decreases of prolactin release from human tumours by
dopamine or bromocriptine (Peillon et al., 197 9; Adams et al., 197 9;
Lawton et al., 1981), whereas others found little or no effect (Tallo et
al., 197 8; Prysor-Jones et al., 1981). Since then a number of more
comprehensive publications on human prolactin-secreting adenomas have
appeared (Bethea et al., 1 982; Spada et al., 1 983; Peillon et al., 1 983;
Chihara et al., 1984, Ishibashi and Yamaji, 1984, 1985). Furthermore,
our knowledge of the control of prolactin secretion in a number of
primate species has increased (Neill et al., 1981; Bethea, 1985; Cronin
et a 1., 1 985 ).
The concentrations of test substances used in in-vitro studies are of
critical importance. Neill et al (1981) found that dopamine
concentrations in pituitary stalk plasma from Rhesus monkeys (females in
the follicular phase) ranged from 0.41-1.23 ng/mL (2.6-7.8 nmol/L). The
corresponding dopamine concentrations in man are unknown but Davies et
al (1984) found levels between 0.2 and 2.0 ng/mL in blood draining from
the tumour beds of resected human prolactin-secreting adenomas and
undetectable dopamine in similar samples from pituitary tumour patients
without hyperprolactinaemia. Although such measurements are difficult to
interpret, the slightly higher dopamine levels in the
hyperprolactinaemic patients may have been due to short-loop feedback by
prolactin causing increased hypothalamic dopamine release.
Spada et al (1983), using static incubation of tumour fragments, found
that human macroprolactinomas showed dose-related inhibition of
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prolactin release by dopamine concentrations between 1 and 10,000
nmol/L. In their study the concentration giving half-maximal effect
(IC^q) was 50 nmol/L for macroprolactinomas (>10 mm diameter), which is
very similar to the values I obtained for non-bromocriptine treated
macroprolactinomas (Section A.2). In contrast to the large tumours,
Spada and colleagues found that the dopamine IC50 was in excess of 500
nmol/L for microprolactinomas.
Broadly similar results were obtained by Bethea et al (1982) using human
prolactinoma cells cultured on extracellular matrix. Dopamine inhibited
prolactin secretion from tumourous and non-tumourous lactotrophs (the
latter from patients with metastatic cancer) in dose-dependent fashion,
with ICijo values of 243 and 76 nmol/L respectively. This study found no
difference in the dopaminergic sensitivity of small and large
prolactinomas. Bethea has recently reported a dopamine IC5Q of around 10
nmol/L for inhibition of prolactin release in the Rhesus monkey using
either dispersed pituitary cells in culture or pituitary stalk-
transected animals treated with dopamine infusion (Bethea, 1985).
Ishibashi and Yamaji (1984) found a similar value for normal human
pituitary cells in culture. Whether tumourous lactotrophs are less
sensitive to the inhibitory actions of dopamine than non-tumourous
lactotrophs remains an issue of considerable controversy.
Very few studies on human prolactinomas have correlated in-vivo and in-
vitro dopaminergic responsiveness. An exception is the study of Chihara
et al (1984). In two patients with prolactin-secreting adenomas dopamine
infusion (2.0 pg/kg/min) did not significantly reduce serum prolactin
concentrations; the tumours removed from these patients and studied in a
fragment perifusion system proved to be resistant to dopamine inhibition
in-vitro. Unfortunately only one dopamine concentration was studied (500
nmol/L) so it is unclear whether the resistance was absolute or whether
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the dose-response curve was markedly shifted to the right.
The rebound release of prolactin from untreated macroprolactinomas when
dopamine was withdrawn from the perifusion medium has been described by
other workers using both normal animal pituitaries and human pituitary
tumours (Lawton et al., 1981; Denef et al., 1984). It has also been
demonstrated in-vivo following the cessation of dopamine infusions (Ho
et al., 1984). Interruption of hypothalamic dopamine release may, at
least in part, account for the marked suckling-induced increase in
prolactin secretion as reviewed by Leong et al (1983). Furthermore
suckling undoubtedly stimulates TRH release in the rat and the normal
lactotroph may become hyperresponsive to TRH following a brief fall in
dopamine (Fagin and Neill, 1981). Whatever the physiological
significance of rebound release of prolactin following dopamine
withdrawal the phenomenon has obvious implications for the study of
inhibitory compounds in a perifusion system since prolactin secretion
rates will be unstable for some time following the withdrawal of
dopamine. This was evidently not appreciated in some earlier studies
(Yeo et al., 1 979). In the experiments reported in this thesis
inhibitory compounds were not introduced until at least one hour after
dopamine withdrawal by which time the rebound phenomenon had passed.
The concentrations of bromocriptine used in earlier in-vitro studies of
human prolactinomas (Mashiter et al., 1977; Adams et al., 1979; Prysor-
Jones et al., 1981) were 100-1000 times higher than either the IC^q
values observed with normal rat pituitary cells in culture (Caron et
al., 1978) or the low nanomolar concentrations measurable in plasma
after therapeutic dosing (Thorner et al., 1980; Bevan et al., 1986).
Prysor-Jones et al (1981) expressed surprise at the apparent resistance
of seven out of ten prolactinomas to bromocriptine at the very high
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concentration of 3 pmol/L. In fact six of their patients had presented
with pressure symptoms from large tumours (three had visual failure)
associated with pre-treatment serum prolactin concentrations of less
than 1800 mU/L. It seems very likely that these tumours were non¬
functioning with associated disconnection hyperprolactinaemia.
Furthermore four of these six patients had very low prolactin production
rates in-vitro and five of the six were apparently resistant to
bromocriptine. No immunocytochemistry was reported but the lack of
bromocriptine-induced changes in the secretory organelles reinforces the
suspicion that most of the tumours were not prolactin-secreting.
Adams et al (1979) also used high bromocriptine concentrations of 1-10
pg/mL (1.3-13 pmol/L) to investigate the inhibition of prolactin release
from dispersed human tumour cells. In contrast, Bethea et al (1982)
found that the bromocriptine IC50 for inhibition of prolactin release
from dispersed prolactinoma cells was 0.05 nmol/L. This latter result
was more comparable to bromocriptine IC^q values obtained from studies
using non-tumourous animal lactotrophs; 2.9 nmol/L (Caron et al., 1978,
dispersed rat cells in culture), 7 nmol/L (Delitala et al., 1980,
perifused dispersed rat cells) and 10 nmol/L (Bethea, 1985, dispersed
monkey cells in culture). Bromocriptine IC^q values for
macroprolactinomas in my studies ranged between 0.1 and 1.0 nmol/L and
were therefore in the same range as previously reported values. As
already discussed in Chapter 3 bromocriptine showed a marked tendency to
adsorb non-specifically to a variety of glass and plastic surfaces; it
is quite possible that some of the discrepancies in the literature are
due to this factor.
The persistence of bromocriptine inhibition of prolactin release in-
vitro for at least 4 hours after removal of the drug from the medium is
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well recognised (Delitala et al., 1980; Cronin et al., 1984). A similar
effect is seen in-vivo as plasma bromocriptine levels fall following an
acute bromocriptine challenge to patients with prolactinomas (Chapter 3,
Figure 3-16). It will be demonstrated in Chapter 8 that bromocriptine
was bound to dopamine receptors in resected pituitary tumours even when
the interval between the last dose of the drug and surgery was as long
as 19 hours. Depolarising concentrations of potassium were able to
overcome this persistent action of bromocriptine in the prolactinoma
perifusions described above. Ishibashi andYamaji (1985) found that high
K+ or the calcium ionophore A23187 were able to partly overcome the
inhibitory effect of dopamine (100 nmol/L) on prolactin secretion from
dispersed adenomatous and non-adenomatous lactotrophs in cell culture.
The interaction between adenylate cyclase and calcium mobilising systems
within the lactotroph is still incompletely understood and will be
discussed further in Chapter 10.
In-vitro dopaminergic responses of macroprolactinomas shrunk by
bromocriptine prior to surgery have not been studied before. Discussion
of these results requires a brief consideration of the current evidence
pertaining to the rate of onset and the rate of reversal of
bromocriptine effects on the tumourous lactotroph. The clinical evidence
implies that suppression of prolactin secretion and tumour cell size
reduction occur within a few days of the commencement of bromocriptine
therapy (Nissim et al., 1982). Hassoun et al (1985) studied the time
course of bromocriptine effects on the morphology of lactotrophs derived
from macroprolactinomas not exposed to the drug in-vivo. Dispersed cells
in culture from three tumours were studied after 1 and 16 days exposure
to bromocriptine at the relatively high concentration of 10 nmol/L.
Reduced prolactin secretion rates and accumulation of intracellular
prolactin-immunoreactive granules occurred in all three tumours after 24
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hours of bromocriptine exposure. Cell size reduction of the type
described in Chapter 2 was seen in two of the three tumours after 16
days but, interestingly, not in the third despite persistent suppression
of prolactin secretion.
The effects of bromocriptine on prolactin secretion and cell size in
prolactinomas are reversible. Thorner et al (1981) documented tumour re-
expansion within 2 weeks of drug withdrawal in two macroprolactinoma
patients treated for one year with bromocriptine. Nissim et al (1982)
found similar early re-expansion in three prolactinomas when therapy was
withdrawn after 6 weeks treatment; in one patient this occurred after 5
days bromocriptine withdrawal. After cessation of prolonged therapy
(mean duration 3.7 years) Johnston et al (1984) found a return of
hyperprolactinaemia in 14 out of 15 prolactinoma patients within 5-14
weeks, though it might have occurred earlier than this. In a
morphological study of prolactinomas which had been exposed to pre¬
operative bromocriptine, cell size reduction was present only in tumours
treated with the drug to within 2 days of surgery. Tumours removed more
than 2 days after bromocriptine had cell morphology identical to
untreated tumours (Landolt et al., 1983). Prysor-Jones et al (1983)
studied the effects of bromocriptine on the morphology of the
spontaneous prolactin-secreting tumours which occur in aging rats.
Tumour and cell size reduction occurred within 2 days of commencing
treatment and there was tumour re-expansion within 3 days of stopping
bromocriptine.
The prolactin secretion rates in the four perifused bromocriptine-
treated macroprolactinomas were low compared with untreated tumours and
each tumour showed minimal immunocytochemical staining for prolactin.
This was despite a bromocriptine-free interval of 40-96 hours.
Furthermore tumour cells showed persistent cell size reduction compared
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with control tumours. The shortest treatment period was 3 weeks and the
longest 36 weeks. The failure of the prolactin secretion rate to
significantly increase following dopamine withdrawal in three of the
tumours suggested that little pre-synthesised prolactin was stored ready
for release. (However, my results show there was a pool of stored
prolactin in these tumours which was releasible following TRH or high K+
stimulation - see page 171). It is concluded that the bromocriptine
actions on prolactin secretion and cell size reduction may persist for
four days or longer following cessation of therapy.
Since all the treated macroprolactinomas regressed as a result of
bromocriptine treatment it would seem likely that each possessed
functional dopamine receptors which mediated the action of the drug. One
tumour regressed without full suppression of prolactin; the possible
reasons for this have been discussed in section A.3. The tumour which
had shown previous partial bromocriptine resistance in-vivo (Figure 6-3,
upper panel) was normally responsive to dopamine and bromocriptine in-
vitro. The reason for the discrepancy is unclear. I conclude that
partial in-vivo bromocriptine resistance can be due to factors other
than lack of dopamine receptors or post-receptor mechanisms.
Do prolactinomas that completely fail to regress during bromocriptine
treatment lack dopamine receptors ? There is no clear answer to this
question since tumours which do not show radiological evidence of
shrinkage may, paradoxically, show cell shrinkage in the resected tumour
(Nissim et al., 1982). Furthermore suppression of prolactin secretion is
not always accompanied by cell size reduction (Hassoun et al., 1985) or
tumour regression (Chiodini et al., 1981). There have been no detailed
in-vitro studies of truly bromocriptine-resistant prolactinomas since it
appears to be quite exceptional for a prolactinoma to be resistant to
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dopamine agonist therapy in terms of complete failure of prolactin to
suppress and tumour mass to regress. The macroprolactinoma described by
Breidahl et al (1983), in which bromocriptine resistance occurred during
therapy with tumour enlargement and increased serum prolactin levels,
was refractory to 1000 nmol/L bromocriptine in-vitro, though detailed
studies were not reported. It is possible that this tumour
dedifferentiated and lost its dopamine receptors or acquired a post-
receptor defect. Bromocriptine resistance developed during therapy in
the prolactinoma described by Ahmed and Shalet (1986) but the tumour
subsequently responded to pergolide. The mechanism of this differential
resistance is obscure.
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B. INTERACTIONS OF TRH AND DOPAMINE
1. Perifusion results
The effect of TRH on prolactin release from eight prolactin-secreting
adenomas was examined in the presence and absence of 5 pM dopamine. The
usual experimental protocol is illustrated by the two prolactinomas in
Figure 6-6. Individual TRH stimulations (10 and 100 ng/mL) were given
for 10 minutes to four tumours and 5 minutes to the other four tumours.
In most cases the initial stimulations were in the presence of 5 pM
dopamine followed by stimulations in medium alone. The results were
qualitatively similar if this order were reversed.
Statistical analysis was performed on the basis of fiducial inference
(Chihara et al., 1984) and prolactin stimulation was judged significant
(P <0.05) when the peak response was beyond 3 standard deviations of the
baseline hormone level (mean of 5 fractions preceding the TRH).
The results for six of the tumours are summarised in Figure 6-7. On the
above statistical criteria none of these tumours showed significant TRH-
induced prolactin release in the presence of 5 pM dopamine. As a group
however the bromocriptine-treated prolactinomas showed a small increase
in prolactin release to TRH 100 ng/mL in the presence of dopamine which
just reached statistical significance using the Mann-Whitney U test. All
six tumours showed significant TRH-induced prolactin release in the
absence of dopamine. Prolactinomas that had received pre-operative
bromocriptine therapy and had low basal prolactin secretion rates showed
percentage increases similar to the untreated adenomas.
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The effects of TRH on prolactin release from two prolactin-secreting
adenomas.
T10 and T100 = TRH, 10 and 100 ng/mL. Dopamine = medium containing 5 pM
dopamine. TRH stimulations were for 10 minutes.
Upper panel shows a prolactinoma (30 mg) not given bromocriptine and
lower panel shows a prolactinoma (28.4 mg) exposed to 20 mg
bromocriptine daily for 36 weeks (last dose 96 hours prior to surgery).
Dopamine prevented TRH-induced prolactin release from both tumours.
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Figure 6-7: Macroprolactinomas: magnitude of the TRH-induced prolactin
responses
The peak prolactin secretion rates following TRH in three untreated (a)
and three bromocriptine-treated (b) prolactinomas expressed as a
percentage of the baseline secretion rate. The general protocol is
illustrated in Figure 6-6. Values shown are mean +_ SEM. Dopamine = 5 pM
dopamine (shaded bars). Medium = dopamine-free perifusion medium (open
bars). B = baseline prolactin secretion rate and T10 and T100 = TRH, 10
and 100 ng/mL.
Statistical analysis was with the Mann-Whitney U test. * denotes P
<0.05 and a significant increase in prolactin secretion rate relative to
baseline. There was no significant difference in the magnitude of the
TRH responses in the absence of dopamine between bromocriptine-treated
and untreated patients.
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One other tumour showed significant TRH-induced (10 and 100 ng/mL)
prolactin release in the presence of 5 pM dopamine though the peak
secretion rates were considerably lower than in the absence of dopamine;
this tumour had apparently normal dopamine receptors on the basis of
dopamine and bromocriptine dose-responses and radioreceptor assay
measurements (Chapter 8).
One further tumour did not respond to TRH 10 ng/mL and showed a
significant increase in prolactin secretion rate only after stimulation
with TRH 100 ng/mL in the absence of dopamine. Whether this was due to
abnormal lactotroph TRH receptor function in this tumour remains
speculative.
Four of the tumours in Figure 6-7 were tested with TRH 1.0 ng/mL in the
absence of dopamine; only two showed a significant stimulation of
prolactin release following this lower dose. There was no statistically
significant difference between the peak prolactin secretion rates
induced by TRH 10 or 100 ng/mL in the absence of dopamine. Furthermore
there was no difference in the magnitude of these peaks between
bromocriptine-treated and untreated macroprolactinomas. The present
studies did not permit a detailed evaluation of the TRH dose-response
relationship for macroprolactinomas but concentrated on using relatively
large doses of TRH to see whether a prolactin response could be elicited
at all. From animal studies one would predict TRH doses of greater than
25 nmol/L to be approaching the top end of the dose-response curve
(Tashjian et al., 1971; Ray and Wall is 1984).
Periadenomatous normal pituitary, perifused in parallel with
prolactinoma tissue from the same patient, showed TRH-induced prolactin
responses identical to those described above (data not shown) suggesting
that similar TRH receptors were present on both tumourous and normal
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lactotrophs. These data contrasted with the results of a perifusion of
periadenomatous pituitary and tumour tissue from a patient with
acromegaly who had shown a marked paradoxical growth hormone response to
TRH in-vivo. Only the tumour tissue responded to TRH in-vitro suggesting
that TRH receptors were present on only the tumourous somatotrophs
(Figure 6-8). These experiments were in agreement with the findings of
Ishibashi andYamaji (1984).
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Figure 6-8: TRH-induced growth hormone responses by a HGH-secreting
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The growth hormone responses of a HGH-secreting adenoma (23.7 mg,
upper panel) and adjacent normal anterior pituitary tissue (5.0 mg,
lower panel) to TRH. Prior to surgery the serum growth hormone
concentration rose from 29.2 mU/L to >320 mU/L, 20 minutes after the
intravenous injection of 200 pg TRH.
Doses of TRH (ng/mL) were administered for 5 minutes, and in
random order, to the tumour tissue. In addition, the anterior
pituitary tissue was exposed to various doses of LHRH. The
identity of the tissue fragments on the two columns was confirmed
histologically and the K+ results are shown in Figure 4-2
(lower).




TRH induces prolactin release by a direct action on the pituitary
(Tashjian et al., 1971) and is present in pituitary stalk plasma in
higher concentrations than those found in peripheral blood (Fink et al.,
1982). The role of TRH in suckling-induced release of prolactin has been
recently reviewed by Leong et al (1983) and de Greef and van der Schoot
(1985). The mechanism of TRH action on the lactotroph involves
phospholipid hydrolysis and the mobilisation of intracellular calcium
(reviewed by Gershengorn, 1986).
Tashjian et al (1971), using the GHg rat lactotroph cell line, showed
that TRH released prolactin in a dose-dependent manner and that the
maximum response was elicited by a concentration of 10 ng/mL (28
nmol/L). A similar relationship has been shown for TRH stimulation of
prolactin from normal animal anterior pituitary cells (Ray and Wallis,
1984). Ishibashi and Yamaji (1984) found that TRH (10 nmol/L) released
prolactin, but not HGH, from dispersed normal human pituitary cells in
culture. Some human prolactin-secreting tumours respond to TRH in-vitro
in similar fashion and Adams et al (1979) found that a dose of 10 ng/mL
gave a maximal response.
In normal human volunteers a marked increase in serum prolactin is
observed following the intravenous injection of 200 pg TRH (Cowden et
al., 1 979; Ghigo et al., 1 985; Johnston et al., 1 985). The prolactin
response to TRH in normal man is abolished by the concurrent
administration of dopamine in pharmacological (Besses et al., 1975) and
physiological (Connell et al., 1985) concentrations. This effect has
also been demonstrated using normal animal pituitary cells in-vitro (Ray
and Wallis, 1984).
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In contrast to normal controls, patients with prolactinomas or
hyperprolactinaemia of any cause (except primary hypothyroidism) show a
greatly impaired serum prolactin response to TRH (See Figure 2-2 and
Cowden et al., 1979; Scanlon et al., 1986). There is now a major body of
evidence that prolactin can influence its own secretion by short-loop
feedback on the hypothalamus causing dopamine release (reviewed by
Franks, 1983 and de Greef and van der Schoot, 1985). The evidence is
based on both animal and human studies. Weber et al (1983) showed that
hypophysial stalk dopamine levels were increased in rats inoculated with
a prolactin-secreting tumour. Clinical studies with domperidone, a
dopamine antagonist which does not cross the blood-brain barrier
(Pourmand et al., 1980), have suggested increased dopaminergic activity
on the pituitary in patients with prolactin-secreting pituitary adenomas
(Scanlon et al., 1981; Rodriguez-Arnao et al., 1983).
If the subnormal response of prolactin to TRH in patients with
prolactinomas is due to the presence of increased hypothalamic dopamine
release the prediction would be that all of these tumours ought to
respond to TRH, in-vitro, in the absence of dopamine. Chihara et al
(1984) investigated 8 prolactinomas from patients who showed a
negligible pre-operative response of serum prolactin to 500 pg TRH. In 3
of the tumours significant stimulation of prolactin release followed
exposure to TRH at the high concentration of 1000 nmol/L, although an
interaction with dopamine was not studied. Conversely 5 of the eight
prolactinomas were apparently resistant to TRH in-vivo and in-vitro. A
possible explanation is that these tumours had absent or deficient TRH
receptors. On the basis of ligand binding experiments Le Dafniet et al
(1985) showed TRH receptors to be clearly present in 13 out of 18
prolactinomas. However their study did not evaluate any aspects of post-
TRH receptor function.
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In my studies all eight prolactinomas showed a prolactin response in-
vitro to the much lower TRH doses of 10-100 ng/mL in the absence of
dopamine. These tumours included 3 whose basal prolactin secretion rates
had been reduced to very low levels by pre-operative bromocriptine
therapy and in which secretion did not greatly increase following
removal of dopamine from the medium. Despite this, the percentage
increases in prolactin secretion following TRH were the same as in the
untreated patients (Figure 6-7). The significance of this finding is
unclear. Ho et al (1985), however, have presented evidence which is
consistent with the existence of separate functional pools of prolactin
within the lactotrophs, one of which is releasible by TRH and another by
dopaminergic modulation. It is conceivable, but entirely speculative,
that bromocriptine has a differential effect on different prolactin
pools.
The other notable finding in my TRH studies was the marked attenuation
of the TRH prolactin response when prolactinoma fragments were exposed
to 5 pM dopamine. In many cases the TRH response was completely
abolished by this concentration of dopamine. A similar effect was noted
in combined PRL/HGH-secreting tumours by Ishibashi and Yamaj i (1984)
using dopamine concentrations of 100 nmol/L. Bromocriptine-treated
macroprolactinomas showed the same responses suggesting that dopamine
receptor down-regulation had not occurred during chronic dopamine
agonist therapy. None of the patients that I studied showed a
significant prolactin response to TRH in-vivo; that they responded in-
vitro is consistent with dopamine inhibition of TRH action in-vivo.
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CHAPTER 7. PERIFUSION RESULTS II: NON-FUNCTIONING TUMOURS
Ten non-functioning tumours were studied, including six from patients
given pre-operative bromocriptine without tumour shrinkage. All were
large tumours and four were associated with modestly elevated serum
prolactin concentrations between 1000 and 2500 mU/L. None of the
patients had clearly elevated serum FSH or LH levels, although three
were post-menopausal women with FSH levels up to 28 u/L, and in no case
did these hormones respond paradoxically to TRH as has been described in
some gonadotrophin-secreting adenomas (Snyder et al., 1980). In the
patients given dopamine agonist therapy there was no suppression of
serum gonadotrophin concentrations during treatment. No patient whose
tumour partly immunostained for FSH/LH showed a significant reduction in
the serum concentrations of these hormones following surgery suggesting
that the major contribution to serum gonadotropins in such a patient
was not from the tumour but from normal pituitary.
Tumours were studied by fragment perifusion and the results were
compared with immunocytochemistry. All the tumours described in this
section had dopamine receptor measurements and this provided an
opportunity to correlate tumour FSH, LH and alpha subunit contents with
the perifusion and immunocytochemistry results. The complete results are
summarised in Table 7-1 and various aspects will be considered in the
rest of this section.
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Table 7-1: Non-functioning tumours; comparison of tumour
immunocytochemistry, perifusion and hormone content




PRL FSH LH a LHRH TRH DA FSH LH a
1 FSH and a - + - nd + - - + - +
2 FSH, LH
and a
- + - + - - nd - - +
3 Nil - - - - - -
4 FSH and a - + - + - " + " -
5 Nil - - - - - -
6 a - - + + nd - - - + +
7 Nil - - - - - -
8 FSH, LH
and a
- ± ± + - - - - - -
9 Nil - - - - - -
10 Nil - - - - - -
(- denotes no hormone detected or no response to perifusion test
stimulus, nd = not done)
Tumours 1-3, 5, 7 and 10 had been exposed to pre-operative bromocriptine
without tumour shrinkage.
Tumours 1, 6, 8 and 10 were associated with serum prolactin
concentrations between 1000 and 2500 mU/L.
Iwmunocytochemistry: Tumours were immunostained for PRL, FSH, LH
and alpha subunit. No tumour showed positive immunostaining in >10%
cells and staining was confined to single cells or small clumps of
cells.
Perifusion: Hormones were reported negative when no FSH, LH, a or PRL
could be detected following K+ depolarisation. Hormones marked "+" were
detected throughout the perifusion period as well as following K+.
Stimulations were with TRH (10 minutes, 1-100 ng/mL), LHRH (10 minutes,
1-100 ng/mL) and dopamine (30-60 minutes, 5 pM).
Hormone contents: The following hormone contents were included as
positive; FSH and LH, >20 units per g tumour homogenised and alpha
subunit, >10 pg per g tumour homogenised (see section C)
The apparent production of LH by tumour 6 was probably due to
crossreaction of alpha subunit in the LH assay.
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A. gonadotroph™ secretion
Four tumours secreted FSH and/or LH and alpha subunit in the perifusion
experiments. Secretion rates were low and between 50 and 150 mg tissue
per column was required to detect this hormone production. This was
consistent with the observation that less than 10% of tumour cells
immunostained for the various hormones. Immunocytochemistry on thin
serial sections of the tumours showed that FSH and/or LH were located in
the same cells as alpha subunit. None of these tumours responded to TRH,
LHRH or dopamine in-vitro and secretion was stimulated only by
depolarising concentrations of K+. One of the perifusion experiments for
tumour 4 is shown in Figure 7-1.
A fifth tumour immunostained for alpha subunit alone and secreted
significant amounts in-vitro (Figure 7-2). In apparent disagreement with
the immunocytochemistry this tumour also appeared to secrete and contain
LH. In fact this was probably due to crossreaction of alpha subunit in
the LH. radioimmunoassay as described in Chapter 3.B. Unfortunately no
serum alpha subunit measurements are available for this patient.
The remaining five tumours showed completely negative immunostaining and
no hormones were detected in the perifusates or tumour extracts.
Nevertheless each of these tumours showed small secretory granules on
ultrastructural examination.
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Time ( hou rs)
Perifusion of non-functioning tumour fragments (78 mg) from tumour no.4
in Table 7-1.
DA = 5 pM dopamine. L1-L100 = LHRH, 1-100 ng/mL. K+ = 55 mM.
Immunocytochemistry showed small clumps of cells positive for both FSH
and alpha subunit and only these hormones were detected in the
perifusate. The tumour contained 41.9 U FSH and 5.3 pg alpha subunit per
g tissue homogenised.
In this experiment neither 5 pM dopamine nor LHRH (1-100 ng/mL)
significantly altered FSH or alpha subunit secretion rates. Following K+
depolarisation there was significant release of both hormones but not LH
or PRL.
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Figure 7-2: Perifusion of non-functioning tumour; release of alpha
subunit
Perifusion of non-functioning tumour fragments (108.7 mg) from tumour
no. 6 in Table 7-1.
DA = 5 pM dopamine. T1-T100 = TRH, 1-100 ng/mL. K+ = 55 mM.
Immunocytochemistry showed clumps of cells positive for alpha subunit
alone. The tumour contained 38.6 jug alpha subunit per g tissue
homogenised.
Dopamine did not inhibit the secretion of alpha subunit neither was the
latter stimulated by TRH (1-100 ng/mL). Following K+ depolarisation
there was significant release of alpha subunit but not FSH or PRL.
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B. PROLACTIN SECRETION
Since four tumours were associated with significant, though modest,
hyperprolactinaemia it was important to ensure that the tumours were not
in fact prolactin-secreting in-vitro. None of the tumours immunostained
for prolactin and prolactin was undetectable in the perifusate from all
these tumours following K+ depolarisation. The tumours were therefore
designated as non-prolactinomas with confidence. The hyperprolactinaemia
was presumed to be on the basis of hypothalamo-pituitary disconnection
and was restored to normal after surgery in all 4 cases.
C. TUMOUR HORMONE CONTENTS
These were calculated by measuring FSH, LH and alpha subunit
concentrations in suitable dilutions of the high speed supernatants
obtained after homogenisation and differential centrifugation of tumours
in the preparation of membranes for dopamine receptor measurement.
Figure 7-3 shows the hormone contents of twenty non-functioning tumours,
including the ten in Table 7-1, and compares the results with those
obtained from TSH and prolactin-secreting adenomas and normal
pituitaries. The non-functioning tumours were subdivided into three
groups representing negative, gonadotrophin (often with alpha subunit)
and alpha subunit immunostaining.
Four of the prolactinomas contained undetectable FSH, LH and alpha
subunit as expected. One tumour (0PRL column, Figure 7-3) contained
detectable amounts of these hormones, presumably due to anterior
pituitary contamination. However when these levels were compared with
those obtained from normal pituitary it could be estimated that the
contamination was, at most, only 1.2%. By a similar estimation the
negatively staining tumour marked by the solid square in Figure 7-3
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The immunohistological category is shown at the foot of the six main
columns: Negative (n=7), gonadotrophin/alpha subunit (5), alpha subunit
(6, in 4 of these the staining was minimal), normal anterior pituitary
(3), TSH/alpha subunit (2) and PRL (5).
Within each immunohistological group the same symbol denotes the FSH, LH
and alpha subunit content of an individual tumour/tissue.
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was probably also contaminated with some anterior pituitary, but by no
more than 3.8%. It was clear therefore that tumour FSH/LH levels of less
than 20 U/g tissue and alpha subunit levels of less than 10 pg/g tissue
could not distinguish tumour cell content from very small amounts of
anterior pituitary contamination.
Only four non-functioning tumours contained more than 10 pg alpha sub-
unit per gram of tumour; all four showed positive immunostaining (but in
<10% cells), accompanied by LH in one and FSH in two tumours. The
highest alpha subunit content in a non-functioning tumour was 482 pg per
gram tissue; the tumour also immunostained for and contained FSH and was
associated with a serum alpha subunit concentration of 17 ng/mL (normal
range <3 ). This tumour level was comparable to the alpha subunit
contents of two TSH-secreting adenomas in which 25% of cells
immunostained for alpha subunit. However one of these tumours gave
gonadotrophin results which suggested as much as 20% anterior pituitary
contamination (■ TSH column, Figure 7-3).
Due to the problem of possible anterior pituitary contamination the
measurement of tumour gonadotrophin contents was a less sensitive method
than immunocytochemistry or tumour perifusion (Table 7-1).
D. CORRELATIONS BETWEEN TUMOUR PERIFUSION AND IMMUNOCYTOCHEMISTRY
The excellent agreement between these two methods when applied to the
characterisation of non-functioning tumours is summarised in Table 7-1.
The only exception was tumour 2 in which immunocytochemistry showed a
few foci of FSH, LH and alpha subunit positive cells but perifusion
showed low levels of FSH and alpha subunit alone; LH was undetectable
even after K+. The discrepancy was probably a reflection of the very low
secretory activity of this tumour.
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There was complete agreement between immunocytochemistry and perifusion
with regard to prolactin. All tumours positive for prolactin
immunocytochemically produced prolactin in-vitro and the converse was
also true.
E. DISCUSSION
The enigma of the non-functioning tumour has been introduced in Chapter
1 and will be discussed further in Chapter 10, particularly in the light
of the dopamine receptor findings. This section briefly reviews the
perifusion results for this group of tumours.
Clearly none of the tumours that I studied in detail were
gonadotrophinomas of the type described by Whitaker et al (1985) or
Snyder et al (1985), with elevated serum gonadotrophin concentrations
and greater than 20% of cells in the resected tumours immunostaining for
the relevant hormones. In fact 5 of the 10 tumours in Table 7-1 showed
no known anterior pituitary hormones in immunocytochemical, perifusion
or hormone content studies, but each contained small secretory granules
at the electron microscopic level.
The four tumours with low levels of gonadotrophin and alpha subunit
correspond to the type of tumour studied by Mashiter et al (1981) and
Surmont et al (1983). It is difficult to assign these tumours as
definite gonadotrophinomas since more than 90% of cells showed
completely negative immunostaining and tumour hormone contents were only
marginally greater than completely non-functioning tumours and very much
lower than normal pituitary (Figure 7-3). Following short-term exposure
to TRH and LHRH in the perifusion studies none of the tumours showed a
significant response. Surmont et al (1983) examined four such tumours
exposed to TRH and LHRH (both at 100 ng/mL) for prolonged periods (12-41
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days) in cell culture. FSH and LH secretion was stimulated by LHRH from
one tumour and LHRH and TRH from two tumours. It is difficult to see how
the difference in exposure time could explain this discrepancy but the
number of tumours studied in each case was small.
The dopaminergic responsiveness of gonadotroph-cell tumours is largely
unknown. Berezin et al (1984) described a patient with a macroadenoma
which was clearly FSH-secreting, despite a lack of immunocytochemical
data, and in whom bromocriptine reduced serum FSH concentrations, but
without tumour shrinkage. None of the tumours in my studies showed a
reduction of serum gonadotrophin levels during bromocriptine therapy or
an inhibition of gonadotrophin release when exposed to 5 pM dopamine in-
vitro.
One of the adenomas studied in detail (No.6, Table 7-1) appeared to
contain and secrete alpha subunit alone, though the number of cells
showing positive immunostaining was less than 10%. Such tumours have
been described previously (Ridgway et al., 1981; Snyder et al., 1985).
The problem of crossreactivity of alpha subunit in the LH assay was
also encountered by Snyder et al (1985) who showed that the LH
immunoreactivity eluted in the alpha subunit position on gel filtration
of culture medium from an alpha subunit secreting adenoma.
In conclusion, the primary cell of origin in many so called non¬
functioning tumours remains unclear and I shall return to this again in
the final chapter.
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CHAPTER 8. DOPAMINE RECEPTOR MEASUREMENTS
Previous studies of pituitary dopamine receptor studies and the method
validation were described in Chapter 5. This chapter contains the
results of the pituitary tumour dopamine receptor measurements.
A. TISSUES STUDIED
Dopaminergic binding was investigated in tumours removed from patients
with non-functioning tumours (20) and prolactinomas (5). The median wet
weight of tissue available for membrane studies was 572 mg (range 107-
1184) for non-functioning and 375 mg (range 222-820) for prolactin-
secreting adenomas. The tumour results were compared with those obtained
from fresh bovine and necropsy human anterior pituitaries.
The clinical details, including pre-operative bromocriptine therapy, and
tumour pathology for the non-functioning tumour and prolactinoma
patients are shown in Tables 8-1 and 8-2. All the non-functioning
O
tumours were large tumours with mean fossa volume 2780 mm and mean
suprasellar extension height 14 mm. Nine of these tumours had been
exposed to pre-operative bromocriptine without tumour shrinkage (six
have been described in Chapter 2). The prolactinomas had a mean fossa
3 ...volume of 2670 mm , though none had a significant suprasellar extension,
and none had been exposed to bromocriptine. Unfortunately there was
insufficient tissue from bromocriptine-treated macroprolactinomas for
receptor studies.
Immunostaining for prolactin was negative in all 20 non-functioning
tumours but strongly positive in all of the prolactin-secreting tumours.
Furthermore, tumour fragments from 4 non-functioning tumours associated
with initial serum prolactin concentrations over 1000 mU/L did not
release prolactin in-vitro following exposure to depolarising
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Table 8-1: Clinical details and tumour pathology for 20 patients with
non-functioning tumours
Code Age Sex Symptoms Serum PRL Immuno- Bromocriptine
(mU/1) staining Dose (mg/day)
(pre-treatment) [Duration-mths]
UNTREATED
1 70 M Hypopit (ACTH/GH)
Visual failure
450 Neg
2 33 F Galactorrhoea 43 50 FSH+ a+









5a 40 M Hypopit (ACTH/GH
TSH/LH)
3 90 Neg
6 51 M Hypopit (ACTH/GH
TSH/LH)
540 a+
7 30 M Visual failure 740 Neg
8 62 F Visual failure 1370 Neg
Onco+++
9 68 F Visual failure 1020 ct+
10 47 F Visual failure 1200 FSH+ a+
Onco+





Blb 59 M Hypopit (ACTH/GH 220 Neg 20 t6]
B2ab
TSH/LH) 40 [4]
53 F Visual failure 520 FSH+ 30 [10]
Onco+++
B3 63 M Hypopit (ACTH/GH
LH)
400 CC+. 20 [7]
B4 54 F Visual failure 1070 FSH+ a+ 10 [1.5]








B6 36 M Visual failure 300 FSH+
Onco++
20 [3]
B7 59 F Visual failure 600
Onco +
5.0 [3]
B8 81 F Visual failure 770 FSH+ LH+
a+ Onco+
7.5 [1]
B9C 39 F Visual failure 150 a± 20 [6]
a = previous transfrontal surgery and radiotherapy
b = last dose of bromocriptine within 24 hours of surgery
c = previous transfrontal surgery
ACTH, GH, TSH, LH denote hormone deficiencies in patients
presenting with hypopituitarism.
Onco = Oncocytic change
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Table 8-2: Clinical details and tumour pathology for five prolactin-
secreting pituitary adenomas






















2° amenorrhoea 12,720 PRL+++






ND = not done
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concentrations of potassium. None of the bromocriptine-treated non¬
functioning tumours showed ultrastructural changes typical of
bromocriptine-treated macroprolactinomas (see Chapter 2.C.5). The modest
elevation of serum prolactin to between 1000 and 5000 mU/1 in 7 patients
with non-functioning tumours was considered to be due to hypothalamo-
pituitary disconnection.
No tumour in the receptor studies showed any histological or perifusion
evidence of contamination with normal anterior pituitary but two showed
evidence of minor contamination (<4%) on the basis of hormone content
studies (see Figure 7-3 and related text). Major oncocytic change (>10%
cells) was found in 5 non-functioning tumours, 3 of which had been
exposed to bromocriptine. A variable pattern of gonadotrophin
immunostaining, confined to <10% cells in each case, was present in 7
non-functioning tumours.
B. HIGH AND LOW AFFINITY DOPAMINE RECEPTORS
All tissues studied showed high affinity dopaminergic binding sites
defined by f H]spiperone. A typical binding curve and corresponding
Scatchard plot for a prolactinoma and a non-functioning tumour are shown
in Figure 8-1. The mean dissociation constant (K^) for the high
affinity dopaminergic binding site was not statistically different
between the three tissues studied (prolactinoma, 0.55 nM; non¬
functioning tumour, 0.92 nM; normal pituitary, 0.51 nM) (Figure 8-2).
The mean number of high affinity sites (Bmaxi) was significantly greater
(P <0.01) in prolactinomas (698 fmol/mg protein) than in non-functioning
tumours (131 fmol/mg protein) or anterior pituitary (136 fmol/mg
protein) (Figure 8-3).
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Figure 8—1: Direct and Scatchard plots of [^H]spiperone binding to









Direct (left) and Scatchard (right) plots of specific [ H]spiperone
binding (0.07 - 10 nM) to membranes from a prolactinoma (closed circles)
and a non-functioning tumour (open circles). Specific binding was 94 and
76% of total tissue binding respectively at concentrations. Each
point represents the difference between two sets of duplicate tubes, one
of which contained 10 pM (+)butaclamol.
1 92
















High affinity dissociation constants (K^) for the tissues studied. Bars
indicate the mean values for each group.
PSPA = prolactin-secreting pituitary adenomas
NFT = non-functioning tumours (no bromocriptine)
NFT (BC) = nine NFTs given pre-operative bromocriptine
AP = normal anterior pituitaries (bovine 3, human 3)
There was no significant difference between the groups using the Mann-
Whitney U test
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PS PA NFT NFT AP
(BC)
High affinity binding site numbers (Bmaxi) for the tissues studied. Note
the logarithmic scale. Abbreviations as for Figure 8-2.
Bars indicate the mean values for each group except for NFT (BC) where
the mean does not include the open circles which denote three NFTs
exposed to bromocriptine within 24 hours of surgery.
Using the Mann-Whitney U test prolactinomas had significantly higher
numbers of high affinity dopaminergic binding sites than the other three
tissue groups (P <0.01).
1 94
There was no difference in binding characteristics between tumours
showing oncocytic change or gonadotrophin immunostaining and the rest of
the non-functioning tumours. The binding characteristics of fresh bovine
and autopsy human pituitary were virtually identical.
All tissues (except 2 prolactinomas) showed an apparent second
dopaminergic binding site of much lower affinity when spiperone
concentrations up to 50 nM were used (Figure 8-4). However in a number
of cases the low affinity parameters and ®max2 could not be
calculated with confidence and these data will not be further
enumerated.
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Figure 8-4: High and low affinity binding sites
Spiperone ( nMI
Upper
(a) Specific [ H]spiperone binding (0.07 - 54 nM) to membranes
from non-functioning tumour B9 (Table 8-1)
(b) Scatchard analysis of specific binding showing two sites:
1 .2 nM, 1^2 nM.
Lower
O
(a) Specific [ H] spiperone binding (0.07 - 54 nM) to bovine
anterior pituitary membranes
(b) Scatchard analysis of specific binding showing two sites:
Kdl 0.46 nM, Kd2 20 nM.
B = bound radioactivity (fmol/mg protein);
F = unbound radioactivity (nM).
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C. SPECIFICITY STUDIES
To further characterise the dopaminergic binding site in non-functioning
tumour membranes specificity experiments were carried out on the high
affinity site using a pool of membranes prepared from 5 tumours that had
not been exposed to bromocriptine. Pargyline (10 pM, Sigma) was included
in the membrane buffer to prevent metabolism or binding of dopamine by
monoamine oxidase. The competitors displayed a rank order of potency
which is typically dopaminergic (Kebabian and Calne, 1979) (Figure 8-5).
Virtually identical results were obtained with bovine anterior pituitary
membranes (data not shown). Stereospecificity of binding was shown using
the isomers of butaclamol; the (-) isomer being lOOOx less active than
the (+) isomer (Figure 8-5)
D. BROMOCRIPTINE INTERACTION WITH NON-FUNCTIONING TUMOUR DOPAMINE RECEPTORS
®maxl ^or ^ t*le bromocriptine-treated non-functioning tumours was
less than 50 fmol/mg protein (tumours B1-B3, open circles Figure 8-3).
These tumours were from the 3 patients who received the last dose of the
drug within 24 hours of surgery. Furthermore, bromocriptine was
detectable in the high speed supernatant in these 3 cases only (Figure
8-6). Membranes from cases B1 and B3 were resuspended in buffer and
centrifuged three times at 100,000 g; 0.6 and 0.2 pmol bromocriptine per
mg membrane protein were recovered in the washings (Figure 8-6).
O
Following this, [ H]spiperone binding significantly increased and Bmax^
values became comparable to those obtained with the other NFTs (Figure
8-6). This suggested that the original Bmaxj values were artifactually
low due to bromocriptine occupation of the dopaminergic binding sites.
197











The competition of various agents for specific [ Hjspiperone binding
(1.8 nM) to a pool of non-functioning tumour membranes (224 pg protein
per tube). Each point represents the mean of duplicate tubes. M denotes
molar concentration of competitor.
5HT, serotonin; ADR, adrenaline; DA, dopamine; DOM, domperidone;
BC, bromocriptine; SPIP, spiperone; (+)BUTAC, (+)butaclamol;
Lower
O
Stereospecificity of [ H]spiperone binding to non-functioning tumour
membranes. Same format as above. (+) = (+)butaclamol;
(-) = (-)butaclamol.
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(a) Bromocriptine (BC) in high speed supernatant (S2) of nine non¬
functioning tumours given pre-operative BC and its relation to the
timing of last BC dose (fmol per mg wet weight tumour homogenised)
(b) Bromocriptine removal by washing of membranes from non-functioning
tumours Bl and B3 - described in the text.
Lower
Scatchard plots for non-functioning tumour Bl (left panel) and B3
(right panel) before (solid circles) and after (open circles)
membrane washing. Open circles represent singlicate determinations
due to limited membranes available.
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E. DISCUSSION
At the outset of this work there was only one report of dopaminergic
binding studies in non-functioning tumours (Bression et al., 1980).
These workers were unable to demonstrate saturable dopaminergic binding
O
in two non-functioning tumours using [ H]domperidone at concentrations
up to 40 nM, a ligand shown to have a high affinity for the dopamine
receptors found in the above studies (Figure 8-5).
During my studies two further reports were published. Serri et al
O
(1984), using enzyme-dispersed tumour cells and [ H]spiperone as
radioligand, showed dopamine receptors in two out of four non¬
functioning tumours. The tumours in this study were not extensively
characterised and immunostaining was performed for only prolactin and
growth hormone. Furthermore it is unclear whether the two non¬
functioning tumours apparently without dopamine receptors received pre¬
operative dopamine agonist treatment which may mask dopamine receptors,
as demonstrated above. The mean for the two tumours with dopaminergic
binding was 0.67 nM, similar to the values obtained in the above twenty
well-characterised non-functioning tumours.
The second report was published in preliminary form by Koga et al (1984)
but has not been followed by a substantive publication. Using
[ H]spiperone these workers found dopamine receptors in membranes from
13 out of 19 non-functioning adenomas; mean and Bmflx values for these
tumours were 2.2 nM and 191 fmol/mg protein, remarkably similar to the
values described above. In their abstract there is no indication of how
well characterised the tumours were or whether any were exposed to pre¬
operative dopamine agonists.
The binding parameters obtained for normal bovine anterior pituitary
were in excellent agreement with those reported by Cronin and Weiner
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(1979). The values for human necropsy pituitary reported here were
indistinguishable from bovine tissue although slightly lower than those
described for fresh anterior pituitary removed from patients with
metastatic cancer (Cronin et al., 1980a). The mean for non¬
functioning tumours, prolactinomas and normal pituitary were not
significantly different in the above studies and competition experiments
using bovine anterior pituitary gave identical results to those in
Figure 8-5 (data not shown). Thus my studies revealed no binding
differences in the high affinity dopamine receptors in any of the four
tissues studied.
Using t H]spiperone concentrations up to 50 nM it was possible to
define, in all tissue types, a second dopaminergic binding site of lower
affinity, similar to that found in prolactinomas by Bression et al
O
(1980) using [ H]domperidone. Cronin et al (1980a) found only a single
class of high affinity sites in prolactinomas and normal pituitary using
O
[ H]spiperone, presumably because the highest concentration used was 6
nM. In separate experiments, not reported above, a similar second site
in bovine anterior pituitary membranes was revealed by
O
[ H]dihydroergocriptine at concentrations of up to 50 nM. The
significance of this site is unclear. Foord et al (1983) have suggested
that it may represent a dopamine uptake pathway; the in the
micromolar range and lack of stereospecificity in their intact pituitary
cell preparation made it an unlikely site for control of hormone
release. The discovery of dopamine associated with the subcellular
fraction containing prolactin secretory granules (Nansel et al., 1979)
allied with the recent characterisation of high affinity dopamine
receptors in the cytosol of bovine anterior pituitary glands (though
constituting only 3% of total dopaminergic binding, Kerdelhue et al.,
1981) provides evidence suggesting an uptake of dopamine into anterior
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pituitary cells.
The situation has been further complicated by the demonstration that the
dopamine receptor responsible for inhibition of prolactin secretion in
the normal pituitary exists in high and low affinity states (Sibley et
al., 1 982; De Lean et al., 1982; Sibley and Creese, 1983). Dopamine
agonists bind to the receptor in its high affinity form and such binding
can be completely abolished by guanine nucleotides (Sibley et al.,
1982). It is clear that the functional state of the receptor is in the
high affinity form (George et al., 1985). Dopamine antagonists, and
paradoxically the ergopeptines, can interact with the receptor in either
affinity state (Sibley and Creese, 1982). There remains considerable
controversy regarding the precise molecular explanation of these
observations but it seems probable that a GTP-sensitive regulatory
protein exists which coordinates receptor binding and post-receptor
mechanisms, particularly adenylate cyclase activity.
Site numbers for the high affinity site in the five prolactinomas
studied were also in close agreement with previously reported values
(Cronin et al., 1980a) and significantly higher than in the non¬
functioning tumour or normal pituitary groups. The difference in site
numbers between prolactinomas and normal pituitary might be explained by
the fact that immunocytochemically most, but not all, dopamine receptors
in the anterior pituitary are related to the lactotroph population
(Goldsmith et al., 1979). This constitutes only 10-30% of cells in
normal anterior pituitary (Asa and Kovacs, 1982) but greater than 90% in
prolactinomas. However the presence of dopamine receptors has been
demonstrated or inferred on other normal and neoplastic pituitary cell
types (Bression et al., 1982; Marcovitz et al., 1982; Foord et al.,
1983; Chanson et al., 1984) and the difference in receptor number may
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reflect a greater receptor density on the tumourous lactotrophs.
It is still uncertain which cell type is represented in non-functioning
tumours; it may be an undifferentiated progenitor cell or alternatively
a dedifferentiated cell derived from a mature cell type (Kovacs et al.,
1980). The receptor data do not resolve this question. There was a
striking similarity in high affinity site numbers between non¬
functioning tumours and normal anterior pituitary which suggests that
the dopamine receptor might be a feature common to several pituitary
cell types.
None of the non-functioning tumours regressed during bromocriptine
therapy. The patients treated to within twenty-four hours of surgery
provided evidence that the drug hound to non-functioning tumour dopamine
receptors in-vivo but this binding did not result in shrinkage. Bmaxj
values after membrane washing increased to within the range of the
untreated group of non-functioning tumours which showed that chronic
bromocriptine therapy had not altered the number of dopamine receptors.
Furthermore, non-functioning tumours which had last been exposed to
bromocriptine between one and fourteen days before surgery had similar
Bmaxi values to the untreated non-functioning tumours.
Similar studies with normal pituitary and prolactinoma tissue exposed to
bromocriptine in-vivo would be necessary to confirm the significance of
these results. The work reported by Di Paulo and Falardeau (1984) is of
considerable interest. These workers induced prolactin-secreting tumours
in rats using oestradiol valerate and treated the rats with sub¬
cutaneous bromocriptine for one month. On a weight basis the rats
received a daily dose of bromocriptine 50 times greater than a typical
dose used to shrink human prolactinomas (7.5 mg daily). Tumours from
rats sacrificed 60 hours after the last dose of bromocriptine showed a
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70% apparent reduction in dopaminergic binding sites (using
o
[ H]spiperone) and the authors concluded that chronic bromocriptine had
reduced dopamine receptor number. An alternative explanation could be
that the massive sub-cutaneous doses of bromocriptine acted as a drug
reservoir and that the apparent fall in dopamine receptor number was due
to continuing bromocriptine receptor action and occupancy; plasma
prolactin concentrations were still fully suppressed at the time of
death.
What prevents dopamine agonist induced tumour regression in patients
with non-functioning tumours ? Perhaps the dopamine receptors are
functionally defective in a analogous way to the rat lactotroph clone
7315a which has apparently normal dopamine receptors but is refractory
to dopamine inhibition of prolactin release in-vitro (Cronin et al.,
1981; Judd et al., 1985). Another possibility is that non-functioning
tumour dopamine receptor density is not great enough to facilitate
shrinkage. Perhaps the most likely explanation is that since non¬
functioning tumours appear to be largely quiescent from the secretion
point of view there is no hormone product to be inhibited by receptor
activation, with subsequent feedback on nucleic acid and protein
synthesis, as is thought to occur in prolactinomas (Brocas et al., 1982;
Bassetti et al., 1984). These possible explanations are discussed in the
final chapter.
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CHAPTER 9. SOME STUDIES OF TWO TSII-SECRETING MACROADENOMAS
A. INTRODUCTION
Only 52 TSH-secreting tumours have been described to date and few have
been subjected to detailed in-vitro investigation. This short chapter
describes in-vitro studies of two further tumours and correlates the
results with the in-vivo TSH responses to TRH and dopaminergic
manipulation. These results are included in this thesis since they
provide an interesting contrast to the previous sections on TRH/dopamine
interactions in the tumourous lactotroph (Chapter 6.B) and dopamine
receptors in non-functioning pituitary tumours (Chapter 8).
The TRH responsiveness of the normal thyrotroph is inhibited by dopamine
in-vitro (Foord et al., 1981) and in-vivo (Connell et al., 1985). In
contrast, most patients with TSH-secreting adenomas do not respond to
TRH, and of the small number investigated nearly all have proved
resistant to dopaminergic suppression of serum TSH concentrations
(Faglia, 1984). Dopamine receptors were present in membranes from the
only tumour so investigated, but this patient showed a paradoxical
increase in serum TSH following L-Dopa (Chanson et al., 1984).
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B. IN-VIVO STUDIES
Both patients underwent transsphenoidal removal of macroadenomas in
which 25-50% of cells immunostained for TSH and alpha subunit.
Patient 1 was thyrotoxic on presentation and had slightly elevated serum
TSH concentrations of 7-8 mU/L (normal <5). Serum alpha subunit was
substantially raised (10.4 ng/mL), as was the alpha subunit/TSH molar
ratio (4.8). There was a small but significant increase in TSH and a
marked rise in alpha subunit following TRH in-vivo (Figure 9-1). Neither
domperidone - a D2 dopamine antagonist - nor bromocriptine affected
serum TSH concentrations (Figures 9-2 and 9-3)
Patient 2 had received radioiodine in the past for presumed Graves
disease and off thyroxine treatment had greatly elevated serum TSH
concentrations of 41-77 mU/L in the presence of low-normal thyroid
hormone concentrations. Serum alpha subunit was only slightly raised
(4.5 ng/mL) and the molar ratio was normal (0.27). There was no increase
in serum TSH or alpha subunit following TRH (Figure 9-1), neither did
dopaminergic manipulation affect serum TSH concentrations (Figures 9-2
and 9-3).
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Figure 9—1: TSH-secreting adenomas: serum TSH and alpha subunit
responses to TRH
In-vivo responses of serum TSH (•) and alpha subunit (A) concentrations
to 200 pg TRH ( iv) in the two patients.
Only patient 1 showed significant hormone release.
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In-vivo responses of serum TSH (circles) and prolactin (squares)
concentrations to 10 mg domperidone (iv) before (solid symbols) and
after (open symbols) surgery, in the two patients.
Before surgery, neither patient showed a significant increase in TSH but
both showed some increase in prolactin.
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In-vivo responses of serum TSH (•) and prolactin (■) concentrations to
2.5 mg bromocriptine in the two patients.
Each showed significant suppression of prolactin but not TSH.
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C. IN-VITRO STUDIES
The in-vitro TSH responses were studied using the tumour cell perifusion
system and there was complete correspondence between the in-vivo and in-
vitro results.
The tumour from patient 1 showed dose-dependent TSH release following
TRH stimulation but this could not be inhibited by dopamine
concentrations as high as 5 pM (Figure 9-4), quite unlike the responses
expected from the normal thyrotroph (Foord et al., 1981). The second
tumour showed no TRH-induced TSH release in-vitro or in-vivo.
Both tumours were completely resistant to the actions of dopamine and
bromocriptine, even at the high concentrations of 5 pM and 10 nmol/L
respectively (Figures 9-5). In contrast, the lactotrophs in the non-
adenomatous pituitary showed normal dopaminergic responsiveness as
indicated by the in-vivo tests (Figures 9-2 and 9-3).
Membranes were prepared from each tumour for dopamine receptor
measurement. Neither tumour showed significant numbers of dopaminergic
O
binding sites as defined by [ H]spiperone. The first tumour had no
discernible binding and the other, which had shown possible anterior
pituitary contamination of up to 20% from hormone content studies (See
Figure 7-3), had ill-defined binding of, at most, 20 fmol/mg protein. A
prolactinoma control in the same assay gave a Bmax value of 318 fmol/mg
protein.
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Perifusion of tumour cells (3 x 10 cells) from patient 1.
The TSH responses to TRH (1-100 ng/mL) were not reduced in the presence
of 5 pM dopamine.
(Tumour cells from patient 2 were unresponsive to TRH in-vitro - data
not shown).
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Tumour fragment perifusion from patient 2 (50 mg per column).
DA = 5 pM dopamine, M = dopamine-free medium, bromocriptine
concentrations as shown.
The experimental design was the same as that used for the prolactinomas
(for example, see Figure 6-3). Each bar represents the mean of the last
6 fractions of each treatment period (+ SEM). A separate control column
is shown on the right of the figure.
There was no significant inhibition of TSH secretion by bromocriptine.
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D. DISCUSSION
The TSH-secreting adenomas provided an interesting comparison with the
other tumours in this thesis. Most of the prolactinomas showed TRH-
induced prolactin release which was abolished by 5 pM dopamine (Chapter
6.B). The first TSH-secreting adenoma showed TRH-induced TSH release
which could not be blocked by dopamine suggesting that a dopamine
receptor or post-receptor defect prevented the inhibition of apparently
normal TRH action. The second showed apparent defects in both TRH and
dopaminergic mechanisms. Most of the previously described tumours have
been resistant to dopamine suppression of TSH (Faglia, 1984), but in-
vitro TRH/dopamine interactions have not been studied before.
The radioreceptor studies suggested that the dopaminergic resistance of
both tumours was due to deficiency of membrane-bound dopamine
receptors. Since normal thyrotrophs possess such receptors (Foord et
al., 1983), perhaps these had been lost during neoplastic
transformation. Only one previous TSH-secreting adenoma has had dopamine
receptor measurements (Chanson et al., 1984). Although this tumour
contained dopaminergic binding sites, it also showed paradoxical
stimulation of TSH by L-Dopa, and may not be typical of most TSH-
secreting adenomas. Of the 21 previous patients with TSH-secreting
tumours challenged with L-Dopa or bromocriptine, 18 (86%) showed no
change in serum TSH concentrations and may have lacked dopamine
receptors. No TSH-secreting tumour has been shown to shrink during
bromocriptine treatment.
Dopaminergic resistance in the TSH-secreting adenomas was therefore due
to a lack of dopamine receptors, in contrast to the non-functioning
tumours where it occurred despite the presence of such receptors in
tumour membranes (Chapter 8).
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CHAPTER 10. CONCLUSIONS
The conclusions to this thesis are in three main sections. Firstly I
shall seek to summarise the guidelines for the management of patients
with large pituitary tumours which resulted from the clinical studies,
and set these in the context of recent publications from other centres.
Secondly I shall discuss the significance of dopamine receptors in
pituitary tumours and possible mechanisms of bromocriptine-induced
tumour regression. Lastly, the finding of dopamine receptors in non¬
functioning pituitary tumours suggested a number of areas for future
research, both to define intracellular mechanisms in these tumours and
to further characterise the cell type represented.
A. GUIDELINES FOR THE MANAGEMENT OF PITUITARY MACROADENOMAS
It is now clear that only large prolactin-secreting pituitary tumours
regress during dopamine agonist therapy. It is therefore important to be
confident of that diagnosis before embarking on a course of dopamine
agonist therapy in a patient with a large pituitary tumour and visual
failure. The results in Chapter 2 show that a large pituitary tumour
associated with a serum prolactin concentration of less than 3000 mU/L
is unlikely to be prolactin-secreting or to shrink during dopamine
agonist therapy. Over the past 3 years the results of dopamine agonist
therapy in a total of 60 non-functioning tumours have been reported
(Barrow et al., 1984; Pullan et al., 1985; Verde et al., 1 985; Grossman
et al., 1985b; Zarate et al., 1985; Bevan et al., 1987b). Of these 60
tumours, only 3 showed evidence of tumour regression and
the diagnosis of non-functioning tumour has been confirmed in surgical
biopsies, usually supplemented with immunocytochemistry. These tumours
have been studied mostly by third and fourth generation computerised
tomography, in contrast to some of the earlier studies which suggested
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that some non-functioning tumours might regress during dopamine agonist
therapy (Wolleson et al., 1982). Of the 60 recently reported cases, 41
received bromocriptine in a dose of at least 7.5 mg daily for 3 months
or longer; treatment in 10 cases was continued for over 1 year. At least
one of the 3 patients with tumours that shrank had a history suggestive
of pituitary apoplexy (Grossman et al., 1985b), and in view of the
frequency of subclinical pituitary tumour haemorrhage (Wakai et al.,
1981), it is conceivable that this was also the explanation in the other
two. Importantly 4 of the tumours described by Verde et al (1985)
continued to enlarge during bromocriptine treatment.
Most patients with non-functioning tumours can be treated successfully
with transsphenoidal tumour decompression, which is the initial
treatment of choice (Chapter 2). Furthermore, this approach will reveal
non-adenomatous pathology masquerading as a pituitary adenoma.
A large pituitary lesion associated with a serum prolactin of more than
8000 mU/L is virtually certain to be a macroprolactinoma and even above
5000 mU/L there is little risk of misdiagnosis. Most macroprolactinomas
can be successfully reduced in size using dopamine agonist therapy which
is appropriate initial management. Very few patients seem to develop
resistance to the bromocriptine, but perhaps this will increase with
longer treatment periods. Furthermore, once the initial response has
been achieved, control of tumour size and serum prolactin concentration
can be maintained in many patients with a greatly reduced dose of
dopamine agonist; Liuzzi et al (1985) found that the bromocriptine dose
could be reduced as low as 0.625 mg daily.
However a number of dilemmas remain. The most important is the
continuing uncertainty regarding the efficacy of longterm medical
therapy alone. Withdrawal of dopamine agonist therapy, even after 7-8
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years of treatment, invariably results in the prompt return of
hyperprolactinaemia (Johnston et al., 1984; Liuzzi et al., 1985). This
must signify the continuing presence of tumourous lactotrophs and a
failure of dopamine agonist therapy to cure the prolactinoma, at least
when given for this length of time. Immediate tumour re-expansion on
drug withdrawal may occur even after one year of therapy (Molitch et
al., 1985), although after more prolonged treatment such early re-
expansion seems uncommon (Johnston et al., 1984). In view of the
bromocriptine-induced fibrosis demonstrated in Chapter 2 this latter
finding is not unexpected, and the return of hyperprolactinaemia
suggests that tumour enlargement would occur in the longterm. Longterm
withdrawal studies are needed to resolve this issue.
A second problem is that a proportion of macroprolactinomas do not
reduce in size during dopamine agonist therapy. Benker et al (19861
reviewed 10 major series comprising a total of 274 patients and found
that 30% of macroprolactinomas did not regress during therapy. A
proportion of these non-responders were probably misclassified non¬
functioning tumours with disconnection hyperprolactinaemia, nevertheless
some which are definitely macroprolactinomas do not shrink. The
mechanism of this is obscure, since a large proportion of non-shrinkers
show marked suppression of serum prolactin concentrations (Liuzzi et
al., 1985). In some cases cystic change or tumour haemorrhage may
obscure the response of the tumourous lactotrophs. In others the pre-
treatment tumour size is probably important, radiological size change
being less easily detected in intermediate sized tumours (10-20 mm) than
in the very large tumours of greater than 20 mm diameter. Fahlbusch and
Buchfelder (1986) reported that 96% of 24 large prolactinomas (>20 mm
diameter) shrank during bromocriptine therapy, which was also my
experience with a smaller series of 12 large macroprolactinomas, all of
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which shrank by at least 25%.
The timing and nature of subsequent definitive therapy remains
controversial. Some recommendations can be made from the clinical
studies in Chapter 2. Firstly there is no doubt that bromocriptine
treatment of macroprolactinomas for longer than 8-10 weeks causes tumour
fibrosis which makes subsequent surgery unproductive and even dangerous.
Should surgery be used at all in patients with bromocriptine-treated
macroprolactinomas? If compact shrinkage has occurred after 4 weeks of
medical treatment then it would seem reasonable to attempt surgical cure
of the tumour. If the shrinkage has been asymmetrical or if dopamine
agonist therapy has been given for longer than 3 months then surgery is
contraindicated and external radiotherapy is more appropriate as
definitive treatment. Of course, bromocriptine alone can be given to
younger patients with fertility needs provided the tumour shrinks well
away from the optic chiasm; but prolonged dopamine agonist therapy
precludes the option of future surgery. If a macroprolactinoma does not
shrink or if resistance develops during prolonged bromocriptine therapy
does this mean that surgery is contraindicated? The answer to this
question is unknown. Prolactinoma re-expansion during bromocriptine
treatment is rare but there seemed to be little operative difficulty in
the tumour described by Breidahl et al (1983). Tumours without
radiological evidence of shrinkage may nevertheless show lactotroph cell
size reduction (Nissim et al., 1982), and presumably may develop
fibrosis, so it is probably safer to avoid surgery in all patients with
large prolactinomas who have received dopamine agonist therapy for
longer than 3 months.
Large pituitary lesions associated with serum prolactin concentrations
between 3000 and 5000 (perhaps 8000) mU/L may or may not be pituitary
adenomas and may or may not be prolactin-secreting (Bevan et al.,
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1987a). The best approach is to treat such cases surgically as this
provides both effective decompression and a histological diagnosis. An
alternative approach is to use the radiological response of the lesion
to bromocriptine as a diagnostic test. However, if the lesion does not
shrink it may be impossible to distinguish the various diagnostic
possibilities since the serum prolactin will probably suppress whatever
the aetiology.
Despite the development of several alternative dopamine agonists,
bromocriptine remains the mostly widely used and studied dopamine
agonist. Recently a depot preparation of bromocriptine in polylactic
microspheres has become available. A single intramuscular injection of
50 mg suppresses prolactin secretion in normal volunteers and patients
with prolactinomas for 4 to 6 weeks (Benker et al., 1986; Grossman et
al., 1986). It has been suggested that this formulation of the drug
might be a useful way of initiating treatment in patients with
macroprolactinomas (Grossman et al., 1986), but its duration of action
seems to be somewhat variable, lasting for only 2 weeks in some patients
(Benker et al., 1986). It would be of interest to use the sensitive
bromocriptine assay described in this thesis to measure plasma levels of
active non-metabolised bromocriptine following such an injection, and to
correlate these levels with the slow rise in serum prolactin which
occurs after 2 to 4 weeks.
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B. DOPAMINE RECEPTORS AND PITUITARY TUMOUR REGRESSION
The evidence presented in this thesis is consistent with the view that
the effects of bromocriptine on lactotroph prolactin secretion and cell
size reduction are mediated via membrane-bound dopamine receptors.
However the work described in Chapter 8 demonstrates that the presence
of dopamine receptors in pituitary tumour membranes does not necessarily
imply that a tumour will regress during dopamine agonist therapy.
In 1982 when this work started the mechanism of bromocriptine-induced
tumour shrinkage was unknown. Considerable progress has been made over
the past 4 years towards understanding it, although the precise
intracellular mechanisms remain unclear. In order to speculate on
possible reasons for the varying responses of different pituitary tumour
types to bromocriptine I shall review the recent evidence pertaining to
the actions of the drug on the tumourous lactotroph.
The inhibitory actions of the drug on DNA synthesis and mitosis in the
normal pituitary were well known (Lloyd et al., 1975) but seemed hardly
relevant to the rapid shrinkage of slow growing pituitary adenomas. It
seemed likely that most progress was going to be made from morphological
studies of tumour tissue removed from patients given pre-operative
bromocriptine, and from experiments on human prolactinoma cells in-
vitro.
The morphological studies have shown that early reduction in tumour size
is due to diminution in lactotroph cell size, particularly the cell
cytoplasm (Tindall et al., 1982; Nissim et al., 1982; Bassetti et al.,
1984; Barrow et al., 1984; Esiri et al., 1986). Ultrastructural studies
have demonstrated a rapid involution of rough endoplasmic reticulum and
Golgi apparatus (Landolt et al., 1985), which is reversible (Landolt et
al., 1983), and to my knowledge, without parallel in any other drug-cell
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interaction. What is the mechanism of this dismantling of the protein
synthetic machinery in the tumourous lactotroph?
In bromocriptine-responsive macroprolactinoma patients serum prolactin
levels fall to 25% of the pre-treatment values 6 hours after the first
tablet (Chapters 2 and 3). This rapid effect on prolactin secretion has
been similarly demonstrated in-vitro, and after 24 hours exposure to
bromocriptine tumourous lactotrophs show a reduction in exocytosis and
an intracellular accumulation of prolactin-immunoreactive granules, but
no reduction in cell size (Hassoun et al., 1985). It seems reasonable to
propose that the initial event in bromocriptine action is the inhibition
of prolactin release.
There is still controversy regarding the precise interaction of the
intracellular messengers responsible for this inhibition. The dopamine
receptor in normal and tumourous lactotrophs is negatively coupled with
adenylate cyclase and reduction in intracellular cAMP levels is an
important mechanism whereby dopamine and bromocriptine inhibit hormone
release (Spada et al., 1983; Enjalbert and Bockaert, 1983; McDonald et
al., 1984). Conversely, compounds which stimulate or simulate adenylate
cyclase activity promote lactotroph prolactin secretion (Spada et al.,
1983; Ishibashi and Yamaji, 1985; Cronin et al., 1985). The GTP
sensitivity of dopamine agonist binding to anterior pituitary membranes
is analogous to the guanine nucleotide dependency of several other
adenylate cyclase-linked receptor systems (Rodbell, 1980).
Other regulators are also involved. Calcium has an important role in
prolactin secretion (Ishibashi and Yamaji, 1985) and, in normal animal
pituitary, dopamine inhibits phosphatidylinositol turnover which in turn
regulates intracellular calcium mobilisation and protein kinase C
activity (Canonico et al., 1983). Exactly how these intracellular
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messengers interact with cAMP in the control of prolactin secretion in
the tumourous lactotroph is still not well understood.
Accepting that a reduction in intracellular cAMP concentration is an
important component of bromocriptine inhibition of prolactin secretion,
how does this relate to subsequent changes in lactotroph cell size? In
1981 Brocas et al showed that bromocriptine administration to rats
produced rapid suppression of serum prolactin concentrations
(undetectable at 24 hours) followed by a delayed effect on prolactin and
prolactin mRNA synthesis (50% reduction after 3 days). Furthermore
ergot-induced inhibition of prolactin mRNA synthesis could be reversed
using long-acting analogues of cAMP (Maurer, 1981). It is likely that
bromocriptine-lowered cAMP levels have the immediate effect of
preventing prolactin release and the later effect of reducing gene
transcription and prolactin synthesis. Whether prolactin itself is able
to exert negative feedback control on the transcription of its mRNA
remains unknown. Using biopsy material from prolactinoma patients given
short-term pre-operative bromocriptine, Landolt et al (1985) have
recently estimated a half-life of 3 days for the removal of lactotroph
rough endoplasmic reticulum and Golgi apparatus. Presumably it involves
a reduction in ribosomal protein and RNA synthesis but the cause of this
phenomenon and whether it is directly related to the inhibition of
prolactin secretion remains obscure. As discussed above serum prolactin
levels may be suppressed in some patients without tumour shrinkage,
though the converse is rarely true.
Bromocriptine not only reduces the synthesis and release of prolactin
but accelerates its lysosomal degradation within the lactotroph. De
Marco et al (1984a) have shown that the drug greatly increases lysosomal
acid prolactin proteolytic activity within 24 hours of administration.
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This activity is probably due to the concerted actions of the cysteine
proteases cathepsins B and D. The overall increase in cellular lysosomal
activity with increased autophagic vacuole formation may be one of the
mechanisms responsible for the removal of rough endoplasmic reticulum
and Golgi. Again the intracellular signal for these changes is unknown.
The occasional "complete disappearance" of giant prolactinomas during
prolonged bromocriptine suggests that the drug may be cytocidal to some
tumours (Gen et al., 1984; Clayton et al., 1985). However
hyperprolactinaemia returned after drug withdrawal even in these cases
(Gen et al., 1984) suggesting that at least some lactotrophs had
escaped. The inhibitory effects of bromocriptine on lactotroph DNA
synthesis are presumably responsible for the cytostatic effects of the
drug demonstrated by Arafah et al (1983) using human prolactinoma cells
growing in soft agar. Significantly these workers were unable to
demonstrate a similar effect on cells from GH, ACTH, FSH or non¬
functioning tumours.
The studies in Chapter 8 clearly demonstrated that non-functioning
pituitary tumours do not shrink during bromocriptine therapy despite the
possession of dopamine receptors which bind the drug. What is the
explanation for this apparent discrepancy?
The relatively low secretory activity of these cells may be responsible;
if no secretory product accumulates within the tumour cells following
bromocriptine treatment then perhaps feedback inhibition on nucleic acid
and protein synthesis cannot occur. Against this is the observation that
GH-secreting tumours rarely shrink and do not show cell size reduction
during dopamine agonist therapy, despite the frequent suppression of
serum GH concentrations (Oppizzi et al., 1984). Little is known about
the actions of dopamine agonists on true gonadotrophinomas; in the
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single case reported by Berezin et al (1984) serum FSH concentrations
were reduced by bromocriptine but tumour shrinkage did not occur.
Another possible explanation for the failure of pituitary tumours other
than prolactinomas to shrink is that the density of membrane-bound
dopamine receptors is too low. In the studies in Chapter 8 the number of
dopaminergic binding sites in prolactinoma membranes was approximately
five times that in non-functioning tumour membranes. The two non¬
functioning tumours reported by Serri et al (1984) had similar numbers
of dopaminergic binding sites to four GH-secreting tumours. Cronin et al
(1980a) reported that site numbers for GH-secreting tumours and normal
anterior pituitary were similar but that not all GH-secreting adenomas
contained dopamine receptors. The two TSH-secreting tumours in Chapter 9
were unresponsive to dopaminergic manipulation in-vivo and in-vitro.
These two tumours lacked the dopamine receptors present in non-tumourous
thyrotroph membranes (Foord et al., 1983), and presumably would not have
regressed during bromocriptine therapy had this been tested.
The localisation of dopamine receptors within non-functioning tumours
would be of interest. For example, similar methodology to that described
by Goldsmith et al (1979) employing a histochemical dopaminergic probe
could be used to determine whether the receptors are uniformly
distributed throughout the tumour or whether they are confined to the
small number of cells immunostaining for gonadotrophins. The former
result seems most likely since 11 of the 20 non-functioning tumours in
Chapter 8 had negative, or virtually negative, immunostaining. Although
some non-tumourous gonadotrophs appear to possess dopaminergic receptors
(Goldsmith et al., 197 9), dopamine does not have a direct effect on
gonadotrophin release from such cells in-vitro (Weiner and Ganong,
1978). In-vivo inhibitory effects of dopamine on LH release are most
likely to be due to an indirect action on the hypothalamic secretion of
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LHRH (Judd et al., 1978), though bromocriptine does not have a similar
effect (Martin et al., 1981).
A third explanation for the failure of non-functioning tumours to shrink
is that they possess a post-dopamine receptor defect which renders the
cells unable either to secrete hormone or to respond to dopamine
receptor activation, in a manner analogous to the rat pituitary tumour
7315a (Judd et al., 1985). Nothing is known of post-receptor mechanisms
in non-functioning tumours and this suggests a promising area for future
research which is discussed below.
A final possibility is that lactotroph size reduction is in some way
specifically related to reduced levels of prolactin itself. This is
entirely speculative but Gout et al (1980) showed that prolactin is an
obligatory growth promoting factor for the malignant Nb2 lymphoma in the
rat.
A schematic diagram of the lactotroph is shown in Figure 10-1 to
illustrate the various sites of action of bromocriptine and to act as a
guide to the last section of this chapter.
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Figure 10-1: Intracellular mechanisms in the lactotroph
A diagrammatic representation of the lactotroph showing the pathway of
prolactin synthesis and release, membrane receptor complexes and the
sites of action of bromocriptine.
Sites of bromocriptine inhibition (*) and stimulation (**)
SG = secretory granules; PRL = prolactin; RER = rough endoplasmic
reticulum; mRNA = prolactin messenger RNA.
Adenylate cyclase complex
C = catalytic unit of adenylate cyclase; and Ng = GTP-sensitive
regulatory proteins, inhibitory and stimulatory.'
Inositol phosphate pathway
PIP2 = phosphatidylinositol 4,5-biphosphate; IPg = inositol 1,4,5-
triphosphate; DG = diacylglycerol; Kinase C = protein kinase C.
AT II = Angiotensin II; GAP = GnRH associated peptide; (?) = unknown
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C. FUTURE RESEARCH
The detailed characterisation of cells from non-functioning pituitary
tumours remains a largely unexplored area of clinical
neuroendocrinology. The demonstration of "lactotroph-like" dopamine
receptors in these cells has suggested two broad directions for future
research. The first would involve a search for other specific cell
markers which might identify the pituitary cell type of origin and, in
particular, reveal any other similarities to the lactotroph. The second
relates to the elucidation of post-dopamine receptor control mechanisms
with the aim of explaining the failure of non-functioning tumours to
shrink during dopamine agonist therapy.
Cell marker studies would require careful interpretation for a variety
of reasons. Firstly, many pituitary adenomas exhibit atypical responses
to secretory stimuli, for example the paradoxical responses of some
gonadotrophinomas to TRH (Snyder et al., 1980), or some GH-secreting
adenomas to TRH or corticotrophin-releasing hormone (Pieters et al.,
1984). Such tumours may therefore exhibit membrane-bound receptors not
representative of their normal cells of origin. Secondly, several
regulatory factors have actions, and possibly receptors, on more than
one pituitary cell type and the demonstration of a wide variety of
possible paracrine control mechanisms has greatly increased the
complexity of anterior pituitary regulation (reviewed by Denef, 1986).
Of central importance would be the further characterisation of the
dopamine receptor complex. Although the dopamine receptors in non¬
functioning tumours and prolactinomas were kinetically similar it is
possible that structural differences exist. New dopaminergic ligands
have been developed for the affinity purification of solubilised
receptors and this may reveal differences between dopamine receptors in
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the two tissue types (Amlaiky et al., 1984; Ramwani and Mishra, 1986;
Shorr, 1985, personal communication). Furthermore these ligands should
also facilitate photoaffinity probe studies of the active site of the
dopamine receptor (Amlaiky et al., 1984). Studies of adenylate cyclase
activity in non-functioning tumours have not been reported and it would
be of great interest to determine whether dopamine receptor and
adenylate cyclase are negatively coupled, as they are in the lactotroph
(Figure 10-1). Furthermore the presence of VIP receptors and VIP
stimulation of adenylate cyclase activity would provide a further
similarity to both the normal and abnormal lactotroph (Spada et al.,
1983, Enjalbert and Bockaert, 1983). If adenylate cyclase were present
in non-functioning tumour cells then the effects of forskolin (a
stimulator of adenylate cyclase), dibutyryl cAMP (a long acting cAMP
analogue) and phosphodiesterase inhibitors, on secretory granule
release, and where appropriate hormone secretion, could be studied.
By further analogy to the lactotroph, TRH receptors could be sought in
non-functioning tumour membranes although, as mentioned above, their
presence might signify abnormal expression rather than necessarily
indicating similarity to the lactotroph. If TRH receptors were present
then it would be pertinent to examine the inositol phosphate system as
this is considered to mediate the actions of TRH on the lactotroph
(Gershengorn, 1986). This is briefly summarised in Figure 10-1. The
effects on granule release of compounds which simulate activation of
this pathway could be examined; the calcium ionophore A23187 to raise
intracellular free calcium levels and phorbol myristate acetate to mimic
stimulation of protein kinase C by diacylglycerol.
Recent reports suggest further ways of distinguishing lactotroph-like
and gonadotroph-like cells in non-functioning tumours. The putative
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precursor molecule for gonadotrophin-releasing hormone contains not only
GnRH which stimulates gonadotrophs, but an associated peptide (GAP)
which, in nanomolar concentrations, inhibits prolactin release from
lactotrophs (Nikolics et al., 1985). Secondly, the renin-angiotensin
system in the normal pituitary seems to be involved in paracrine
interaction between gonadotrophs and lactotrophs. Angiotensin II (AT II)
is present within the LH containing granules of the gonadotroph,
converting enzyme-like activity is present in the gonadotroph and AT II
stimulates prolactin release from the lactotroph although the
intracellular mechanisms remain controversial (Steele et al., 1982;
Aguilera et al., 1982; Schramme and Denef, 1984; Marie et al., 1985).
From these reports lactotroph-like cells would be predicted to possess
specific binding sites for GAP and AT II (Figure 10-1).
As already noted most non-functioning tumours contain secretory
granules, yet many show completely negative immunostaining for
recognised anterior pituitary hormones. A proportion may be secreting
hormones as yet unidentified but in others cellular hormone levels may
be too low to be detected by conventional immunocytochemistry. In these
cases it is probable that the more sensitive techniques of recombinant
DNA technology will enable the detection of low tissue levels of
specific mRNA. This technology has not yet been extensively applied to
the study of human pituitary tumours but as the cDNA probes become
available this will undoubtedly increase. Such probes have been prepared
for human alpha subunit, LH/3and prolactin and their use has been
recently reported by Jameson et al (1986). These workers described a
pituitary tumour which was clearly hypersecreting alpha subunit since
serum levels were elevated and many clumps of cells showed positive
immunostaining for the hormone. The tumour contained not only alpha
subunit mRNA (as shown by blot hybridisation of extracted RNA to the
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specific cDNA probe) but also beta subunit mRNA more characteristic of
chorionic gonadotrophin than LH, suggesting defective promoter site
activation in the tumourous cells. The mRNA measurements were made on
total extracted RNA so it was impossible to comment on gene expression
in tumour cells showing no hormone immunostaining; the application of in
situ hybridisation techniques may reveal such information. Furthermore
it would be of great interest to see whether there is detectable mRNA
for prolactin or gonadotrophin subunits in non-functioning tumours
completely negative with conventional immunostaining.
In final conclusion, the studies described in this thesis have resulted
in useful guidelines for the clinical management of patients with large
pituitary tumours. In particular, the responsiveness of different
pituitary tumour types to dopamine agonist therapy has been clarified.
The unexpected finding of dopamine receptors in non-functioning tumours
has raised several new questions which promise many years of further
research. If intracellular post-receptor defects can be defined, then
this should, in the longterm, permit definition of genetic defects in
these tumours whose origin and pathogenesis remain an enigma.
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APPENDIX: PATHOLOGY METHODS
These techniques were carried out by Dr M.M.Esiri and the laboratory
staff of the Department of Neuropathology, Radcliffe Infirmary, Oxford.
I did not personally perform this experimental work, hence its inclusion
as an appendix.
1.Routine pituitary tumour histology
Tumour fragments were fixed in 10% neutral formalin for 15-30 hours and
embedded in paraffin wax. Routine staining was performed with
haematoxylin and eosin, and orange G/PAS.
2. Immunocytochemistry
Immunohistology was performed using the immunoperoxidase (PAP) technique
with rabbit antisera to human PRL, GH, ACTH, /JTSH, /?FSH, /JLH and aFSH,
used at dilutions ranging from 1:50 to 1:400 depending on the results of
test dilutions carried out on surgical specimens of tumours and normal
pituitary glands obtained at necropsy. Antisera were of high specificity
and supplied by Dr S.Raiti (NIAMDD). Additional antisera to GH (Dako),
PRL (LKB) and ACTH (Wellcome) were also used. Control sections were
treated with normal rabbit serum or specific antiserum preabsorbed with
the appropriate hormone.
3. Reticulin staining
Sections of neutral formalin fixed tumour (6-8 pm) were stained by
Gordon and Sweet's method for reticulin. Using this stain, reticulin
appeared black and collagen brown; both were recorded as fibrous tissue
in the tumour fibrosis study (Chapter 2.C). In this study reticulin-
stained sections from all tumours were coded and examined by MME without
knowledge of tumour type or treatment. Sections were projected on a
Nikon profile projector (model V16) at a final magnification of xlOO and
a point counting grid measuring 20 x 20 cm with points at 1 cm intervals
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was placed over the tumour image. This covered an area of tumour
equivalent to 2 x 2 mm. The proportion of randomly selected tumour area
occupied by tumour cells and fibrous tissue was measured by counting the
number of grid points overlying each. Multiple interrupted serial
sections at 50 pm intervals were counted in tumours whose area in one
section was insufficient to cover at least 80% of the grid.
4. Electron microscopy
Tumour specimens were diced into 1 mm pieces, fixed immediately in 2.5%
glutaraldehyde in phosphate buffer (pH 7.4) and embedded in Spurr
medium. Ultrathin sections were stained with 2% lead citrate and uranyl
acetate and examined in a Philips 301 transmission electron microscope.
Ultrastructural examination revealed oncocytic change, defined as an
abundance of mitochondria in >10% tumour cells, in several non¬
functioning tumours. It was graded + (<10% cells), ++ (10-50% cells) or
+++ (>50% cells).
5. Cell morphometry
Cells from bromocriptine-treated and untreated prolactinomas were
examined at the electron microscopic level (x3000-6000 magnification).
Nuclear and total cell areas were measured from photographs using a
semi-automatic image analyser (MOP, Reichert).
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ADDENDUM
Points for clarification arising fro* the viva examination of this
thesis (16.12.87)
1.Clinical management of macroprolactino*as; the role of bromocriptine
This paragraph clarifies the discussion on pages 65 and 215-217
regarding my recommendations for bromocriptine therapy in patients with
large prolactin-secreting pituitary adenomas (serum prolactin >5000
mU/L). Bromocriptine, followed at some stage by external radiotherapy,
is the preferred treatment for nearly all such lesions, and surgery now
has a minor role in their management. There are three situations where
surgery might be used occasionally. Firstly, if short-term (<2 months)
bromocriptine produces compact shrinkage resulting in an intrasellar
tumour (uncommon with large adenomas) then some of these patients may be
cured by subsequent surgery; this possibility remains unproven.
Secondly, some macroprolactinomas have considerable residual suprasellar
tissue even after prolonged (>1 year) bromocriptine therapy and it may
be considered desirable to debulk such tumours surgically prior to
radiotherapy; tumour fibrosis may make this difficult however. Lastly,
macroprolactinomas which do not shrink at all during bromocriptine
therapy will require surgery if there is significant suprasellar tumour,
especially if visual failure is present. However these cases comprise
the minority and most patients with macroprolactinomas now avoid
surgery.
2. Interpretation of serum prolactin levels in the intermediate range;
implications for therapy
This section clarifies some aspects of Chapter 2 (section A) and the
discussion on pages 217-218. Further analysis of the data in Chapter 2
1
and of similar data recently reported by Ross et al (1985) gives some
indication of the percentage of large pituitary lesions (>1500 mm3 fossa
volume, usually with extrasellar extension) associated with intermediate
serum prolactins of 2500-6000 mU/L, that are not macroprolactinomas. In
my series the figure is 38% (5/13 patients) rising to 50% (5/10) if
patients with serum prolactins not fully diluted are excluded. Of the
patients described by Ross et al (1985) 41% (7/17) did not have
macroprolactinomas - 54% (7/13) if those with undiluted prolactins are
excluded. In summary, about one half of such lesions are not
prolactinomas and will not therefore respond to bromocriptine.
There is debate as to whether these patients should receive surgery or
bromocriptine in the first instance. The decision will depend on a
variety of factors including local surgical expertise, the severity of
any visual failure, patient preference and clinical judgement. With a
50% chance of the lesion not being a prolactinoma, particularly if
vision is severely impaired, I consider that early surgery is desirable.
However a closely supervised trial of bromocriptine is perfectly
reasonable provided that surgery is performed if there is any
deterioration or if there has been no shrinkage of the lesion after
treatment for no longer than 3 months. Using bromocriptine, visual
failure will persist for longer if the lesion is not a prolactinoma but
up to 50% of patients will avoid surgery with its small but definite
morbidity.
3. Duration of the bromocriptine trial and the fibrosis conclusions
This point clarifies aspects of Chapter 2 (section C). It is accepted
that had the trial of bromocriptine continued for longer than 36 weeks
(longest duration in a prolactinoma patient) then more prolactinoma
2
shrinkage might have been achieved. However, my results and those of
others (Weiss et al., 1983; Barrow et al., 1984) indicate that most of
the early shrinkage occurs by about 6 weeks. The further regression
sometimes seen during more prolonged therapy (up to 2 years) occurs at a
much slower rate (Gen et al., 1984; Clayton et al., 1985). Since my
objective was to examine the effect of surgery on bromocriptine-treated
tumours this was performed when the early shrinkage was maximal, the
adverse experience with tumour fibrosis precluding surgery after more
prolonged bromocriptine.
Two points have been made about the fibrous tissue study. The first is
that the number of tumours was relatively small with only 4
prolactinomas shown to contain excess fibrous tissue after bromocriptine
(Fig 2-12) and the second that untreated adenomas occasionally contain
excess fibrous tissue. The criticism of small numbers is accepted but
the surgical difficulty provided by the tough tumour texture in these 4
cases was greater than that encountered by Mr CBT Adams in a series of
more than 300 consecutive operations on pituitary adenomas of all types.
Despite the small numbers I believe the preoperative bromocriptine given
for at least 3 months to be highly relevant to the problems encountered
(Esiri et al., 1 986 ; Bevan et al., 1 987b). Lastly, none of the tumours
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